thct_10q.htm

0001477932-19-003523.txt : 20190614 0001477932-19-003523.hdr.sgml : 20190614 20190614172122 ACCESSION NUMBER: 0001477932-19-003523 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20190430 FILED AS OF DATE: 20190614 DATE AS OF CHANGE: 20190614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THC Therapeutics, Inc. CENTRAL INDEX KEY: 0001404935 STANDARD INDUSTRIAL CLASSIFICATION: FARM MACHINERY & EQUIPMENT [3523] IRS NUMBER: 260164981 FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55994 FILM NUMBER: 19899799 BUSINESS ADDRESS: STREET 1: 645 FRONT ST., #2202 CITY: SAN DIEGO STATE: CA ZIP: 92101 BUSINESS PHONE: 702-602-8422 MAIL ADDRESS: STREET 1: 645 FRONT ST., #2202 CITY: SAN DIEGO STATE: CA ZIP: 92101 FORMER COMPANY: FORMER CONFORMED NAME: HARMONIC ENERGY, INC. DATE OF NAME CHANGE: 20100728 FORMER COMPANY: FORMER CONFORMED NAME: HARMINIC ENERGY, INC. DATE OF NAME CHANGE: 20100728 FORMER COMPANY: FORMER CONFORMED NAME: Aviation Surveillance Systems, Inc. DATE OF NAME CHANGE: 20090512 10-Q 1 thct_10q.htm FORM 10-Q thct_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2019

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 000-55994

THC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		26-0164981
(State or other jurisdiction of incorporation)		(IRS Employer Identification Number)

645 Front St., #2202

San Diego, CA 92101

(Address of principal executive offices)

(702) 602-8422

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such ﬁles). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No

As of June 12, 2019, the Company had 13,834,098 shares of common stock outstanding.

PLANTATION CORP.

INDEX

Page
PART I. FINANCIAL INFORMATION
Item 1.
Financial Statements
Consolidated Balance Sheets at April 30, 2019 (unaudited), and July 31, 2018
3
Consolidated Statement of Operations for the three and nine months ended April 30, 2019, and April 30, 2018 (unaudited)
4
Consolidated Statement of Stockholders’ Equity (deficit) for the nine months ended April 30, 2019, and April 30, 2018 (unaudited)
5
Consolidated Statement of Cash Flows for the nine months ended April 30, 2019, and April 30, 2018 (unaudited)
6
Notes to Financial Statements (unaudited)
7
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
18
Item 3.
Quantitative and Qualitative Disclosures about Market Risks
22
Item 4.
Controls and Procedures
22
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
23
Item 1A.
Risk Factors
23
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
23
Item 3.
Defaults Upon Senior Securities
23
Item 4.
Mine Safety Disclosures
23
Item 5.
Other Information
23
Item 6.
Exhibits
24

SIGNATURES
25

THC THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

April 30,
2019

July 31,
2018

ASSETS

Current assets

Cash

$ 32,344

$ 2,969

Total current assets

32,344

2,969

Fixed Assets, net

42,475

58,297

Intangible Assets, net

26,188

28,287

Rights to Robotcache Coins

-

2,429,981

Total assets

101,007

2,519,534

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities

Accounts payable and accrued liabilities

$ 195,583

$ 178,165

Accrued liabilities due to related parties

163,693

7,728

Advances from related parties

142,353

159,566

Notes payable

48,200

76,200

Convertible Notes payable, net

138,864

100,000

Derivative liability

349,939

59,785

Total current liabilities

1,038,632

581,444

Total liabilities

1,038,632

581,444

Stockholders' equity (deficit)

Common stock; $0.001 par value; 500,000,000 shares authorized; 13,771,032 and 13,004,740 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively

13,771

13,004

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 236,500 and 222,500 series A and B shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively

Preferred A stock; $0.001 par value; 3,000,000 shares authorized; 220,000 and 206,000 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively

220

206

Preferred B stock; $0.001 par value; 16,500 shares authorized; 16,500 and 16,500 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively

17

17

Stock payable

128,180

190,245

Additional paid-in capital

34,427,625

11,128,690

Accumulated deficit

(35,507,438 )

(9,394,072 )
Total stockholders' equity (deficit)

(937,625 )

1,938,090

Total liabilities and stockholders' equity (deficit)

$ 101,007

$ 2,519,534

The accompanying notes are an integral part of these financial statements.

3

Table of Contents

THC THERAPEUTICS INC.

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

For the Three Months Ended

For the Nine Months Ended

April 30,
2019

April 30,
2018

April 30,
2019

April 30,
2018

Revenues

$ -

$ -

$ -

$ -

Cost of revenues

-

-

-

-

Gross profit

-

-

-

-

Operating expenses

Professional fees

35,424

23,192

90,836

46,336

Consulting fees

18,579,500

135,486

19,093,383

257,641

Payroll expense

46,937

20,569

88,074

41,137

General and administrative expenses

25,009

41,142

76,667

108,191

Depreciation and amortization

6,232

6,213

19,116

19,012

Total operating expenses

18,693,102

226,602

19,368,076

472,317

Loss from operations

(18,693,102 )

(226,602 )

(19,368,076 )

(472,317 )

Other income (expense)

Gain/(loss) on change in derivative liability

(3,237,594 )

11,273

(4,051,115 )

39,274

Gain/(loss) on settlement of debts

-

-

(37,500 )

(132,234 )
Impairment expense

-

-

(2,429,981 )

-

Interest Expense

(200,393 )

(28,729 )

(226,694 )

(88,622 )
Total other income (expense)

(3,437,987 )

(17,456 )

(6,745,290 )

(181,582 )

Net income (loss)

$ (22,131,089 )

$ (244,058 )

$ (26,113,366 )

$ (653,899 )

Basic income (loss) per common share

$ (1.66 )

$ (0.02 )

$ (1.99 )

$ (0.05 )

Basic weighted average common shares outstanding

13,309,529

12,063,758

13,127,462

11,938,914

The accompanying notes are an integral part of these financial statements.

4

Table of Contents

THC THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT

(UNAUDITED)

For the Nine Months Ended April 30, 2018

Preferred A Stock

Preferred B Stock

Common Stock

Additional
Paid-in

Stock

Accumulated

Total Stockholders'

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Payable

Deficit

Deficit

Balance, July 31, 2017

200,000

200

16,500

17

11,878,990

11,879

3,046,707

-

(3,254,672 )

(195,869 )
Shares for services

-

-

-

-

25,750

26

149,137

48,263

-

197,426

Shares issued for cash investments

-

-

-

-

-

-

-

65,000

-

65,000

Imputed interest

-

-

-

-

-

-

2,121

-

-

2,121

Debt discount

-

-

-

-

-

-

7,590

-

-

7,590

Shares issued for settlement of debt

-

-

-

-

-

-

106,275

59,432

-

165,707

Shares issued for equity investments

-

-

-

-

250,000

250

1,563,750

-

-

1,564,000

Shares issued for investments in coin offerings

-

-

250,000

250

1,563,750

-

-

1,564,000

Net loss

-

-

-

-

-

-

-

-

(653,899 )

(653,899 )
Balance, April 30, 2018

200,000

200

16,500

17

12,404,740

12,405

6,439,330

172,695

(3,908,571 )

2,716,076

For the Nine Months Ended April 30, 2019

Preferred A Stock

Preferred B Stock

Common Stock

Additional
Paid-in

Stock

Accumulated

Total Stockholders'

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Payable

Deficit

Deficit

Balance, July 31, 2018

206,000

206

16,500

17

13,004,740

13,005

11,128,689

190,245

(9,394,072 )

1,938,090
Shares and warrants for services

14,000

14

-

-

356,200

356

19,129,900

(37,065 )

-

19,093,205

Shares and warrants issued for cash investments

-

-

-

-

6,250

6

24,994

(25,000 )

-

-

Settlement of derivative liabilities

-

-

-

-

304,042

304

4,092,719

-

-

4,093,023

Imputed interest

-

-

-

-

-

-

1,803

-

-

1,803

Shares issued for settlement of debt

-

-

-

-

99,800

100

49,520

-

-

49,620

Net loss

-

-

-

-

-

-

-

-

(26,113,366 )

(26,113,366 )
Balance, April 30, 2019

220,000

220

16,500

17

13,771,032

13,771

34,427,625

128,180

(35,507,438 )

(937,625 )

The accompanying notes are an integral part of these financial statements.

5

Table of Contents

THC THERAPEUTICS INC.

CONSOLIDATED STATEMENT OF CASHFLOWS

(UNAUDITED)

For the Nine Months Ended

April 30,
2019

April 30,
2018

Cash Flows from Operating Activities

Net loss

$ (26,113,366 )

$ (653,899 )
Adjustments to reconcile net loss to net cash used by operating activities:

Loss on change in derivative liabilities

3,591,477

(39,274 )
Initial loss on derivative liabilities

459,638

Impairment expense

2,429,981

-

Amortization of original issue discount

-

5,610

Amortization of debt discount

154,932

69,185

Increase in note pricipal as a result of penalties

30,907

-

Stock based compensation

19,093,205

242,119

Depreciation and amortization

19,116

19,012

Inputed interest

1,803

2,121

Loss on settlement of debts

37,500

132,234

Changes in operating assets and liabilities

(Increase) decrease in deposits

-

3,208

Increase in prepaid assets

-

-

Increase (decrease) in accounts payable

26,378

24,678

Increase (decrease) in accounts payable related party

155,965

44,884

Net cash from operating activities

(112,464 )

(150,122 )

Cash Flows from investing

Purchase of intangible assets

(1,195 )

(532 )
Net cash used in investing activities

(1,195 )

(532 )

Cash Flows from Financing Activities

Proceeds from related party debts

89,504

142,344

Payments on related party debts

(106,717 )

(72,840 )
Proceeds of convertible loans, net

177,500

-

Proceeds from sale of common stock and warrants

-

65,000

Proceeds from loans

-

30,000

Payments on loans

(17,253 )

(11,800 )
Net cash from financing activities

143,034

152,704

Net increase (decrease) in Cash

29,375

2,050

Beginning cash balance

2,969

187

Ending cash balance

$ 32,344

$ 2,237

Supplemental disclosure of cash flow information

Cash paid for interest

$ -

$ -

Cash paid for tax

$ -

$ -

The accompanying notes are an integral part of these financial statements.

6

Table of Contents

THC THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDTED)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – THC Therapeutics, Inc., (referred to as the “Company”) is focused developing its patented product, the dHydronator®, a sanitizing herb dryer. The main function of the dHydronator is to greatly accelerate the drying time of a herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, but it has been specifically tested for use with cannabis, and it can reduce the drying time for cannabis from 10-14 days to less than 14 hours.

History – The Company was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc.

On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. The Company’s health spa plans are part of the Company’s strategic focus on revenue generation and creating shareholder value.

On January 17, 2018, the Company changed its name to Millennium Blockchain Inc.

On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

THC Therapeutics, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2. BASIS OF PRESENTATION AND GOING CONCERN

Basis of Presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Audited Financial Statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent Annual Audited Financial Statements have been omitted.

Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $35,507,438 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

3. SUMMARY OF SIGNIFICANT POLICIES

This summary of significant accounting policies of THC Therapeutics, Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

7

Table of Contents

Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and Cash Equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $32,344 and $2,969 in cash and no cash equivalents as of April 30, 2019 and July 31, 2018, respectively.

Concentration Risk – At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of April 30, 2019, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue Recognition:

Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Goodwill and Intangible Assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other.” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Long-Lived Assets – In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the nine months ended April 30, 2019 and 2018 the Company recorded an impairment expense of $2,429,981 and $0, respectively.

Segment Reporting – Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.

8

Table of Contents

Income Taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-Based Compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2019 and 2018, totaled $19,093,205 and $242,119, respectively.

Earnings (Loss) Per Share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share.” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

Advertising Costs – The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $26,383 and $24,274 during the nine months ended of April 30, 2019 and 2018, respectively.

Recently Issued Accounting Pronouncements – In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASU 2018-07 effective August 1, 2019 for. Upon adoption of the standard is not expected to have an impact on our financial position or results of operations for the nine months ending April 30, 2019 and 2018.

In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018.

We will plan to adopt ASC 842 effective August 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on August 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less.

The Company has evaluated all other recent accounting pronouncements, and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

4. FIXED ASSETS

Fixed assets consist of the following as of April 30, 2019 and July 31, 2018:

April 30,
2019

July 31,
2018

dHydronator prototype

$ 27,100

$ 27,100

Float Spa and associated equipment

60,000

60,000

Office furniture and equipment

532

532

Less: accumulated depreciation

(45,157 )

(29,335 )
Fixed assets, net

$ 42,475

$ 58,297

Depreciation expense for the nine months ended April 30, 2019, and 2018, was $15,822 and $15,777, respectively.

9

Table of Contents

5. INTANGIBLE ASSETS

Intangible assets consist of the following as of April 30, 2019 and July 31, 2018:

April 30,
2019

July 31,
2018

Patents and patents pending

$ 19,699

$ 18,504

Trademarks

1,275

1,275

Website and domain names

15,098

15,098

Less: accumulated depreciation

(9,884 )

(6,590 )
Intangible assets, net

$ 26,188

$ 28,287

Amortization expense for the nine months ended April 30, 2019, and 2018, was $3,294 and $3,235 respectively.

6. ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY

On July 31, 2018, the Company entered into a Common Stock Purchase Agreement with and closed on (i) the purchase of rights to 10,536,315 “IRON” cryptographic tokens of Robot Cache, S.L., a Spanish limited company (“Robot Cache”), and (ii) a right of first refusal to purchase up to 3% of the capital stock of Robot Cache in a subsequent equity financing, in consideration of the Company’s issuance of 600,000 shares of the Company’s common stock to Robot Cache, and non-cashless warrants to purchase 300,000 shares of the Company’s common.

These non-cashless warrants are exercisable through the earlier of July 31, 2021, and the date that is 30 days after the date that the 5-day volume-weighted average price of the Company’s common stock exceeds the exercise price for the warrants by 25%. The exercise price for the warrants is staggered as follows: 500,000 shares at $7.50/share, 500,000 shares at $10.00/share, 500,000 shares at $15.00/share, 500,000 shares at $20.00/share, and 1,000,000 shares at $50.00/share.

In accordance with ASC 820, the company valued its investment in rights to Robot Cache’s tokens and equity based upon the unadjusted quoted prices of its common stock and the fair value of the warrants issued as consideration on the execution date of the agreement. The Company determined the value of the shares issued as consideration to be $2.80 per common share or $1,680,000. The stock warrants were valued at $749,981 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $2.80; exercise prices: from $7.50 to $50.00 per share; term: 3 years; risk-free interest rate: 2.77%; and volatility: 232%. The investment was recorded at cost basis and on the date of the investment.

During the quarter ending January 31, 2019, the Company was notified that due to Robot Cache’s regulatory constraints, the Company would not be receiving Robot Cache tokens. Robot Cache expressed an intent to restructure the investment with a replacement equity instrument. The Company was unable to determine with any certainty the value of the replacement equity instrument that may be issued; as a result, the Company has impaired the Robot Cache rights in full, and an impairment expense of $2,429,981 was recorded.

7. ADVANCES FROM RELATED PARTIES

Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, previously agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. Advances are due within ten (10) days of demand and bear interest at 5% annually.

10

Table of Contents

Advances from related parties consist of the following as of April 30, 2019:

Principal as of

Nine months ending
April 30, 2019

Principal as of

Accrued
interest balance
As of

July 31,
2018

Funds
advanced

Funds
repaid

April 30,
2019

April 30,
2019

B. Romanek, President and CEO

$ 96,023

$ 82,654

$ (106,713 )

$ 71,960

$ 9,907

Shareholder Relative of our President and CEO

63,543

6,850

-

70,363

4,006

TOTAL

$ 159,566

$ 89,504

$ (106,717 )

$ 142,353

$ 13,913

8. RELATED PARTY TRANSACTIONS

On November 1, 2017, we entered into an employment agreement with Brandon Romanek, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provides services to the Company in exchange for $78,000 per year plus vacation and bonuses as approved annually by the board of directors, as well as reimbursement of expenses incurred.

On February 1, 2019, we emended the employment agreement with Brandon Romanek, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provides services to the Company in exchange for $178,000 per year plus vacation and bonuses as approved annually by the board of directors, as well as reimbursement of expenses incurred.

During the nine months ending April 30, 2019, the Company accrued $88,074 due to Mr. Romanek related to this agreement. As of April 30, 2019, Mr. Romanek has allowed the Company to defer all compensation earned to date related to his employment agreements totaling $149,780.

On April 25, 2019, Fiorenzo “Enzo” Villani was appointed a member of the Company’s Board of Directors. The Company issued 13,000 shares of the Company’s Series A Preferred Stock to Mr. Villani in consideration of his appointment as a member of the Company’s Board of Directors. The shares were deemed fully earned at the date of grant. In accordance with ASC 820, the Company valued the shares issued based upon the unadjusted quoted prices of its common stock on the execution date of the agreement to which the preferred stock issued as consideration are convertible and determined the value to be $13.55 per common share or $1,355 per preferred share or $17,615,000. He will also be issued 1,661 shares of the Company’s common stock per quarter beginning July 31, 2019.

9. NOTES PAYABLE

Notes Payable at consists of the following:

April 30,

July 31,

2019

2018

On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of April 30, 2019, $11,800 in principal payments had been paid. The Company imputed interest at a rate of 5%; during the nine months ending April 30, 2019, the Company recorded imputed interest of $1,803.

48,200

48,200

On July 3, 2018, the Company issued a $28,000 promissory note; the note carries an interest rate of 12% and is payable in 24 monthly installments of $1,307 beginning November 1, 2018. As of April 30, 2019, $17,253 in principal payments had been paid. During the six months ending April 30, 2019, the Company recorded interest expense of $1,115 during the nine months ending April 30, 2019.

On January 4, 2018, the Company settled all outstanding principal and interest through the execution of settlement agreement in which the Company agreed to issue the debtholder 99,880 shares of the Company’s common stock. The fair value of the shares was $49,620; a loss on settlement of debt of $37,500 was recorded as a result of the debt settlement.

-

28,000

Total

48,200

76,200

11

Table of Contents

10. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable at consists of the following:

April 30,

July 31,

2019

2018

On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $100,000 in connection with the original issue discount and the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note.

During the quarter ending April 30, 2019, the noteholder notified the Company that it had elected to enforcing certain default rights. As a result, the principal amount of the note increased by $33,932 and the interest rate increased to 16%. They further notified the Company that they had chosen to waive all other default rights.

Further, the Company recognized a derivative liability of $170,560 and an initial loss of $78,060 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $61,955.

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $78,966 and $21,034 during the years ended July 31, 2018 and 2017, respectively.

$ 133,932

100,000

Unamortized debt discount

-

-

Total, net of unamortized discount

133,932

100,000

On March 25, 2019, we entered into a master convertible promissory note pursuant to which we may borrow up to $250,000 in $50,000 tranches.

On March 25, 2019 we borrowed $50,000, net of debt issuance costs and investor legal fees of $7,000 resulting in the Company receiving $43,000.

Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on March 25, 2020. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price equal to the lesser of (i) the lowest Trading Price during the previous twenty-five (25) Trading Day period ending on the latest complete Trading Day prior to the date of this Note or (ii) Variable Conversion Price of 60% multiplied by the lowest Trading Price for the Common Stock during the twenty-five (25) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.

The Company recorded a debt discount in the amount of $50,000 in connection with the original issuance discount, offering costs and initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $4,932 during the nine months ended April 30, 2019.

Further, the Company recognized a derivative liability of $170,215 and an initial loss of $120,218 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $57,981.

50,000

-

Unamortized debt discount

(45,068 )

-

Total, net of unamortized discount

4,932

-

Total

$ 138,864

$ -

12

Table of Contents

Convertible notes settled

On January 4, 2019, we entered into a convertible promissory note pursuant to which we borrowed $150,000, net of debt issuance costs of $15,500 resulting in the Company receiving $134,500. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on October 3, 2019. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 50% of the lowest trading price of our common stock during the previous 20 days to the date of the notice of conversion.

The Company recorded a debt discount in the amount of $150,000 in connection with the initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $150,000 during the nine months ended April 30, 2019.

Further, the Company recognized a derivative liability of $289,420 and an initial loss of $154,920 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $3,649,041.

On September 21, 2018, all principal and accrued interest of $150,000 and $5,474, respectively was converted into 256,082 shares of the Company’s common stock.

Derivative liability

The Company accounts for the fair value of the conversion features of its convertible debt in accordance with ASC Topic No. 815-15 “Derivatives and Hedging; Embedded Derivatives” (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Company values the embedded derivatives using the Black-Scholes pricing model.

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2018, and April 30, 2019:

Amount

Balance July 31, 2017

$ 146,229

Debt discount originated from derivative liabilities

-

Initial loss recorded

-

Adjustment to derivative liability due to debt settlement

-

Change in fair market value of derivative liabilities

(86,444 )
Balance July 31, 2018

$ 59,785

Debt discount originated from derivative liabilities

177,500

Initial loss recorded

459,638

Adjustment to derivative liability due to debt settlement

(3,938,461 )
Change in fair market value of derivative liabilities

3,591,477

Balance April 30, 2019

$ 349,939

The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at the date of issuance and April 30, 2019:

Fair value assumptions – derivative notes:

Date of
issuance

April 30,
2019

Risk free interest rate

1.14-2.57
%

2.39 %
Expected term (years)

1.00-0.75

0.90-0.01

Expected volatility

390.76-458.59
%

457.23 %
Expected dividends

0

0

13

Table of Contents

11. STOCK WARRANTS

The following is a summary of warrant activity during the year ended July 31, 2018, and nine months ending April 30, 2019:

Number of
Shares

Weighted Average Exercise Price

Balance, July 31, 2017

12,500

$ 10.00

Warrants granted and assumed

403,750

$ 21.56

Warrants expired

-

-

Warrants canceled

-

-

Warrants exercised

-

-

Balance, July 31, 2018

416,250

$ 21.21

Warrants granted and assumed

195,000

2.05

Warrants expired

-

-

Warrants canceled

-

-

Warrants exercised

-

-

Balance, April 30, 2019

611,250

$ 15.10

611,250 of the warrants outstanding as of April 30, 2019 were exercisable.

On March 25, 2019, the Company issued stock warrants to purchase 5,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $10.00. The stock warrants are exercisable any time after issuance and have a life of 3 years. The value the warrants is embedded in the debt discount of the associated convertible promissory note. The valuation of the debt discount associated with the warrants was $36,247 which was made using the following assumptions: stock price at grant: $7.25; exercise price: $10.00; term: 3 years; risk-free interest rate: 2.49%; volatility: 459%.

On January 4, 2019, the Company issued stock warrants to purchase 150,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $1.00. The stock warrants are exercisable any time after issuance and have a life of 5 years. The value the warrants is embedded in the debt discount of the associated convertible promissory note. The valuation of the debt discount associated with the warrants was $74,699 which was made using the following assumptions: stock price at grant: $0.50; exercise price: $1.00; term: 5 years; risk-free interest rate: 2.49%; volatility: 391%.

On November 29, 2018, Company issued 20,000 stock warrants to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The stock warrants were valued at $19,954 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $1.01; exercise price: $5.00; term: 2 years; risk-free interest rate: 2.81%; volatility: 394%.

14

Table of Contents

12. SHAREHOLDERS’ DEFICIT

Overview

The Company’s authorized capital stock consists of 500,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock.

As of April 30, 2019, and July 31, 2018, the Company had 13,771,032 and 13,004,740 shares of common stock issued and outstanding, respectively.

As of April 30, 2019, and July 31, 2018, the Company had 220,000 and 206,000 shares of Series A Preferred Stock issued and outstanding, respectively.

As of April 30, 2019, and July 31, 2018, the Company had 16,500 and 16,500 shares of Series B Preferred Stock issued and outstanding, respectively.

The Company also has 47,130 shares payable in relation to prior agreements which were valued based upon their respective agreement dates at $128,180.

On December 7, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the Company’s 1:10 reverse stock split of the Company’s common stock and preferred stock. The reverse stock split took effect on December 10, 2018. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the stock split as if such stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split.

Series A Preferred Stock

On January 24, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series A Preferred Stock,” consisting of three million (3,000,000) shares, par value $0.001.

Under the Certificate of Designation, holders of the Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (100) shares of common stock for every one (1) share of Series A Preferred Stock. The holders are further entitled to vote together with the holders of the Company’s common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference.

Series B Preferred Stock

On May 12, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series B Preferred Stock,” consisting of up to one hundred twenty thousand (120,000) shares, par value $0.001. On June 5, 2017, the Company amended the designation to increase the number of shares of Series B Preferred Stock to one hundred sixty-five thousand (165,000) shares, par value $0.001.

Under the Certificate of Designation, as amended, holders of Series B Preferred Stock are entitled to a liquidation preference on the stated value of $10.00 per share. The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $10.00 divided by the prior day’s closing price as quoted on OTC Markets. Holders of Series B Preferred Stock are not entitled to any voting or dividend rights.

As of April 30, 2019, no shares of Series B Preferred Stock eligible for mandatory conversion have been converted into common stock.

Issuances of Common and Preferred Stock for the nine months ended April 30, 2019

On August 27, 2018, the Company agreed to issue 1,000 shares of the Company’s Series A Preferred Stock to a legal consultant for services rendered in the quarter ending October 31, 2018. The shares were deemed fully earned at the date of grant. In accordance with ASC 820, the Company valued the shares issued based upon the unadjusted quoted prices of its common stock on the execution date of the agreement to which the preferred stock issued as consideration are convertible and determined the value to be $3.148 per common share or $314.80 per preferred share or $314,800.

15

Table of Contents

Shares issued and payable for services

On December 16, 2017, the Company agreed to issue 16,250 shares of common stock to a financial consultant for accounting services. The shares were fair valued at $48,263 at the date of grant. The shares are fully vested. 16,200 shares were issued during the nine months ended April 30, 2019 and 50 shares remain payable to the consultant.

On June 1, 2018, the Company agreed to issue 5,000 shares of common stock to a financial consultant for accounting services rendered during the month of June 2018. The shares were fair valued at $17,550 at the date of grant. The shares vested immediately upon issuance. The shares were issued during the nine months ended April 30, 2019.

On September 28, 2018, the Company agreed to issue 50,000 shares of common stock to a financial consultant for accounting services rendered during the quarter ending October 31, 2018. The shares were fair valued at $35,000 at the date of grant. The shares vested immediately upon issuance.

On November 28, 2018, the Company agreed to issue 25,000 shares of common stock to a healthcare consultant for services rendered during the quarter ended January 31, 2019. The shares were fair valued at $26,225 at the date of grant. The shares vested immediately upon issuance. As of January 31, 2019, the shares had not yet been issued.

On November 29, 2018, the Company agreed to issue 15,000 shares of common stock and 20,000 warrants to purchase shares of the Company’s common stock at a price of $5.00 for a period of two years to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The shares and warrants were fair valued at $35,089 at the date of grant. The shares vested immediately upon issuance. 12,500 shares were issued during the nine months ended April 30, 2019, and 2,500 shares remain payable to the Consultant.

On November 29, 2018, the Company agreed to issue 12,500 shares of common stock and 20,000 warrants to purchase shares of the Company’s common stock at a price of $5.00 for a period of two years to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The shares and warrants were fair valued at $32,567 at the date of grant. The shares vested immediately upon issuance.

On January 29, 2019, the Company agreed to issue 100,000 shares of common stock to a business advisory consultant for services rendered in the quarter ending January 31, 2019. The shares were fair valued at $70,000 at the date of grant. The shares vested immediately upon issuance.

Shares issued and payable for private placements

On March 5, 2018, the Company received $25,000 from an investor pursuant to a private placement agreement with the investor to purchase 6,250 shares of the Company’s common stock and 6,250 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of three years. The shares were issued during the nine months ended April 30, 2019.

On April 6, 2018, the Company received $40,000 from an investor pursuant to a private placement agreement with the investor to purchase 10,000 shares of the Company’s common stock and 25,000 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of five years. As of April 30, 2019, the shares had not yet been issued.

Shares payable for debt settlement

On March 31, 2018, the Company and a lender agreed to settle a $30,000 promissory note and associated accrued interest of $3,473. The Company agreed to issue 9,500 shares of the Company’s common stock and warrants to purchase 19,500 shares of the Company’s common stock at $0.20 for a three-year term. In return for the consideration, the Lender agreed to release the Company from all amounts owed. As of April 30, 2019, the shares had not yet been issued.

On January 4, 2019, the Company and a lender agreed to settle a $10,747 promissory note and associated accrued interest of $1,373. The Company agreed to issue 99,880 shares of the Company’s common stock. In return for the consideration the Lender agreed to release the Company from all amounts owed. 99,800 shares were issued during the nine months ended April 30, 2019 and 80 shares remain payable to the lender.

13. COMMITMENTS AND CONTINGENCIES

The Company does not own any real property. Currently the Company leases approximately 750 square feet of 1,300 shared mixed-use office and living space in San Diego, California, at a monthly rent of $3,300, of which 50% is reimbursed by our CEO, Mr. Romanek, for his personal shared use of the space. The lease term ended January 31, 2019, as of April 30, 2019 the Company’s continues to lease the space on a month-to-month basis. There is no obligation for the landlord to continue to lease the Company the space on the same terms in future months.

16

Table of Contents

14. SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to April 30, 2019, to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements other the events disclosed below.

Rescission of prior agreement

On May 3, 2019, the Company and BurstIQ rescinded the Simple Agreement for Future Tokens (the “SAFT”) and Simple Agreement for Future Equity (the “SAFE”) previously entered into by the parties, the parties released claims against the other, and 500,000 shares of Company common stock previously issued to BurstIQ pursuant to the SAFT and SAFE shall be returned and cancelled.

Conversion of convertible promissory notes

On May 27, 2019, a Noteholder elected to convert $68,932 of principal and $17,042 of accrued interest into 18,499 shares of the Company common stock in accordance with the rights under their convertible promissory note dated May 9, 2017

On June 7, 2019, a Noteholder elected to convert $35,000 of principal, $30,000 in default principal and $16,384 of accrued interest into 26,596 shares of the Company common stock in accordance with the rights under their convertible promissory note dated May 9, 2017.

Repayment of a promissory note

On May 3, 2019, The Company repaid $48,200 in outstanding principal under its promissory note dated May 12, 2017. The Company has no further obligations under the note as a result of the repayment.

Convertible promissory note

On May 1, 2019, we entered into a convertible promissory note pursuant to which we borrowed $200,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on May 1, 2021. The note is convertible six months after the issuance date at the noteholder’s option into shares of our common stock at a Variable Conversion Price of 65% multiplied by the lowest Trading Price for the Common Stock during the ten (10) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.

17

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements in this report, including statements in the following discussion, are what are known as “forward looking statements,” which are basically statements about the future. For that reason, these statements involve risk and uncertainty since no one can accurately predict the future. Words such as “plans,” “intends,” “will,” “hopes,” “seeks,” “anticipates,” “expects” and the like often identify such forward looking statements, but are not the only indication that a statement is a forward-looking statement. Such forward looking statements include statements concerning our plans and objectives with respect to the present and future operations of the Company, and statements which express or imply that such present and future operations will or may produce revenues, income or profits. Numerous factors and future events could cause the Company to change such plans and objectives or fail to successfully implement such plans or achieve such objectives, or cause such present and future operations to fail to produce revenues, income or profits. Therefore, the reader is advised that the following discussion should be considered in light of the discussion of risks and other factors contained in this report on Form 10-K and in the Company’s other filings with the Securities and Exchange Commission. No statements contained in the following discussion should be construed as a guarantee or assurance of future performance or future results.

Overview

THC Therapeutics, Inc. (the “Company”), was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc. On January 17, 2018, the Company changed its name to Millennium Blockchain Inc. On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc. THC Therapeutics, Inc., together with its subsidiaries, is collectively referred to herein as the “Company,” and “THC Therapeutics.”

The Company is focused on developing a sanitizing herb dryer, the dHydronator®, which has been specifically designed for the drying and sanitizing (i.e., reducing the bacterial count) of freshly harvested cannabis, and other herbs, flowers, and tea leaves.

Corporate History

THC Therapeutics, Inc., was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc. On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. On January 17, 2018, the Company changed its name to Millennium BlockChain Inc. On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

The Company’s fiscal year end is July 31^st, its telephone number is (702) 602-8422, and the address of its principal executive office is 645 Front St., #2202, San Diego, California, 92101.

Description of Business

The Company is focused on operations in the wellness industry. The Company is developing a sanitizing herb dryer, the dHydronator®, with multiple design, function, and usage patents. This innovative, laboratory-proven product is specifically designed for the drying and sanitizing (i.e., reducing the bacterial count) of freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator® can reduce moisture content of cannabis to 10-15% in only 10-14 hours. Traditional herbal drying times can take up to two weeks. Additionally, after the Company has launched the dHydronator®, and depending on available funding, the Company intends to establish a float spa facility that will allow each guest to customize their wellness experience, at their own pace, based on their individual needs.

Effective November 20, 2017, the Company entered into a Joint Venture Agreement with ADVFN plc of the United Kingdom (“ADVFN”) to create a joint venture entity, MJAC InvestorsHub International Conferences Limited, to be owned 50/50 by the Company and ADVFN. Effective April 1, 2018, we and ADVFN terminated the joint venture agreement.

Wellness Operations

THC Therapeutics is focused on the wellness industry, with plans to develop a patented herb dryer as well as an innovative float spa facility in Las Vegas, Nevada, or southern California.

The Company is developing a sanitizing herb dryer, the dHydronator®, with multiple design, function, and usage patents. This innovative, laboratory-proven¹ product is specifically designed for the drying and sanitizing (i.e., reducing the bacterial count) of freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator® can reduce moisture content of cannabis to 10-15% in only 10-14 hours, and can significantly reduce the bacterial count of the cannabis during the drying process. Traditional herbal drying times can take up to two weeks. The dHydronator will not eliminate all bacteria from the cannabis or other plant materials.

18

Table of Contents

The Company has a functioning prototype of the dHydronator® similar in design to that shown below, which is now protected by a patent with the United States Patent and Trademark Office (see “Patent, Trademark, License & Franchise Restrictions and Contractual Obligations & Concessions” below), and once the Company has sufficient funds available, the Company plans to source parts for serial manufacturing and negotiate and secure serial manufacturing and assembly. The Company also plans to hire sales and marketing staff as funds are available.

¹Tests were conducted in 2016-2017 by independent cannabis-testing labs: first by CannLabs on the first-generation dHydronator® prototype, and later by Digipath Labs on the second-generation prototype. Optimal cannabis moisture content is 8-12%. The initial testing by CannLabs showed that (i) moisture content across five wet cannabis samples was reduced to an average moisture content of 13.81% with a standard deviation of 4.04% after 12 hours of drying, and 8.86% with a standard deviation of 2.25% after 16 hours of drying, and (ii) after autoclaving cannabis flowers to ensure sterility and then spiking multiple samples with 100 CFU of E. Coli and Salmonella bacteria and Aspergillus niger mold, testing for the presence of the bacteria and mold by both quantitative polymerase chain reaction (qPCR) and traditional plating methods, which testing concluded that the dHydronator® prototype eliminated or reduced the bacteria and mold contamination, but did not quantify the results. The subsequent testing by Digipath Labs on the second-generation prototype covered multiple strains and independent tests to confirm the prior findings. The strains tested were Lucy Diamond, Cotton Candy, Blue Dream, Kings Cut, Pot of Gold and Diablo. The optimal drying time was determined to be 10-14 hours in the first test. The Company’s proprietary sanitizing technology brought the failing TAC (total aerobic count) from over 300,000 CFU/g down to 78,000 CFU/g (anything less than 100,000 CFU/g is considered “passing”) in the second test. In the third test, after drying 14 hours and 15.5 hours in the dHydronator® and using the Company’s proprietary sanitizing technology for a longer period, the moisture content had been reduced from 80% (at 0 hours) to 10.89% (at 14 hours) and 8.83% (at 15.5 hours), the THCA% had been reduced from 21.2% (at 0 hours) to 17.26% (at 14 hours) and 18.26% (at 15.5 hours), and the TAC had been reduced from 210,000 CFU/g (at 0 hours) to 1,500 CFU/g (at 14 hours) and 500 CFU/g (at 15.5 hours). In the fourth experiment, after 12 hours and 15.5 hours of drying in the dHydronator® and using the proprietary sanitizing technology for a longer period than required, the moisture content had reduced from 80% to 12.00% (at 12 hours) and 7.44% (at 15.5 hours), the THCA% had been reduced from 21.2% to 20.08% (at 12 hours) and 19.43% (at 15.5 hours), and the TAC had been reduced from 190,000 CFU/g to 51,000 CFU/g (at 12 hours) and 2,300 CFU/g (at 15.5 hours). In the fifth test, prior moisture and THCA% results were tested, but this time using the Company’s proprietary sanitizing technology for a much shorter time period, using two samples of a different cannabis strain, and testing the expanded cannabinoid profile data of each sample, and after 12 hours of drying two different samples, moisture content for the two samples decreased from 74% and 74% to 9.17% and 9.90%, respectively, and THCA% increased from 14.45% and 14.94% before drying to 16.81% and 17.2%, respectively, after 12 hours of drying. Test six was a test of the same strain as test five but using a different lot of plant material, and moisture content decreased from 81% to 11.5% after 12 hours of drying, while TCHA% increased from 21.28% to 22.6% after 12 hours of drying. The seventh through ninth tests confirmed prior results.

More specifically, once we have at least $2,000,000 in in available cash flow or funds from other operations and if we receive the patent, we intend to engage in further development efforts as follows: (i) finalizing case design, with an estimated tooling expense of approximately $300,000-$500,000; manufacturing pre-production units for field testing and presentation to potential partners and distributors, with an estimated expense of $250,000; (iii) hiring a subject-matter expert and consultants or employees in the home herb garden and legal cannabis marketplace to manage the development and sales of herb dryer, with an estimated expense of $400,000 for 12 months; (iv) engaging in further detailed laboratory of our herb drying with respect to cannabis plants and home herb garden plants, with an estimated expense of $50,000 to $100,000 for 12 months; (v) establishing a relationship with a market research and/or marketing company to explore creative strategies, advertising concepts, and consumer opinion, explore applications of our intellectual property in the existing wholesale and retail distribution channels for home herb, garden products and legal cannabis markets, and determine the best path for sales, distribution and licensing of our intellectual property, with an estimated expense of $1,000,000 for 12 months.

19

Table of Contents

Additionally, on May 12, 2017, the Company entered into an asset purchase agreement with a third party under which it acquired four (4) float spa units and associated equipment. With the acquisition of these assets, the Company intends to establish a float spa facility that will allow each guest to customize their wellness experience, at their own pace, based on their individual needs.

Legacy Crypto-Related Assets

The Company had previously focused some of its efforts on seeking partnerships with blockchain technology companies (each a “Target Company”). During calendar 2018, the Company issued shares of its common stock and preferred stock to three Target Companies, BurstIQ, ImpactPPA, and Robot Cache, in exchange for rights to tokens and/or equity purchase rights in the Target Companies. We have not received any tokens or equity of any of the Target Companies, we have rescinded our agreements with BurstIQ, we are currently negotiating terminations or rescissions of our agreements with ImpactPPA and Robot Cache, and we do not believe we will ever acquire any tokens or equity of any of the Target Companies.

Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto for the three and nine months ending April 30, 2019, and related management discussion herein.

Our financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United States (“GAAP”).

Going Concern Qualification

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred cumulative net losses of $35,507,438 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern.

Net Loss from Operations

The Company had a net loss of $26,113,366 for the nine months ended April 30, 2019, as compared to a net loss of $653,899 for the nine months ended April 30, 2018.

Liquidity and Capital Resources

At April 30, 2019, we had $32,344 of cash on hand and an accumulated deficit of $34,427,625. Our primary source of liquidity has been from borrowing from related parties and third parties, and the sale of common stock. As of April 30, 2019, the Company owed $142,353 in outstanding related party notes, with $13,913 in accrued interest on those notes, and $187,064 in outstanding notes payable, net of debt discounts of $45,068 due to outside parties, with $31,527 in accrued interest on these notes.

Net cash used in operating activities was $112,464 during the nine months ended April 30, 2019.

Net cash used in investing activities was $1,195 during the nine months ended April 30, 2019.

Net cash provided by financial activities was $143,034 during the nine months ended April 30, 2019.

Our expenses to date are largely due to professional fees that include accounting, audit and legal fees. To date, we have had minimal revenues, and we require additional financing in order to finance our business activities on an ongoing basis.

20

Table of Contents

Cash Flow

Our primary source of liquidity has been cash from shareholder loans, third party loans, and cash from the issuance of common stock.

Working Capital

We had current assets of $34,344 and current liabilities of $1,038,632, resulting in working capital deficit of $1,006,288 at April 30, 2019.

Results of Operations for the three months ended April 30, 2019, compared with the three months ended April 30, 2018

Revenues

We had no revenue during the three months ended April 30, 2019, as we are still developing our herb dryer product.

Operating and Administrative Expenses

Operating expenses increased by $18,466,500, from $226,602 in the three months ended April 30, 2018, to $18,693,102 in the three months ended April 30, 2019. Operating expenses primarily consist of other general and administrative expenses (G&A), research & development applications and professional fees. G&A expenses, made up primarily of office expense, bank charges, advertising, press releases, postage and delivery expense, travel expense and the dues and subscriptions, decreased by $16,133, from $42,142 in the three months ended April 30, 2018, to $25,009 in the three months ended April 30, 2019. Professional fees, made up of accounting and legal fees, increased by $21,232, from $23,192 in the three months ended April 30, 2018, to $35,424 in the three months ended April 30, 2019. These are fees we pay to accountants and attorneys throughout the year for performing various tasks. Consulting fees made up primarily of consulting fees and stock-based compensation to consultants, increased by $18,444,014, from $135,486 in the three months ended April 30, 2018, to $18,579,500 in the three months ended April 30, 2019. The bulk of the increase was the result of increased stock-based compensation issued in the quarter ending April 30, 2019, for the appointment of our new member of the Board of Directors, Mr. Villani, as compared to the same period in 2018.

Other Income (Expense)

Gain/(loss) on change in derivative liability increased by $3,248,867 during the three months ended April 30, 2019, as compared to the same period in 2018, due to change in derivative liabilities caused by fluctuations in the price of our common stock between reporting periods. Interest expense increased by $171,664 during the nine months ended April 30, 2019, as compared to the same period in 2018, due to an increase in outstanding loans, and amortization of debt discounts associated with convertible notes during the same period.

Results of Operations for the nine months ended April 30, 2019, compared with the nine months ended April 30, 2018

Revenues

We had no revenue during the nine months ended April 30, 2019, as we are still developing our sanitizing herb dryer product.

Operating and Administrative Expenses

Operating expenses increased by $18,895,759, from $472,317 in the nine months ended April 30, 2018, to $19,368,076 in the nine months ended April 30, 2019. Operating expenses primarily consist of other general and administrative expenses (G&A), research & development applications and professional fees. G&A expenses, made up primarily of office expense, bank charges, advertising, press releases, postage and delivery expense, travel expense and the dues and subscriptions, decreased by $31,524, from $108,191 in the nine months ended April 30, 2018, to $76,667 in the nine months ended April 30, 2019. Professional fees, made up of accounting and legal fees, increased by $44,500, from $46,336 in the nine months ended April 30, 2018, to $90,836 in the nine months ended April 30, 2019. These are fees we pay to accountants and attorneys throughout the year for performing various tasks. Consulting fees made up primarily of consulting fees and stock-based compensation to consultants, increased by $18,835,742, from $257,641 in the nine months ended April 30, 2018, to $19,093,383 in the nine months ended April 30, 2019. The bulk of the increase was the result of increased stock-based compensation issued in the nine months ending April 30, 2019, for the appointment of our new member of the Board of Directors, Mr. Villani, as compared to the same period in 2018.

21

Table of Contents

Other Income (Expense)

Gain/(loss) on change in derivative liability increased by $4,090,389 during the nine months ended April 30, 2019, as compared to the same period in 2018, due to settlements of derivative liabilities and change in derivative liabilities caused by fluctuations in the price of our common stock between reporting periods. Loss on settlement of debts decreased by $94,734 during the nine months ended April 30, 2019, as compared to the same period in 2018, because the company settle less debts in the prior period. Interest expense decreased by $138,072 during the nine months ended April 30, 2019, as compared to the same period in 2018, due to decrease in outstanding loans, and convertible notes during the same period. Impairment expense increased by $2,429,981 during the nine months ended April 30, 2019, as compared to the same period in 2018, because the Company did not impair any assets in the prior comparative period.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean the company’s controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC’s rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer (“CEO”) (who is also our chief financial officer (“CFO”)), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures are not designed to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported with the time periods specified. Our CEO and CFO also concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.

During the period, we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. The Company does not have an Audit Committee to oversee management activities, and the Company is dependent on third party consultants for the financial reporting function.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended April 30, 2019, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

22

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company is not a party to any significant pending legal proceedings other than as disclosed below, and no other such proceedings are known to be contemplated. No director, officer or affiliate of the Company and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

On May 3, 2019, THC Therapeutics, Inc. (the “Company”) entered into a settlement agreement with BurstIQ Analytics Corporation, a Colorado corporation (“BurstIQ”), dated April 29, 2019, pursuant to which (i) the Company and BurstIQ rescinded the Simple Agreement for Future Tokens (the “SAFT”) and Simple Agreement for Future Equity (the “SAFE”) previously entered into by the parties, (ii) the suit filed by BurstIQ against the Company in the District Court for Denver County, Colorado (case no. 2018CV034649) shall be dismissed with prejudice, (iii) the parties released claims against the other, and (iv) 500,000 shares of Company common stock previously issued to BurstIQ pursuant to the SAFT and SAFE shall be cancelled.

ITEM 1A. RISK FACTORS.

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On January 4, 2019, the Company and a lender agreed to settle a $10,747 promissory note and associated accrued interest of $1,373. The Company agreed to issue 99,880 shares of the Company’s common stock to the lender. In return for the consideration, the lender agreed to release the Company from all amounts owed. 99,800 shares were issued during the nine months ended April 30, 2019, and 80 shares remain payable to the lender.

On January 29, 2019, the Company agreed to issue 100,000 shares of common stock to a business advisory consultant for services rendered in the quarter ending January 31, 2019.

These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, as there was no general solicitation and the transactions did not involve a public offering.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

ITEM 5. OTHER INFORMATION.

None.

23

Table of Contents

ITEM 6. EXHIBITS.

Number		Description
3.1		Bylaws (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.2		Articles of Incorporation filed May 1, 2007 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.3		Articles of Amendment filed January 23, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.4		Articles of Amendment filed January 17, 2018 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.5		Certificate of Designation for Series A Preferred Stock filed January 24, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.6		Certificate of Designation for Series B Preferred Stock May 12, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.7		Amended Certificate of Designation for Series B Preferred Stock filed June 5, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

3.8		Articles of Amendment filed September 28, 2018 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.1		Asset Purchase Agreement with Brandon Romanek dated January 20, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.2		Asset Purchase Agreement with Urban Oasis Float Center, LLC dated June 1, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.3		MPQ Tokens Purchase Agreement with ImpactPPA Limited dated May 8, 2018 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.4		Employment Agreement with Brandon Romanek dated November 1, 2017 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.5		Common Stock Purchase Agreement with Robot Cache, S.L. dated July 31, 2018 (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

10.6*		Employment Agreement with Enzo Villani dated April 25, 2019

21.		Subsidiaries (incorporated by reference to our Registration Statement on Form 10 filed on October 19, 2018)

31.1*		Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of CFO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

32.2*		Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema Document

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

____________

* Filed herewith.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

24

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	THC THERAPEUTICS, INC.

Date: June 14, 2019	By:	/s/ Brandon Romanek
		Brandon Romanek
		CEO

EX-10.6 2 thct_ex106.htm EMPLOYMENT AGREEMENT thct_ex106.htm

EXHIBIT 10.6

THC Therapeutics Inc-THCT

DIRECTOR AGREEMENT

THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 4/25/2019, and is by and between THC Therapeutics, Inc., a Nevada corporation and a public company traded on the quotation board operated by OTC Markets Group, Inc. [OTC: THCT] (hereinafter referred to as the “Company”), and Fiorenzo A. Villani (hereinafter referred to as the “Director”).

WHEREAS, it is essential to the Company to retain and attract as directors the most capable persons available to serve on the board of directors of the Company (the “Board”).

WHEREAS, the Board believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and desires to appoint the Director to fill an existing vacancy on the Board and to perform the duties of a Director.

WHEREAS the Director desires to be so appointed for such position and to perform the duties required of such position in accordance with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows: 

1. DUTIES.  

a. The Director will serve as a director of the Company and perform all duties as a director of the Company, including without limitation (a) attending meetings of the Board, likely to occur quarterly on an in-person basis or more frequently by telephone, (b) serving, if requested, on one or more committees of the Board (each a “Committee”) and attending meetings of each Committee of which Director is a member, and (c) using reasonable efforts to promote the business of the Company. In fulfilling his responsibilities as a director of the Company, Director agrees that he shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.

b. The Director will perform such duties described herein in accordance with the applicable laws and rules and regulations pertaining to the Director’s performance hereunder, including without limitation, laws, rules and regulations relating to a public company.

c. The Director will at all times act as a fiduciary in the service and best interests of the Company.  In addition, the Director agrees to (i) provide all information regarding himself or herself as the Company requires to satisfy its disclosure obligations under applicable securities laws; (ii) timely file with the Securities and Exchange Commission all reports and schedules required of the Director in his or her personal capacity by virtue of his or her relationship with the Company (e.g. Forms 3, 4 and 5 as contemplated by Section 16(a) of the Securities Exchange Act of 1934).

2. [RESERVED].

3. TERM.  The term of this Agreement (the “Directorship Term”) shall commence as of the date of the Director’s appointment by the Board of Directors of the Company and shall continue until the next annual meeting of the stockholders, or until the Director’s removal or resignation. 

4. COMPENSATION.  For all services to be rendered by the Director in any capacity hereunder, the Company and Director agree as follows: 

At execution of this agreement, Thirteen Thousand (13,000) Series A shares Preferred Shares will be to Thrust Capital, Ltd, A Bermuda limited liability company 100% controlled by Fiorenzo A. Villani. Thirteen thousand (13,000) Series A Preferred Shares will be delivered within 7 business days of the closing of this agreement Series A shares convert into 100 shares of common stock = 1.3 million shares after all shares are converted.

B. For services rendered by Director pursuant to this Agreement, the Company agrees to pay the Director shares of Company common stock equivalent to a payment of $90,000 per annum, payable quarterly on the first day of each fiscal quarter beginning [July 31st], valued based on the closing price listed on the OTCMarkets OTCQB service as of the date hereof. Such stock will be considered restricted stock under the Securities Act of 1933, and Rule 144 promulgated thereunder. Shares will be prorated the first year

C. NO OTHER BENEFITS OR COMPENSATION. Director acknowledges and agrees that he/she is not granted and is not entitled to any other benefits or compensation from the Company for the services provided under this Agreement.

5. EXPENSES.  In addition to the compensation provided in paragraph 4, the Company will reimburse the Director for reasonable travel costs associated with attending four Board of Director meetings in Las Vegas/San Diego each year, as well as other pre-approved reasonable business related expenses incurred in good faith in the performance of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a signed statement itemizing the expenses incurred.  Such statement shall be accompanied by sufficient documentary matter to support the expenditures.

6. LIMITATION OF LIABILITY. In no event shall the Director be individually liable or have personal recourse to the Company or its stockholders for any damages for breach of fiduciary duty as an Director of the Company, unless Director’s act or failure to act involves intentional gross misconduct, fraud, criminal acts or a knowing violation of law.

7. D&O INSURANCE. The Company does not currently maintain a policy or policies of Director and Officer (D&O) liability insurance, and the Director acknowledges this fact. Upon the Company’s receipt of D&O liability insurance coverage, the Director shall be included as an additional insured under such D&O insurance policy.

8. DIRECTOR COVENANTS:

a. Unauthorized Disclosure.  The Director agrees and understands that in the Director’s position with the Company, the Director  will have has been and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company’s products, promotions, pricing, sourcing, development, financing, expansion plans, business policies and practices, and other forms of information considered by the Company to be confidential and in the nature of trade secrets. The Director agrees that during the Directorship Term and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent of the Company, or use such information for his or her own benefit or for the benefit of any third person; provided, however, that the Director may, after giving prior notice to the Company to the extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental regulations or judicial or regulatory process. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy at the Company’s direction all property, notes, memoranda, writings, lists, files, reports, customer lists, correspondence, technical data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form, which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s position with the Company during or prior to the Directorship Term.

b. [Reserved].

c. Insider Trading Guidelines.  Director agrees to never participate in any insider trading and will comply with any policies adopted by the Company that are applicable to directors, such as an Insider Trading Policy.

d. Remedies.  The Director agrees that any breach of the terms of this Section 8 would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; the Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from the Director.

e. Survival.  The provisions of this Section 8 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of the covenants and agreements of this Section 8.

9. TERMINATION.  With or without cause, either party may terminate this Agreement at any time upon BOARD VOTE FROM 75% OF THE BOARD WOULD TERMINATE A BOARD MEMBER and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination. Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing the Director with immediate effect at any time for any reason. 

10. [RESERVED].  

11. EFFECT OF WAIVER.  The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed as a waiver of any subsequent breach thereof. 

12. NOTICES. All notices must be in writing. A notice may be delivered to a party at the address that follows a party’s signature BELOW or to a new address that a party designates in writing. A notice may be delivered in person, by certified mail, or by overnight courier.  

13. GOVERNING LAW.  This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the laws of the State of Nevada without reference to that state’s conflicts of laws principles. 

14. ASSIGNMENT.  The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder shall inure to the benefit of, and be enforceable by or against, its successors and assigns.  The duties and obligations of the Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without the prior written consent of the Company. 

15. MISCELLANEOUS.  If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such invalidity or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same manner as if the invalid or illegal provision had not been contained herein. 

16. PARAGRAPH HEADINGS.  The paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

17. COUNTERPARTS.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument.  Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes. 

18. ENTIRE AGREEMENT.  Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to such subject matter.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have caused this Director Agreement to be duly executed and signed effective as of the day and year first above written.

THE COMPANY:

THC Therapeutics, Inc.

/s/ Brandon Romanek
Name: Brandon Romanek
Title: Founder & CEO

THE DIRECTOR:

Fiorenzo A. Villani,

Managing Partner, Thrust Capital, Ltd.

/s/ Fiorenzo A. Villani
Individually

EX-31.1 3 thct_ex311.htm CERTIFICATION thct_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Brandon Romanek, certify that:

1.	I have reviewed this Form 10-Q of THC Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: June 14, 2019	By:	/s/ Brandon Romanek
		Brandon Romanek
		Chief Executive Officer

EX-31.2 4 thct_ex312.htm CERTIFICATION thct_ex312.htm

EXHIBIT 31.2

CERTIFICATIONS

I, Brandon Romanek, certify that:

1.	I have reviewed this Form 10-Q of THC Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: June 14, 2019	By:	/s/ Brandon Romanek
		Brandon Romanek
		Chief Financial Officer

EX-32.1 5 thct_ex321.htm CERTIFICATION thct_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of THC Therapeutics, Inc. (the “Company”) on Form 10-Q for the fiscal period ended April 30, 2019 (the “Report”), I, Brandon Romanek, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1)	The Report fully complies with the requirement of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

2)	The information contained in the Report fairly presents, in all material respects, the Company’s financial position and results of operations.


Date: June 14, 2019	By:	/s/ Brandon Romanek
		Brandon Romanek
		Chief Executive Officer

EX-32.2 6 thct_ex322.htm CERTIFICATION thct_ex322.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of THC Therapeutics, Inc. (the “Company”) on Form 10-Q for the fiscal period ended April 30, 2019 (the “Report”), I, Brandon Romanek, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1)	The Report fully complies with the requirement of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

2)	The information contained in the Report fairly presents, in all material respects, the Company’s financial position and results of operations.


Date: June 14, 2019	By:	/s/ Brandon Romanek
		Brandon Romanek
		Chief Financial Officer

EX-101.INS 7 thct-20190430.xml XBRL INSTANCE DOCUMENT 0001404935 2018-08-01 2019-04-30 0001404935 2019-04-30 0001404935 2018-07-31 0001404935 us-gaap:PreferredClassAMember 2019-04-30 0001404935 us-gaap:PreferredClassAMember 2018-07-31 0001404935 us-gaap:PreferredClassBMember 2018-07-31 0001404935 2017-08-01 2018-04-30 0001404935 2017-07-31 0001404935 us-gaap:PatentsMember 2018-07-31 0001404935 us-gaap:TrademarksMember 2018-07-31 0001404935 us-gaap:InternetDomainNamesMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember 2018-07-01 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceOneMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceOneMember 2018-07-01 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceTwoMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceTwoMember 2018-07-01 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceThreeMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceThreeMember 2018-07-01 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceFourMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceFourMember 2018-07-01 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceFiveMember 2018-07-31 0001404935 THCT:CommonStockPurchaseAgreementMember THCT:ExercisePriceFiveMember 2018-07-01 2018-07-31 0001404935 us-gaap:WarrantMember 2018-08-01 2019-04-30 0001404935 THCT:BRomanekPresidentAndCEOMember 2018-08-01 2019-04-30 0001404935 THCT:ShareholderRelativeOfOurPresidentAndCEOMember 2018-08-01 2019-04-30 0001404935 THCT:BRomanekPresidentAndCEOMember 2018-07-31 0001404935 THCT:ShareholderRelativeOfOurPresidentAndCEOMember 2018-07-31 0001404935 us-gaap:ChiefExecutiveOfficerMember 2018-08-01 2019-04-30 0001404935 THCT:NotesPayableOneMember 2018-07-31 0001404935 THCT:NotesPayableTwoMember 2018-07-31 0001404935 2017-08-01 2018-07-31 0001404935 THCT:DerivativeLiabilitiesMember 2018-08-01 2019-04-30 0001404935 THCT:DerivativeLiabilitiesMember srt:MaximumMember 2018-08-01 2019-04-30 0001404935 THCT:DerivativeLiabilitiesMember srt:MinimumMember 2018-08-01 2019-04-30 0001404935 us-gaap:WarrantMember 2017-08-01 2018-07-31 0001404935 us-gaap:WarrantMember 2017-07-31 0001404935 us-gaap:WarrantMember 2018-07-31 0001404935 2018-12-01 2018-12-07 0001404935 us-gaap:PreferredClassAMember 2017-01-24 0001404935 us-gaap:PreferredClassAMember 2017-01-01 2017-01-24 0001404935 us-gaap:PreferredClassBMember THCT:ConsultantMember 2018-08-27 0001404935 THCT:ConsultantMember 2017-12-16 0001404935 THCT:ConsultantMember THCT:JuneOneTwoThousandEighteenMember 2019-04-30 0001404935 THCT:ConsultantMember 2018-09-28 0001404935 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2018-03-05 0001404935 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2018-03-01 2018-03-05 0001404935 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2018-04-06 0001404935 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2018-04-01 2018-04-06 0001404935 us-gaap:CommercialPaperMember 2018-03-31 0001404935 us-gaap:CommercialPaperMember us-gaap:WarrantMember 2018-03-31 0001404935 us-gaap:CommercialPaperMember us-gaap:WarrantMember 2018-03-01 2018-03-31 0001404935 us-gaap:PreferredClassBMember 2017-05-12 0001404935 2019-02-01 2019-04-30 0001404935 2018-02-01 2018-04-30 0001404935 us-gaap:PreferredClassBMember 2019-04-30 0001404935 THCT:PriorAgreementMember 2019-04-30 0001404935 us-gaap:PreferredClassBMember 2017-06-05 0001404935 us-gaap:PreferredClassBMember 2017-06-01 2017-06-05 0001404935 THCT:ConsultantMember 2019-04-30 0001404935 THCT:ConsultantMember 2018-11-28 0001404935 us-gaap:CommercialPaperMember 2019-01-04 0001404935 THCT:ConsultantMember 2018-11-29 0001404935 THCT:ConsultantMember us-gaap:WarrantMember 2018-11-29 0001404935 THCT:ConsultantMember us-gaap:WarrantMember 2018-11-01 2018-11-29 0001404935 THCT:ConsultantMember THCT:NovemberTewentyNine2018Member 2019-04-30 0001404935 THCT:ConsultantOneMember 2018-11-29 0001404935 THCT:ConsultantOneMember us-gaap:WarrantMember 2018-11-29 0001404935 THCT:ConsultantOneMember us-gaap:WarrantMember 2018-11-01 2018-11-29 0001404935 THCT:ConsultantOneMember THCT:NovemberTewentyNine2018Member 2019-04-30 0001404935 THCT:ConsultantMember 2019-01-29 0001404935 2007-05-01 2019-01-31 0001404935 us-gaap:PatentsMember 2019-04-30 0001404935 us-gaap:TrademarksMember 2019-04-30 0001404935 us-gaap:InternetDomainNamesMember 2019-04-30 0001404935 us-gaap:WarrantMember 2019-04-30 0001404935 us-gaap:WarrantMember srt:MinimumMember 2019-04-30 0001404935 us-gaap:WarrantMember srt:MaximumMember 2019-04-30 0001404935 THCT:BRomanekPresidentAndCEOMember 2019-04-30 0001404935 THCT:ShareholderRelativeOfOurPresidentAndCEOMember 2019-04-30 0001404935 us-gaap:ChiefExecutiveOfficerMember 2019-04-30 0001404935 THCT:NotesPayableOneMember 2019-04-30 0001404935 THCT:NotesPayableTwoMember 2019-04-30 0001404935 us-gaap:ConvertibleNotesPayableMember 2019-04-30 0001404935 us-gaap:ConvertibleNotesPayableMember 2018-07-31 0001404935 THCT:ConvertibleNotesPayableOneMember 2019-04-30 0001404935 THCT:ConvertibleNotesPayableOneMember 2018-07-31 0001404935 THCT:DerivativeLiabilitiesMember THCT:DateOfIssuanceMember srt:MinimumMember 2018-08-01 2019-04-30 0001404935 THCT:DerivativeLiabilitiesMember THCT:DateOfIssuanceMember srt:MaximumMember 2018-08-01 2019-04-30 0001404935 THCT:ConsultantMember 2018-11-01 2018-11-29 0001404935 THCT:LenderMember 2019-01-04 0001404935 THCT:LenderMember 2019-01-01 2019-01-04 0001404935 THCT:NotesPayableThreeMember 2019-04-30 0001404935 THCT:NotesPayableThreeMember 2018-01-31 0001404935 2019-06-12 0001404935 THCT:PreferredAStockMember 2017-08-01 2018-04-30 0001404935 THCT:PreferredAStockMember 2018-08-01 2019-04-30 0001404935 THCT:PreferredAStockMember 2017-07-31 0001404935 THCT:PreferredAStockMember 2018-04-30 0001404935 THCT:PreferredAStockMember 2018-07-31 0001404935 THCT:PreferredAStockMember 2019-04-30 0001404935 THCT:PreferredBStockMember 2017-08-01 2018-04-30 0001404935 THCT:PreferredBStockMember 2018-08-01 2019-04-30 0001404935 THCT:PreferredBStockMember 2017-07-31 0001404935 THCT:PreferredBStockMember 2018-04-30 0001404935 THCT:PreferredBStockMember 2018-07-31 0001404935 THCT:PreferredBStockMember 2019-04-30 0001404935 us-gaap:CommonStockMember 2017-08-01 2018-04-30 0001404935 us-gaap:CommonStockMember 2018-08-01 2019-04-30 0001404935 us-gaap:CommonStockMember 2017-07-31 0001404935 us-gaap:CommonStockMember 2018-04-30 0001404935 us-gaap:CommonStockMember 2018-07-31 0001404935 us-gaap:CommonStockMember 2019-04-30 0001404935 us-gaap:AdditionalPaidInCapitalMember 2017-08-01 2018-04-30 0001404935 us-gaap:AdditionalPaidInCapitalMember 2018-08-01 2019-04-30 0001404935 us-gaap:AdditionalPaidInCapitalMember 2017-07-31 0001404935 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0001404935 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001404935 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001404935 THCT:StockPayableMember 2017-08-01 2018-04-30 0001404935 THCT:StockPayableMember 2018-08-01 2019-04-30 0001404935 THCT:StockPayableMember 2017-07-31 0001404935 THCT:StockPayableMember 2018-04-30 0001404935 THCT:StockPayableMember 2018-07-31 0001404935 THCT:StockPayableMember 2019-04-30 0001404935 us-gaap:RetainedEarningsMember 2017-08-01 2018-04-30 0001404935 us-gaap:RetainedEarningsMember 2018-08-01 2019-04-30 0001404935 us-gaap:RetainedEarningsMember 2017-07-31 0001404935 us-gaap:RetainedEarningsMember 2018-04-30 0001404935 us-gaap:RetainedEarningsMember 2018-07-31 0001404935 us-gaap:RetainedEarningsMember 2019-04-30 0001404935 2018-04-30 0001404935 us-gaap:ChiefExecutiveOfficerMember THCT:OnFebruary12019Member 2018-08-01 2019-04-30 0001404935 THCT:BoardOfDirectorsMember us-gaap:SeriesAPreferredStockMember 2019-04-25 0001404935 2019-07-31 0001404935 THCT:DerivativeLiabilitiesMember THCT:DateOfIssuanceMember 2018-08-01 2019-04-30 0001404935 us-gaap:ConvertibleNotesPayableMember 2019-01-04 0001404935 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-01-04 0001404935 2018-09-21 0001404935 2019-09-01 2019-09-21 0001404935 THCT:LenderMember 2019-03-25 0001404935 THCT:LenderMember 2019-03-01 2019-03-25 0001404935 THCT:LenderMember 2019-04-30 0001404935 us-gaap:CommercialPaperMember 2019-04-30 0001404935 us-gaap:SubsequentEventMember THCT:RescissionOfPriorAgreementMember THCT:BurstIQMember 2019-05-03 0001404935 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2019-05-01 2019-05-31 0001404935 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2019-05-31 0001404935 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2019-06-01 2019-06-07 0001404935 us-gaap:SubsequentEventMember us-gaap:ConvertibleNotesPayableMember 2019-06-07 0001404935 us-gaap:SubsequentEventMember THCT:PromissoryNoteMember 2019-05-01 2019-05-03 0001404935 us-gaap:SubsequentEventMember THCT:OnMay12019Member us-gaap:ConvertibleNotesPayableMember 2019-04-30 0001404935 us-gaap:SubsequentEventMember THCT:OnMay12019Member us-gaap:ConvertibleNotesPayableMember 2018-08-01 2019-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure THCT:Number THC Therapeutics, Inc. 0001404935 2019-04-30 --07-31 Yes false Non-accelerated Filer true Q3 2019 13834098 10-Q

142353

159566

96023

63543

71960

70363

48200

76200

48200

28000

349939

59785

146229

220

206

0.001

10000000

3000000

16500

3000000

120000

16500

165000

236500

222500

220000

206000

16500

13000

236500

222500

220000

206000

16500

90836

46336

78000

35424

23192

178000

-26113366

-653899

-22131089

-244058

-35507438

-653899

-26113366

89504

142344

82654

6850

-106717

-72840

-106713

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $32,344 and $2,969 in cash and no cash equivalents as of April 30, 2019 and July 31, 2018, respectively.

false

138864

100000

138864

150000

200000

0.001

500000000

13771032

13004740

16200

12500

1661

500000

13771032

13004740

Description of business – THC Therapeutics, Inc., (referred to as the “Company”) is focused developing its patented product, the dHydronator®, a sanitizing herb dryer. The main function of the dHydronator is to greatly accelerate the drying time of a herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, but it has been specifically tested for use with cannabis, and it can reduce the drying time for cannabis from 10-14 days to less than 14 hours.   History – The Company was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc.   On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. The Company’s health spa plans are part of the Company’s strategic focus on revenue generation and creating shareholder value.   On January 17, 2018, the Company changed its name to Millennium Blockchain Inc.   On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.   THC Therapeutics, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.

Basis of Presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Audited Financial Statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent Annual Audited Financial Statements have been omitted.   Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $35,507,438 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

This summary of significant accounting policies of THC Therapeutics, Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.   Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.    Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.   Cash and Cash Equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $32,344 and $2,969 in cash and no cash equivalents as of April 30, 2019 and July 31, 2018, respectively.   Concentration Risk – At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of April 30, 2019, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.   Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.   As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.   The three levels of the fair value hierarchy are described below:   Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;   Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;   Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).   Revenue Recognition:   Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.   Goodwill and Intangible Assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other.” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.   Long-Lived Assets – In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the nine months ended April 30, 2019 and 2018 the Company recorded an impairment expense of $2,429,981 and $0, respectively.   Segment Reporting – Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.    Income Taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.   Stock-Based Compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.   Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2019 and 2018, totaled $19,093,205 and $242,119, respectively.   Earnings (Loss) Per Share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share.” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.   Advertising Costs – The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $26,383 and $24,274 during the nine months ended of April 30, 2019 and 2018, respectively.   Recently Issued Accounting Pronouncements – In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASU 2018-07 effective August 1, 2019 for. Upon adoption of the standard is not expected to have an impact on our financial position or results of operations for the nine months ending April 30, 2019 and 2018.   In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018.   We will plan to adopt ASC 842 effective August 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on August 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less.   The Company has evaluated all other recent accounting pronouncements, and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

Fixed assets consist of the following as of April 30, 2019 and July 31, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">July 31, 2018</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">dHydronator prototype</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">27,100</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">27,100</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Float Spa and associated equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">60,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">60,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Office furniture and equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">532</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">532</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Less: accumulated depreciation</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(45,157</td> <td style="vertical-align: bottom; padding-bottom: 0.75pt; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(29,335</td> <td style="vertical-align: bottom; padding-bottom: 0.75pt; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Fixed assets, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">42,475</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">58,297</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   Depreciation expense for the nine months ended April 30, 2019, and 2018, was $15,822 and $15,777, respectively.

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of April 30, 2019, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="text-align: center">Principal as of</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt">Nine months ending April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: center">Principal as of</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2">Accrued interest balance As of</td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">July 31, 2018</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Funds advanced</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Funds repaid</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">B. Romanek, President and CEO</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">96,023</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">82,654</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">(106,713</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">71,960</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">9,907</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Shareholder Relative of our President and CEO</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">63,543</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">6,850</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">70,363</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">4,006</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">TOTAL</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">159,566</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">89,504</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(106,717</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">142,353</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">13,913</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2018, and April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Amount</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance July 31, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">146,229</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Debt discount originated from derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Initial loss recorded</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Adjustment to derivative liability due to debt settlement</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Change in fair market value of derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(86,444</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance July 31, 2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">59,785</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Debt discount originated from derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">177,500</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Initial loss recorded</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">459,638</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Adjustment to derivative liability due to debt settlement</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(3,938,461</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Change in fair market value of derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">3,591,477</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance April 30, 2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">349,939</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at the date of issuance and April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">Fair value assumptions – derivative notes:</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Date of issuance</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk free interest rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">1.14-2.57</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.39</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected term (years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">1.00-0.75</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">0.90-0.01</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">390.76-458.59</td> <td style="vertical-align: bottom; text-align: justify">% </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">457.23</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected dividends</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">Number of Shares</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, July 31, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">12,500</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">10.00</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants granted and assumed</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">403,750</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">21.56</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants canceled</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, July 31, 2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">416,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">21.21</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants granted and assumed</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">195,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.05</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants canceled</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, April 30, 2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">611,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">15.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

32344

2969

42475

58297

26188

28287

2429981

101007

2519534

195583

178165

163693

7728

5474

1038632

581444

1038632

581444

128180 190245

34427625

11128690

-35507438

-9394072

-937625

1938090

101007

2519534

13771

13004

19368076

472317

18693102

226602

19116

19012

6232

6213

76667

108191

25009

41142

88074 41137 46937 20569 19093383 257641 18579500 135486

-19368076

-472317

-18693102

-226602

-6745290

-181582

-3437987

-17456

226694

88622

200393

28729

2429981

-1.99

-0.05

-1.66

-0.02

13127462

11938914

13309529

12063758

-112464

-150122

155965

44884

26378

24678

3208

37500 132234 1803 2121 2121 1803

19093205

242119

154932

69185

5610

-1195

-532

1195

532

143034

152704

30000

177500

29375

2050

32344

2969

187

2237

250000 1564000 250 1563750 250000 1564000 250 1563750

200000

206000

220000

16500

11878990

12404740

13004740

13771032

-937625

1938090

-195869

3.148

200

206

220

11879

12405

13005

13771

3046707

6439330

11128689

34427625

172695

190245

128180

-3254672

-3908571

-9394072

-35507438

2716076

13.55

25750

197426

149137

48263

65000 65000 49620 165707 100 106275 49520 59432 14000 356200 19093205 14 356 19129900 -37065 6250 6 24994 -25000 304042 4093023 304 4092719

65000

30907 2007-05-01

26383

24274

27100 27100 60000 60000

532

45157

29335

15822

15777

18504

1275

15098

19699

1275

15098

-9884

-6590

3294

3235

10536315

600000

1000

16250

5000

50000

6250

10000

9500

19500

25000

99880

15000

20000

12500

20000

100000

99880

300000 These non-cashless warrants are exercisable through the earlier of July 31, 2021, and the date that is 30 days after the date that the 5-day volume-weighted average price of the Company’s common stock exceeds the exercise price for the warrants by 25%.

500000

1000000

7.50

10.00

15.00

20.00

50.00

749981

19954

1.01

2.80

0.50

7.25

7.50

50.00

0.0277

0.0239

0.0114

0.0257

0.0281

0.0249

2.32

4.5723

3.9076

4.5859

3.94

3.91

4.59

P3Y

P0Y10M25D

P0Y0M4D

P0Y9M0D

P1Y0M0D

P2Y

P5Y

P3Y

1680000

13913

9907

4006

0.05

88074

149780

1355 314800 48263 17550 35000 26225 70000 17615000

133932

100000

50000

-45068

133932

100000

4932

177500

459638

-3938461 3591477 -86444

0.00

15500

0.10

The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 50% of the lowest trading price of our common stock during the previous 20 days to the date of the notice of conversion.

The note is convertible six months after the issuance date at the noteholder’s option into shares of our common stock at a Variable Conversion Price of 65% multiplied by the lowest Trading Price for the Common Stock during the ten (10) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.

2019-10-03

2021-05-01

150000

74699

150000

36247

289420

154920

150000

68932

35000

134500

256082

12500

416250

611250

195000

403750

10.00

21.21

15.10

2.05

21.56

20000 150000 5000 1.00 10.00

5.00

1.00

10.00

1:10

47130 50 2500 128180

The Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (10) shares of common stock for every one (1) share of Series A Preferred Stock

The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $10.00 divided by the prior day's closing price as quoted on OTC Markets

The holders are further entitled to vote together with the holders of the Company's common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference

1.00

314.80 1355 35089 32567

25000

40000

6250 25000 P3Y P5Y P3Y P2Y P2Y

2.00

0.20

5.00

30000 10747 3473 1373 80 Currently the Company leases approximately 750 square feet of 1,300 shared mixed-use office and living space in San Diego, California, at a monthly rent of $3,300, of which 50% is reimbursed by our CEO, Mr. Romanek, for his personal shared use of the space. 3300 month-to-month 30000

17042

16384

18499 26596

48200

-4051115

39274

-3237594

11273

37500

132234

17253

11800

Intangible assets consist of the following as of April 30, 2019 and July 31, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">July 31, 2018</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Patents and patents pending</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">19,699</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">18,504</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Trademarks</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">1,275</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">1,275</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Website and domain names</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">15,098</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">15,098</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Less: accumulated depreciation</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(9,884</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(6,590</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Intangible assets, net</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">26,188</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">28,287</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   Amortization expense for the nine months ended April 30, 2019, and 2018, was $3,294 and $3,235 respectively.

On July 31, 2018, the Company entered into a Common Stock Purchase Agreement with and closed on (i) the purchase of rights to 10,536,315 “IRON” cryptographic tokens of Robot Cache, S.L., a Spanish limited company (“Robot Cache”), and (ii) a right of first refusal to purchase up to 3% of the capital stock of Robot Cache in a subsequent equity financing, in consideration of the Company’s issuance of 600,000 shares of the Company’s common stock to Robot Cache, and non-cashless warrants to purchase 300,000 shares of the Company’s common.   These non-cashless warrants are exercisable through the earlier of July 31, 2021, and the date that is 30 days after the date that the 5-day volume-weighted average price of the Company’s common stock exceeds the exercise price for the warrants by 25%. The exercise price for the warrants is staggered as follows: 500,000 shares at $7.50/share, 500,000 shares at $10.00/share, 500,000 shares at $15.00/share, 500,000 shares at $20.00/share, and 1,000,000 shares at $50.00/share.   In accordance with ASC 820, the company valued its investment in rights to Robot Cache’s tokens and equity based upon the unadjusted quoted prices of its common stock and the fair value of the warrants issued as consideration on the execution date of the agreement. The Company determined the value of the shares issued as consideration to be $2.80 per common share or $1,680,000. The stock warrants were valued at $749,981 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $2.80; exercise prices: from $7.50 to $50.00 per share; term: 3 years; risk-free interest rate: 2.77%; and volatility: 232%. The investment was recorded at cost basis and on the date of the investment.   During the quarter ending January 31, 2019, the Company was notified that due to Robot Cache’s regulatory constraints, the Company would not be receiving Robot Cache tokens. Robot Cache expressed an intent to restructure the investment with a replacement equity instrument. The Company was unable to determine with any certainty the value of the replacement equity instrument that may be issued; as a result, the Company has impaired the Robot Cache rights in full, and an impairment expense of $2,429,981 was recorded. Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, previously agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. Advances are due within ten (10) days of demand and bear interest at 5% annually.   Advances from related parties consist of the following as of April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="text-align: center">Principal as of</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt">Nine months ending April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: center">Principal as of</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2">Accrued interest balance As of</td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">July 31, 2018</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Funds advanced</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Funds repaid</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">B. Romanek, President and CEO</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">96,023</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">82,654</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">(106,713</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">71,960</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">9,907</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Shareholder Relative of our President and CEO</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">63,543</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">6,850</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">70,363</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">4,006</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">TOTAL</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">159,566</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">89,504</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">(106,717</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">142,353</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">13,913</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

On November 1, 2017, we entered into an employment agreement with Brandon Romanek, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provides services to the Company in exchange for $78,000 per year plus vacation and bonuses as approved annually by the board of directors, as well as reimbursement of expenses incurred.   On February 1, 2019, we emended the employment agreement with Brandon Romanek, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provides services to the Company in exchange for $178,000 per year plus vacation and bonuses as approved annually by the board of directors, as well as reimbursement of expenses incurred.   During the nine months ending April 30, 2019, the Company accrued $88,074 due to Mr. Romanek related to this agreement. As of April 30, 2019, Mr. Romanek has allowed the Company to defer all compensation earned to date related to his employment agreements totaling $149,780.   On April 25, 2019, Fiorenzo “Enzo” Villani was appointed a member of the Company’s Board of Directors. The Company issued 13,000 shares of the Company’s Series A Preferred Stock to Mr. Villani in consideration of his appointment as a member of the Company’s Board of Directors. The shares were deemed fully earned at the date of grant. In accordance with ASC 820, the Company valued the shares issued based upon the unadjusted quoted prices of its common stock on the execution date of the agreement to which the preferred stock issued as consideration are convertible and determined the value to be $13.55 per common share or $1,355 per preferred share or $17,615,000. He will also be issued 1,661 shares of the Company’s common stock per quarter beginning July 31, 2019.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">Notes Payable at consists of the following:</td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="text-align: center">April 30,</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: center">July 31,</td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2018</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of April 30, 2019, $11,800 in principal payments had been paid. The Company imputed interest at a rate of 5%; during the nine months ending April 30, 2019, the Company recorded imputed interest of $1,803.</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">48,200</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">48,200</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top">On July 3, 2018, the Company issued a $28,000 promissory note; the note carries an interest rate of 12% and is payable in 24 monthly installments of $1,307 beginning November 1, 2018. As of April 30, 2019, $17,253 in principal payments had been paid. During the six months ending April 30, 2019, the Company recorded interest expense of $1,115 during the nine months ending April 30, 2019.   On January 4, 2018, the Company settled all outstanding principal and interest through the execution of settlement agreement in which the Company agreed to issue the debtholder 99,880 shares of the Company’s common stock. The fair value of the shares was $49,620; a loss on settlement of debt of $37,500 was recorded as a result of the debt settlement.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">28,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Total</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">48,200</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">76,200</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

Convertible Notes Payable at consists of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="text-align: center">April 30,</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="text-align: center">July 31,</td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2019</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">2018</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top">On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $100,000 in connection with the original issue discount and the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note.   During the quarter ending April 30, 2019, the noteholder notified the Company that it had elected to enforcing certain default rights. As a result, the principal amount of the note increased by $33,932 and the interest rate increased to 16%. They further notified the Company that they had chosen to waive all other default rights.   Further, the Company recognized a derivative liability of $170,560 and an initial loss of $78,060 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $61,955.   The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $78,966 and $21,034 during the years ended July 31, 2018 and 2017, respectively.</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">133,932</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">100,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Unamortized debt discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Total, net of unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">133,932</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">100,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top">On March 25, 2019, we entered into a master convertible promissory note pursuant to which we may borrow up to $250,000 in $50,000 tranches.   On March 25, 2019 we borrowed $50,000, net of debt issuance costs and investor legal fees of $7,000 resulting in the Company receiving $43,000.   Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on March 25, 2020. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price equal to the lesser of (i) the lowest Trading Price during the previous twenty-five (25) Trading Day period ending on the latest complete Trading Day prior to the date of this Note or (ii) Variable Conversion Price of 60% multiplied by the lowest Trading Price for the Common Stock during the twenty-five (25) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.   The Company recorded a debt discount in the amount of $50,000 in connection with the original issuance discount, offering costs and initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $4,932 during the nine months ended April 30, 2019.   Further, the Company recognized a derivative liability of $170,215 and an initial loss of $120,218 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $57,981.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">50,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Unamortized debt discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(45,068</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Total, net of unamortized discount</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,932</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Total</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">138,864</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>    Convertible notes settled   On January 4, 2019, we entered into a convertible promissory note pursuant to which we borrowed $150,000, net of debt issuance costs of $15,500 resulting in the Company receiving $134,500. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on October 3, 2019. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 50% of the lowest trading price of our common stock during the previous 20 days to the date of the notice of conversion.   The Company recorded a debt discount in the amount of $150,000 in connection with the initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $150,000 during the nine months ended April 30, 2019.   Further, the Company recognized a derivative liability of $289,420 and an initial loss of $154,920 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $3,649,041.   On September 21, 2018, all principal and accrued interest of $150,000 and $5,474, respectively was converted into 256,082 shares of the Company’s common stock.   Derivative liability   The Company accounts for the fair value of the conversion features of its convertible debt in accordance with ASC Topic No. 815-15 “Derivatives and Hedging; Embedded Derivatives” (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Company values the embedded derivatives using the Black-Scholes pricing model.   The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2018, and April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Amount</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance July 31, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">146,229</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Debt discount originated from derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Initial loss recorded</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Adjustment to derivative liability due to debt settlement</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Change in fair market value of derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">(86,444</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance July 31, 2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">59,785</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Debt discount originated from derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">177,500</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Initial loss recorded</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">459,638</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Adjustment to derivative liability due to debt settlement</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">(3,938,461</td> <td style="vertical-align: bottom; text-align: justify">)</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Change in fair market value of derivative liabilities</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">3,591,477</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance April 30, 2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">349,939</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at the date of issuance and April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">Fair value assumptions – derivative notes:</td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Date of issuance</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">April 30, 2019</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Risk free interest rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">1.14-2.57</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.39</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected term (years)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">1.00-0.75</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">0.90-0.01</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Expected volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="text-align: right">390.76-458.59</td> <td style="vertical-align: bottom; text-align: justify">% </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">457.23</td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Expected dividends</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table> The following is a summary of warrant activity during the year ended July 31, 2018, and nine months ending April 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">Number of Shares</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, July 31, 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">12,500</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; width: 9%; text-align: right">10.00</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants granted and assumed</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">403,750</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify">$</td> <td style="vertical-align: bottom; text-align: right">21.56</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants canceled</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, July 31, 2018</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">416,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">21.21</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants granted and assumed</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">195,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">2.05</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants canceled</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify">Warrants exercised</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right">-</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, April 30, 2019</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">611,250</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: justify">$</td> <td style="vertical-align: bottom; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right">15.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   611,250 of the warrants outstanding as of April 30, 2019 were exercisable.   On March 25, 2019, the Company issued stock warrants to purchase 5,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $10.00. The stock warrants are exercisable any time after issuance and have a life of 3 years. The value the warrants is embedded in the debt discount of the associated convertible promissory note. The valuation of the debt discount associated with the warrants was $36,247 which was made using the following assumptions: stock price at grant: $7.25; exercise price: $10.00; term: 3 years; risk-free interest rate: 2.49%; volatility: 459%.   On January 4, 2019, the Company issued stock warrants to purchase 150,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $1.00. The stock warrants are exercisable any time after issuance and have a life of 5 years. The value the warrants is embedded in the debt discount of the associated convertible promissory note. The valuation of the debt discount associated with the warrants was $74,699 which was made using the following assumptions: stock price at grant: $0.50; exercise price: $1.00; term: 5 years; risk-free interest rate: 2.49%; volatility: 391%.   On November 29, 2018, Company issued 20,000 stock warrants to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The stock warrants were valued at $19,954 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $1.01; exercise price: $5.00; term: 2 years; risk-free interest rate: 2.81%; volatility: 394%.   On November 29, 2018, Company issued 20,000 stock warrants to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The stock warrants were valued at $19,954 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $1.01; exercise price: $5.00; term: 2 years; risk-free interest rate: 2.81%; volatility: 394%.

The Company’s authorized capital stock consists of 500,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock.   As of April 30, 2019, and July 31, 2018, the Company had 13,771,032 and 13,004,740 shares of common stock issued and outstanding, respectively.   As of April 30, 2019, and July 31, 2018, the Company had 220,000 and 206,000 shares of Series A Preferred Stock issued and outstanding, respectively.   As of April 30, 2019, and July 31, 2018, the Company had 16,500 and 16,500 shares of Series B Preferred Stock issued and outstanding, respectively.   The Company also has 47,130 shares payable in relation to prior agreements which were valued based upon their respective agreement dates at $128,180.   On December 7, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the Company’s 1:10 reverse stock split of the Company’s common stock and preferred stock. The reverse stock split took effect on December 10, 2018. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the stock split as if such stock split occurred on the first day of the first period presented. Certain amounts in the notes to the financial statements may be slightly different than previously reported due to rounding of fractional shares as a result of the reverse stock split.   Series A Preferred Stock   On January 24, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series A Preferred Stock,” consisting of three million (3,000,000) shares, par value $0.001.   Under the Certificate of Designation, holders of the Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (100) shares of common stock for every one (1) share of Series A Preferred Stock. The holders are further entitled to vote together with the holders of the Company’s common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference.   Series B Preferred Stock   On May 12, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series B Preferred Stock,” consisting of up to one hundred twenty thousand (120,000) shares, par value $0.001. On June 5, 2017, the Company amended the designation to increase the number of shares of Series B Preferred Stock to one hundred sixty-five thousand (165,000) shares, par value $0.001.   Under the Certificate of Designation, as amended, holders of Series B Preferred Stock are entitled to a liquidation preference on the stated value of $10.00 per share. The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $10.00 divided by the prior day’s closing price as quoted on OTC Markets. Holders of Series B Preferred Stock are not entitled to any voting or dividend rights.   As of April 30, 2019, no shares of Series B Preferred Stock eligible for mandatory conversion have been converted into common stock.   Issuances of Common and Preferred Stock for the nine months ended April 30, 2019   On April 25, 2019, Fiorenzo “Enzo” Villani was appointed a member of the Company’s Board of Directors. The Company issued 13,000 shares of the Company’s Series A Preferred Stock to Mr. Villani in consideration of his appointment as a member of the Company’s Board of Directors. The shares were deemed fully earned at the date of grant. In accordance with ASC 820, the Company valued the shares issued based upon the unadjusted quoted prices of its common stock on the execution date of the agreement to which the preferred stock issued as consideration are convertible and determined the value to be $13.55 per common share or $1,355 per preferred share or $17,615,000.   On August 27, 2018, the Company agreed to issue 1,000 shares of the Company’s Series A Preferred Stock to a legal consultant for services rendered in the quarter ending October 31, 2018. The shares were deemed fully earned at the date of grant. In accordance with ASC 820, the Company valued the shares issued based upon the unadjusted quoted prices of its common stock on the execution date of the agreement to which the preferred stock issued as consideration are convertible and determined the value to be $3.148 per common share or $314.80 per preferred share or $314,800.    Shares issued and payable for services   On December 16, 2017, the Company agreed to issue 16,250 shares of common stock to a financial consultant for accounting services. The shares were fair valued at $48,263 at the date of grant. The shares are fully vested. 16,200 shares were issued during the nine months ended April 30, 2019 and 50 shares remain payable to the consultant.   On June 1, 2018, the Company agreed to issue 5,000 shares of common stock to a financial consultant for accounting services rendered during the month of June 2018. The shares were fair valued at $17,550 at the date of grant. The shares vested immediately upon issuance. The shares were issued during the nine months ended April 30, 2019.   On September 28, 2018, the Company agreed to issue 50,000 shares of common stock to a financial consultant for accounting services rendered during the quarter ending October 31, 2018. The shares were fair valued at $35,000 at the date of grant. The shares vested immediately upon issuance.   On November 28, 2018, the Company agreed to issue 25,000 shares of common stock to a healthcare consultant for services rendered during the quarter ended January 31, 2019. The shares were fair valued at $26,225 at the date of grant. The shares vested immediately upon issuance. As of January 31, 2019, the shares had not yet been issued.   On November 29, 2018, the Company agreed to issue 15,000 shares of common stock and 20,000 warrants to purchase shares of the Company’s common stock at a price of $5.00 for a period of two years to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The shares and warrants were fair valued at $35,089 at the date of grant. The shares vested immediately upon issuance. 12,500 shares were issued during the nine months ended April 30, 2019, and 2,500 shares remain payable to the Consultant.   On November 29, 2018, the Company agreed to issue 12,500 shares of common stock and 20,000 warrants to purchase shares of the Company’s common stock at a price of $5.00 for a period of two years to a business advisory consultant for services rendered during the quarter ended January 31, 2019. The shares and warrants were fair valued at $32,567 at the date of grant. The shares vested immediately upon issuance.   On January 29, 2019, the Company agreed to issue 100,000 shares of common stock to a business advisory consultant for services rendered in the quarter ending January 31, 2019. The shares were fair valued at $70,000 at the date of grant. The shares vested immediately upon issuance.   Shares issued and payable for private placements   On March 5, 2018, the Company received $25,000 from an investor pursuant to a private placement agreement with the investor to purchase 6,250 shares of the Company’s common stock and 6,250 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of three years. The shares were issued during the nine months ended April 30, 2019.   On April 6, 2018, the Company received $40,000 from an investor pursuant to a private placement agreement with the investor to purchase 10,000 shares of the Company’s common stock and 25,000 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of five years. As of April 30, 2019, the shares had not yet been issued.   Shares payable for debt settlement   On March 31, 2018, the Company and a lender agreed to settle a $30,000 promissory note and associated accrued interest of $3,473. The Company agreed to issue 9,500 shares of the Company’s common stock and warrants to purchase 19,500 shares of the Company’s common stock at $0.20 for a three-year term. In return for the consideration, the Lender agreed to release the Company from all amounts owed. As of April 30, 2019, the shares had not yet been issued.   On January 4, 2019, the Company and a lender agreed to settle a $10,747 promissory note and associated accrued interest of $1,373. The Company agreed to issue 99,880 shares of the Company’s common stock. In return for the consideration the Lender agreed to release the Company from all amounts owed. 99,800 shares were issued during the nine months ended April 30, 2019 and 80 shares remain payable to the lender.

The Company does not own any real property. Currently the Company leases approximately 750 square feet of 1,300 shared mixed-use office and living space in San Diego, California, at a monthly rent of $3,300, of which 50% is reimbursed by our CEO, Mr. Romanek, for his personal shared use of the space. The lease term ended January 31, 2019, as of April 30, 2019 the Company’s continues to lease the space on a month-to-month basis. There is no obligation for the landlord to continue to lease the Company the space on the same terms in future months.

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to April 30, 2019, to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements other the events disclosed below.   Rescission of prior agreement   On May 3, 2019, the Company and BurstIQ rescinded the Simple Agreement for Future Tokens (the “SAFT”) and Simple Agreement for Future Equity (the “SAFE”) previously entered into by the parties, the parties released claims against the other, and 500,000 shares of Company common stock previously issued to BurstIQ pursuant to the SAFT and SAFE shall be returned and cancelled.   Conversion of convertible promissory notes   On May 27, 2019, a Noteholder elected to convert $68,932 of principal and $17,042 of accrued interest into 18,499 shares of the Company common stock in accordance with the rights under their convertible promissory note dated May 9, 2017   On June 7, 2019, a Noteholder elected to convert $35,000 of principal, $30,000 in default principal and $16,384 of accrued interest into 26,596 shares of the Company common stock in accordance with the rights under their convertible promissory note dated May 9, 2017.   Repayment of a promissory note   On May 3, 2019, The Company repaid $48,200 in outstanding principal under its promissory note dated May 12, 2017. The Company has no further obligations under the note as a result of the repayment.   Convertible promissory note   On May 1, 2019, we entered into a convertible promissory note pursuant to which we borrowed $200,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on May 1, 2021. The note is convertible six months after the issuance date at the noteholder’s option into shares of our common stock at a Variable Conversion Price of 65% multiplied by the lowest Trading Price for the Common Stock during the ten (10) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.

The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.   As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.   The three levels of the fair value hierarchy are described below:   Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;   Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;   Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other.” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the nine months ended April 30, 2019 and 2018 the Company recorded an impairment expense of $2,429,981 and $0, respectively.

Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.

The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.   Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2019 and 2018, totaled $19,093,205 and $242,119, respectively.

The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share.” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $26,383 and $24,274 during the nine months ended of April 30, 2019 and 2018, respectively.

In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASU 2018-07 effective August 1, 2019 for. Upon adoption of the standard is not expected to have an impact on our financial position or results of operations for the nine months ending April 30, 2019 and 2018.   In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018.   We will plan to adopt ASC 842 effective August 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on August 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less.   The Company has evaluated all other recent accounting pronouncements, and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

7590 7590 99800 Nevada false

EX-101.SCH 8 thct-20190430.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENT OF CASHFLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ADVANCES FROM RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - STOCK WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SHAREHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ADVANCES FROM RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCK WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - FIXED ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - FIXED ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - ADVANCES FROM RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - ADVANCES FROM RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCK WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - STOCK WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SHAREHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 thct-20190430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 thct-20190430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 thct-20190430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Preferred A stock [Member] Preferred B stock [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents And Patents Pending [Member] Trademarks [Member] Website And Domain Names [Member] Plan Name [Axis] Common Stock Purchase Agreement [Member] Exercise Price Range [Axis] Exercise Price One [Member] Exercise Price Two [Member] Exercise Price Three [Member] Exercise Price Four [Member] Exercise Price Five [Member] Equity Components [Axis] Warrant [Member] Related Party [Axis] B Romanek, President and CEO [Member] Shareholder Relative of our President and CEO [Member] Chief Executive Officer [Member] Short-term Debt, Type [Axis] Notes Payable One [Member] Notes Payable Two [Member] Financial Instrument [Axis] Derivative Liabilities [Member] Range [Axis] Maximum [Member] Minimum [Member] Consultant [Member] Report Date [Axis] June 1, 2018 [Member] Investor [Member] Sale of Stock [Axis] Private Placement [Member] Cash and Cash Equivalents [Axis] Promissory note [Member] Prior Agreement [Member] November 29, 2018 [Member] Consultant One [Member] Convertible Promissory Note [Member] Convertible Promissory Note One [Member] Award Date [Axis] Date Of Issuance [Member] Lender [Member] Notes Payable Three [Member] Preferred A Stock Preferred B Stock Common Stock Additional Paid-In Capital Stock Payable Accumulated Deficit On February 1, 2019 [Member] Board of Directors [Member] Series A Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Rescission of prior agreement [Member] BurstIQ [Member] Debt Instrument [Axis] Promissory Note [Member] On May 1, 2019 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Current Fiscal Year End Date Is Entity's Reporting Status Current? Is Entity Emerging Growth Company? Entity Filer Category Entity Small Business Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Statement [Table] Statement [Line Items] ASSETS Current assets Cash Total current assets Fixed Assets, net Intangible Assets, net Rights to Robotcache Coins Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities Accounts payable and accrued liabilities Accrued liabilities due to related parties Advances from related parties Notes payable Convertible Notes payable, net Derivative liability Total current liabilities Total liabilities Stockholders' equity (deficit) Common stock; $0.001 par value; 500,000,000 shares authorized; 13,771,032 and 13,004,740 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively Preferred stock value Stock payable Additional paid-in capital Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Stockholders' deficit: Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Consolidated Statement Of Operations Revenues Cost of revenues Gross profit Operating expenses Professional fees Consulting fees Payroll expense General and administrative expenses Depreciation and amortization Total operating expenses Loss from operations Other income (expense) Gain/(loss) on change in derivative liability Gain/(loss) on settlement of debts Impairment expense Interest Expense Total other income (expense) Net income (loss) Basic income (loss) per common share Basic weighted average common shares outstanding Beginning balance, shares Beginning balance, amount Shares for services,shares Shares for services, amount Shares issued for cash investments Imputed interest Debt discount Shares and warrants for services, shares Shares and warrants for services, amount Shares and warrants issued for cash investments, shares Shares and warrants issued for cash investments, amount Settlement of derivative liabilities, shares Settlement of derivative liabilities, amount Shares issued for settlement of debt, shares Shares issued for settlement of debt, amount Shares issued for equity investments, shares Shares issued for equity investments, amount Shares issued for investments in coin offerings, shares Shares issued for investments in coin offerings, amount Net loss Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used by operating activities: Loss on change in derivative liabilities Impairment expense Amortization of original issue discount Amortization of debt discount Increase in note principal as a result of penalties Stock based compensation Loss on settlement of debts Changes in operating assets and liabilities (Increase) decrease in deposits Increase in prepaid assets Increase (decrease) in accounts payable Increase (decrease) in accounts payable related party Net cash from operating activities Cash Flows from investing Purchase of intangible assets Net cash used in investing activities Cash Flows from Financing Activities Proceeds from related party debts Payments on related party debts Proceeds of convertible loans, net Proceeds from sale of common stock and warrants Proceeds from loans Payments on loans Net cash from financing activities Net increase (decrease) in Cash Beginning cash balance Ending cash balance Supplemental disclosure of cash flow information Cash paid for interest Cash paid for tax Notes to Financial Statements Note 1 - DESCRIPTION OF BUSINESS AND HISTORY Note 2 - BASIS OF PRESENTATION AND GOING CONCERN Note 3 - SUMMARY OF SIGNIFICANT POLICIES EX-101.PRE 12 thct-20190430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 thct_10qimg1.jpg begin 644 thct_10qimg1.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Apr. 30, 2019	Jun. 12, 2019
Document And Entity Information
Entity Registrant Name	THC Therapeutics, Inc.
Entity Central Index Key	0001404935
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2019
Current Fiscal Year End Date	--07-31
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Common Stock, Shares Outstanding		13,834,098
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Shell Company	false

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Current assets
Cash	$ 32,344	$ 2,969
Total current assets	32,344	2,969
Fixed Assets, net	42,475	58,297
Intangible Assets, net	26,188	28,287
Rights to Robotcache Coins		2,429,981
Total assets	101,007	2,519,534
Current liabilities
Accounts payable and accrued liabilities	195,583	178,165
Accrued liabilities due to related parties	163,693	7,728
Advances from related parties	142,353	159,566
Notes payable	48,200	76,200
Convertible Notes payable, net	138,864	100,000
Derivative liability	349,939	59,785
Total current liabilities	1,038,632	581,444
Total liabilities	1,038,632	581,444
Stockholders' equity (deficit)
Common stock; $0.001 par value; 500,000,000 shares authorized; 13,771,032 and 13,004,740 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively	13,771	13,004
Stock payable	128,180	190,245
Additional paid-in capital	34,427,625	11,128,690
Accumulated deficit	(35,507,438)	(9,394,072)
Total stockholders' equity (deficit)	(937,625)	1,938,090
Total liabilities and stockholders' equity (deficit)	101,007	2,519,534
Preferred A stock [Member]
Stockholders' equity (deficit)
Preferred stock value	220	206
Preferred B stock [Member]
Stockholders' equity (deficit)
Preferred stock value	$ 17	$ 17

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018	Jun. 05, 2017	May 12, 2017	Jan. 24, 2017
Stockholders' deficit:
Common stock, par value		$ 0.001	$ 0.001
Common stock, shares authorized		500,000,000	500,000,000
Common stock, shares issued	1,661	13,771,032	13,004,740
Common stock, outstanding		13,771,032	13,004,740
Preferred stock, par value		$ 0.001	$ 0.001
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, shares issued		236,500	222,500
Preferred stock, shares outstanding		236,500	222,500
Preferred A stock [Member]
Stockholders' deficit:
Preferred stock, par value		$ 0.001	$ 0.001			$ 0.001
Preferred stock, shares authorized		3,000,000	3,000,000			3,000,000
Preferred stock, shares issued		220,000	206,000
Preferred stock, shares outstanding		220,000	206,000
Preferred B stock [Member]
Stockholders' deficit:
Preferred stock, par value		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized		16,500	16,500	165,000	120,000
Preferred stock, shares issued		16,500	16,500
Preferred stock, shares outstanding		16,500	16,500

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Consolidated Statement Of Operations
Revenues
Cost of revenues
Gross profit
Operating expenses
Professional fees	35,424	23,192	90,836	46,336
Consulting fees	18,579,500	135,486	19,093,383	257,641
Payroll expense	46,937	20,569	88,074	41,137
General and administrative expenses	25,009	41,142	76,667	108,191
Depreciation and amortization	6,232	6,213	19,116	19,012
Total operating expenses	18,693,102	226,602	19,368,076	472,317
Loss from operations	(18,693,102)	(226,602)	(19,368,076)	(472,317)
Other income (expense)
Gain/(loss) on change in derivative liability	(3,237,594)	11,273	(4,051,115)	39,274
Gain/(loss) on settlement of debts			(37,500)	(132,234)
Impairment expense			(2,429,981)
Interest Expense	(200,393)	(28,729)	(226,694)	(88,622)
Total other income (expense)	(3,437,987)	(17,456)	(6,745,290)	(181,582)
Net income (loss)	$ (22,131,089)	$ (244,058)	$ (26,113,366)	$ (653,899)
Basic income (loss) per common share	$ (1.66)	$ (0.02)	$ (1.99)	$ (0.05)
Basic weighted average common shares outstanding	13,309,529	12,063,758	13,127,462	11,938,914

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT (UNAUDITED) - USD ($)	Preferred A Stock	Preferred B Stock	Common Stock	Additional Paid-In Capital	Stock Payable	Accumulated Deficit	Total
Beginning balance, shares at Jul. 31, 2017	200,000	16,500	11,878,990
Beginning balance, amount at Jul. 31, 2017	$ 200	$ 17	$ 11,879	$ 3,046,707		$ (3,254,672)	$ (195,869)
Shares for services,shares			25,750
Shares for services, amount			$ 26	$ 149,137	$ 48,263		$ 197,426
Shares issued for cash investments					65,000		65,000
Imputed interest				2,121			2,121
Debt discount				7,590			7,590
Shares issued for settlement of debt, amount				106,275	59,432		165,707
Shares issued for equity investments, shares			250,000
Shares issued for equity investments, amount			$ 250	$ 1,563,750			1,564,000
Shares issued for investments in coin offerings, shares			250,000
Shares issued for investments in coin offerings, amount			$ 250	$ 1,563,750			1,564,000
Net loss						$ (653,899)	$ (653,899)
Ending balance, shares at Apr. 30, 2018	200,000	16,500	12,404,740
Ending balance, amount at Apr. 30, 2018	$ 200	$ 17	$ 12,405	$ 6,439,330	$ 172,695	$ (3,908,571)	$ 2,716,076
Beginning balance, shares at Jul. 31, 2018	206,000	16,500	13,004,740
Beginning balance, amount at Jul. 31, 2018	$ 206	$ 17	$ 13,005	$ 11,128,689	$ 190,245	$ (9,394,072)	$ 1,938,090
Imputed interest				$ 1,803			$ 1,803
Debt discount
Shares and warrants for services, shares	14,000		356,200
Shares and warrants for services, amount	$ 14		$ 356	19,129,900	(37,065)		19,093,205
Shares and warrants issued for cash investments, shares			6,250
Shares and warrants issued for cash investments, amount			$ 6	24,994	(25,000)
Settlement of derivative liabilities, shares			304,042
Settlement of derivative liabilities, amount			$ 304	4,092,719			4,093,023
Shares issued for settlement of debt, shares			99,800
Shares issued for settlement of debt, amount			$ 100	$ 49,520			49,620
Net loss						$ (26,113,366)	$ (26,113,366)
Ending balance, shares at Apr. 30, 2019	220,000	16,500	13,771,032
Ending balance, amount at Apr. 30, 2019	$ 220	$ 17	$ 13,771	$ 34,427,625	$ 128,180	$ (35,507,438)	$ (937,625)

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF CASHFLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Cash Flows from Operating Activities
Net loss	$ (26,113,366)	$ (653,899)
Adjustments to reconcile net loss to net cash used by operating activities:
Loss on change in derivative liabilities	4,051,115	(39,274)
Impairment expense	2,429,981
Amortization of original issue discount		5,610
Amortization of debt discount	154,932	69,185
Increase in note principal as a result of penalties	30,907
Stock based compensation	19,093,205	242,119
Depreciation and amortization	19,116	19,012
Imputed interest	1,803	2,121
Loss on settlement of debts	37,500	132,234
Changes in operating assets and liabilities
(Increase) decrease in deposits		3,208
Increase in prepaid assets
Increase (decrease) in accounts payable	26,378	24,678
Increase (decrease) in accounts payable related party	155,965	44,884
Net cash from operating activities	(112,464)	(150,122)
Cash Flows from investing
Purchase of intangible assets	(1,195)	(532)
Net cash used in investing activities	(1,195)	(532)
Cash Flows from Financing Activities
Proceeds from related party debts	89,504	142,344
Payments on related party debts	(106,717)	(72,840)
Proceeds of convertible loans, net	177,500
Proceeds from sale of common stock and warrants		65,000
Proceeds from loans		30,000
Payments on loans	(17,253)	(11,800)
Net cash from financing activities	143,034	152,704
Net increase (decrease) in Cash	29,375	2,050
Beginning cash balance	2,969	187
Ending cash balance	32,344	2,237
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for tax

XML 20 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 1 - DESCRIPTION OF BUSINESS AND HISTORY

On January 17, 2018, the Company changed its name to Millennium Blockchain Inc.

On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

THC Therapeutics, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.

XML 21 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND GOING CONCERN

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 2 - BASIS OF PRESENTATION AND GOING CONCERN

XML 22 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 3 - SUMMARY OF SIGNIFICANT POLICIES

The three levels of the fair value hierarchy are described below:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

Revenue Recognition:

Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2019 and 2018, totaled $19,093,205 and $242,119, respectively.

XML 23 R10.htm IDEA: XBRL DOCUMENT

FIXED ASSETS

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 4 - FIXED ASSETS

Fixed assets consist of the following as of April 30, 2019 and July 31, 2018:

	April 30, 2019			July 31, 2018
dHydronator prototype	$	27,100		$	27,100
Float Spa and associated equipment		60,000			60,000
Office furniture and equipment		532			532
Less: accumulated depreciation		(45,157	)		(29,335	)
Fixed assets, net	$	42,475		$	58,297

Depreciation expense for the nine months ended April 30, 2019, and 2018, was $15,822 and $15,777, respectively.

XML 24 R11.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 5 - INTANGIBLE ASSETS

Intangible assets consist of the following as of April 30, 2019 and July 31, 2018:

	April 30, 2019			July 31, 2018
Patents and patents pending	$	19,699		$	18,504
Trademarks		1,275			1,275
Website and domain names		15,098			15,098
Less: accumulated depreciation		(9,884	)		(6,590	)
Intangible assets, net	$	26,188		$	28,287

Amortization expense for the nine months ended April 30, 2019, and 2018, was $3,294 and $3,235 respectively.

XML 25 R12.htm IDEA: XBRL DOCUMENT

ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 6 - ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY

XML 26 R13.htm IDEA: XBRL DOCUMENT

ADVANCES FROM RELATED PARTIES

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 7 - ADVANCES FROM RELATED PARTIES

Advances from related parties consist of the following as of April 30, 2019:

	Principal as of		Nine months ending April 30, 2019					Principal as of		Accrued interest balance As of
	July 31, 2018		Funds advanced		Funds repaid			April 30, 2019		April 30, 2019
B. Romanek, President and CEO	$	96,023	$	82,654	$	(106,713	)	$	71,960	$	9,907
Shareholder Relative of our President and CEO		63,543		6,850		-			70,363		4,006
TOTAL	$	159,566	$	89,504	$	(106,717	)	$	142,353	$	13,913

XML 27 R14.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 8 - RELATED PARTY TRANSACTIONS

XML 28 R15.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 9 - NOTES PAYABLE

Notes Payable at consists of the following:	April 30,		July 31,
	2019		2018
On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of April 30, 2019, $11,800 in principal payments had been paid. The Company imputed interest at a rate of 5%; during the nine months ending April 30, 2019, the Company recorded imputed interest of $1,803.		48,200		48,200

On July 3, 2018, the Company issued a $28,000 promissory note; the note carries an interest rate of 12% and is payable in 24 monthly installments of $1,307 beginning November 1, 2018. As of April 30, 2019, $17,253 in principal payments had been paid. During the six months ending April 30, 2019, the Company recorded interest expense of $1,115 during the nine months ending April 30, 2019. On January 4, 2018, the Company settled all outstanding principal and interest through the execution of settlement agreement in which the Company agreed to issue the debtholder 99,880 shares of the Company’s common stock. The fair value of the shares was $49,620; a loss on settlement of debt of $37,500 was recorded as a result of the debt settlement.		-		28,000

Total		48,200		76,200

XML 29 R16.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 10 - CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable at consists of the following:

	April 30,			July 31,
	2019			2018

On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $100,000 in connection with the original issue discount and the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. During the quarter ending April 30, 2019, the noteholder notified the Company that it had elected to enforcing certain default rights. As a result, the principal amount of the note increased by $33,932 and the interest rate increased to 16%. They further notified the Company that they had chosen to waive all other default rights. Further, the Company recognized a derivative liability of $170,560 and an initial loss of $78,060 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $61,955. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $78,966 and $21,034 during the years ended July 31, 2018 and 2017, respectively.	$	133,932			100,000

Unamortized debt discount		-			-
Total, net of unamortized discount		133,932			100,000

On March 25, 2019, we entered into a master convertible promissory note pursuant to which we may borrow up to $250,000 in $50,000 tranches. On March 25, 2019 we borrowed $50,000, net of debt issuance costs and investor legal fees of $7,000 resulting in the Company receiving $43,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on March 25, 2020. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price equal to the lesser of (i) the lowest Trading Price during the previous twenty-five (25) Trading Day period ending on the latest complete Trading Day prior to the date of this Note or (ii) Variable Conversion Price of 60% multiplied by the lowest Trading Price for the Common Stock during the twenty-five (25) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Company recorded a debt discount in the amount of $50,000 in connection with the original issuance discount, offering costs and initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $4,932 during the nine months ended April 30, 2019. Further, the Company recognized a derivative liability of $170,215 and an initial loss of $120,218 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $57,981.		50,000			-
Unamortized debt discount		(45,068	)		-
Total, net of unamortized discount		4,932			-

Total	$	138,864		$	-

Convertible notes settled

On September 21, 2018, all principal and accrued interest of $150,000 and $5,474, respectively was converted into 256,082 shares of the Company’s common stock.

Derivative liability

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2018, and April 30, 2019:

	Amount
Balance July 31, 2017	$	146,229
Debt discount originated from derivative liabilities		-
Initial loss recorded		-
Adjustment to derivative liability due to debt settlement		-
Change in fair market value of derivative liabilities		(86,444	)
Balance July 31, 2018	$	59,785
Debt discount originated from derivative liabilities		177,500
Initial loss recorded		459,638
Adjustment to derivative liability due to debt settlement		(3,938,461	)
Change in fair market value of derivative liabilities		3,591,477
Balance April 30, 2019	$	349,939

The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at the date of issuance and April 30, 2019:

Fair value assumptions – derivative notes:	Date of issuance			April 30, 2019
Risk free interest rate	1.14-2.57		%		2.39	%
Expected term (years)	1.00-0.75			0.90-0.01
Expected volatility	390.76-458.59		%		457.23	%
Expected dividends		0			0

XML 30 R17.htm IDEA: XBRL DOCUMENT

STOCK WARRANTS

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 11 - STOCK WARRANTS

The following is a summary of warrant activity during the year ended July 31, 2018, and nine months ending April 30, 2019:

	Number of Shares		Weighted Average Exercise Price
Balance, July 31, 2017		12,500	$	10.00

Warrants granted and assumed		403,750	$	21.56
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, July 31, 2018		416,250	$	21.21

Warrants granted and assumed		195,000		2.05
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, April 30, 2019		611,250	$	15.10

611,250 of the warrants outstanding as of April 30, 2019 were exercisable.

XML 31 R18.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS’ DEFICIT

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

NOTE 12 - SHAREHOLDERS’ DEFICIT

The Company’s authorized capital stock consists of 500,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock.

As of April 30, 2019, and July 31, 2018, the Company had 13,771,032 and 13,004,740 shares of common stock issued and outstanding, respectively.

As of April 30, 2019, and July 31, 2018, the Company had 220,000 and 206,000 shares of Series A Preferred Stock issued and outstanding, respectively.

As of April 30, 2019, and July 31, 2018, the Company had 16,500 and 16,500 shares of Series B Preferred Stock issued and outstanding, respectively.

The Company also has 47,130 shares payable in relation to prior agreements which were valued based upon their respective agreement dates at $128,180.

Series A Preferred Stock

Series B Preferred Stock

As of April 30, 2019, no shares of Series B Preferred Stock eligible for mandatory conversion have been converted into common stock.

Issuances of Common and Preferred Stock for the nine months ended April 30, 2019

Shares issued and payable for services

Shares issued and payable for private placements

Shares payable for debt settlement

XML 32 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Apr. 30, 2019
Notes to Financial Statements
Note 13 - COMMITMENTS AND CONTINGENCIES	The Company does not own any real property. Currently the Company leases approximately 750 square feet of 1,300 shared mixed-use office and living space in San Diego, California, at a monthly rent of $3,300, of which 50% is reimbursed by our CEO, Mr. Romanek, for his personal shared use of the space. The lease term ended January 31, 2019, as of April 30, 2019 the Company’s continues to lease the space on a month-to-month basis. There is no obligation for the landlord to continue to lease the Company the space on the same terms in future months.

XML 33 R20.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Apr. 30, 2019

Notes to Financial Statements

Note 14 - SUBSEQUENT EVENTS

Rescission of prior agreement

Conversion of convertible promissory notes

Repayment of a promissory note

On May 3, 2019, The Company repaid $48,200 in outstanding principal under its promissory note dated May 12, 2017. The Company has no further obligations under the note as a result of the repayment.

Convertible promissory note

XML 34 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT POLICIES (Policies)	Apr. 30, 2019
Summary Of Significant Policies
Principles of Consolidation	The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.
Use of Estimates	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $32,344 and $2,969 in cash and no cash equivalents as of April 30, 2019 and July 31, 2018, respectively.
Concentration Risk	At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of April 30, 2019, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Fair Value of Financial Instruments	The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items. As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Revenue Recognition	Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered. Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.
Goodwill and Intangible Assets	The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other.” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.
Long-Lived Assets	In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. During the nine months ended April 30, 2019 and 2018 the Company recorded an impairment expense of $2,429,981 and $0, respectively.
Segment Reporting	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.
Income Taxes	The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Stock-Based Compensation	The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values. Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2019 and 2018, totaled $19,093,205 and $242,119, respectively.
Earnings (Loss) Per Share	The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share.” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.
Advertising Costs	The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $26,383 and $24,274 during the nine months ended of April 30, 2019 and 2018, respectively.
Recently Issued Accounting Pronouncements	In June 2018, the FASB issued ASU 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. ASU 2018-07 is effective is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASU 2018-07 effective August 1, 2019 for. Upon adoption of the standard is not expected to have an impact on our financial position or results of operations for the nine months ending April 30, 2019 and 2018. In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASC 842 effective August 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on August 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. The Company has evaluated all other recent accounting pronouncements, and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

XML 35 R22.htm IDEA: XBRL DOCUMENT

FIXED ASSETS (Tables)

9 Months Ended

Apr. 30, 2019

Fixed Assets

Schedule of fixed assets

	April 30, 2019			July 31, 2018
dHydronator prototype	$	27,100		$	27,100
Float Spa and associated equipment		60,000			60,000
Office furniture and equipment		532			532
Less: accumulated depreciation		(45,157	)		(29,335	)
Fixed assets, net	$	42,475		$	58,297

XML 36 R23.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

9 Months Ended

Apr. 30, 2019

Intangible Assets

Schedule of Intangible assets

	April 30, 2019			July 31, 2018
Patents and patents pending	$	19,699		$	18,504
Trademarks		1,275			1,275
Website and domain names		15,098			15,098
Less: accumulated depreciation		(9,884	)		(6,590	)
Intangible assets, net	$	26,188		$	28,287

XML 37 R24.htm IDEA: XBRL DOCUMENT

ADVANCES FROM RELATED PARTIES (Tables)

9 Months Ended

Apr. 30, 2019

Advances From Related Parties

Schedule of advances from related parties

	Principal as of		Nine months ending April 30, 2019					Principal as of		Accrued interest balance As of
	July 31, 2018		Funds advanced		Funds repaid			April 30, 2019		April 30, 2019
B. Romanek, President and CEO	$	96,023	$	82,654	$	(106,713	)	$	71,960	$	9,907
Shareholder Relative of our President and CEO		63,543		6,850		-			70,363		4,006
TOTAL	$	159,566	$	89,504	$	(106,717	)	$	142,353	$	13,913

XML 38 R25.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

9 Months Ended

Apr. 30, 2019

Notes Payable

Schedule of Notes Payable

Notes Payable at consists of the following:	April 30,		July 31,
	2019		2018
On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of April 30, 2019, $11,800 in principal payments had been paid. The Company imputed interest at a rate of 5%; during the nine months ending April 30, 2019, the Company recorded imputed interest of $1,803.		48,200		48,200

On July 3, 2018, the Company issued a $28,000 promissory note; the note carries an interest rate of 12% and is payable in 24 monthly installments of $1,307 beginning November 1, 2018. As of April 30, 2019, $17,253 in principal payments had been paid. During the six months ending April 30, 2019, the Company recorded interest expense of $1,115 during the nine months ending April 30, 2019. On January 4, 2018, the Company settled all outstanding principal and interest through the execution of settlement agreement in which the Company agreed to issue the debtholder 99,880 shares of the Company’s common stock. The fair value of the shares was $49,620; a loss on settlement of debt of $37,500 was recorded as a result of the debt settlement.		-		28,000

Total		48,200		76,200

XML 39 R26.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Tables)

9 Months Ended

Apr. 30, 2019

Convertible Notes Payable

Schedule Of Convertible Notes Payable

Convertible Notes Payable at consists of the following:

	April 30,			July 31,
	2019			2018

On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $100,000 in connection with the original issue discount and the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. During the quarter ending April 30, 2019, the noteholder notified the Company that it had elected to enforcing certain default rights. As a result, the principal amount of the note increased by $33,932 and the interest rate increased to 16%. They further notified the Company that they had chosen to waive all other default rights. Further, the Company recognized a derivative liability of $170,560 and an initial loss of $78,060 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $61,955. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $78,966 and $21,034 during the years ended July 31, 2018 and 2017, respectively.	$	133,932			100,000

Unamortized debt discount		-			-
Total, net of unamortized discount		133,932			100,000

On March 25, 2019, we entered into a master convertible promissory note pursuant to which we may borrow up to $250,000 in $50,000 tranches. On March 25, 2019 we borrowed $50,000, net of debt issuance costs and investor legal fees of $7,000 resulting in the Company receiving $43,000. Interest under the convertible promissory note is 10% per annum, and the principal and all accrued but unpaid interest is due on March 25, 2020. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price equal to the lesser of (i) the lowest Trading Price during the previous twenty-five (25) Trading Day period ending on the latest complete Trading Day prior to the date of this Note or (ii) Variable Conversion Price of 60% multiplied by the lowest Trading Price for the Common Stock during the twenty-five (25) Trading Day period ending on the last complete Trading Day prior to the Conversion Date. The Company recorded a debt discount in the amount of $50,000 in connection with the original issuance discount, offering costs and initial valuation of the derivative liability related to the embedded conversion option of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. The aggregate debt discount has been accreted and charged to interest expenses as a financing expense in the amount of $4,932 during the nine months ended April 30, 2019. Further, the Company recognized a derivative liability of $170,215 and an initial loss of $120,218 based on the Black-Scholes pricing model. During the nine months ending April 30, 2019, the Company recorded an additional loss on derivative liability of $57,981.		50,000			-
Unamortized debt discount		(45,068	)		-
Total, net of unamortized discount		4,932			-

Total	$	138,864		$	-

Schedule of derivative liabilities

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2018, and April 30, 2019:

	Amount
Balance July 31, 2017	$	146,229
Debt discount originated from derivative liabilities		-
Initial loss recorded		-
Adjustment to derivative liability due to debt settlement		-
Change in fair market value of derivative liabilities		(86,444	)
Balance July 31, 2018	$	59,785
Debt discount originated from derivative liabilities		177,500
Initial loss recorded		459,638
Adjustment to derivative liability due to debt settlement		(3,938,461	)
Change in fair market value of derivative liabilities		3,591,477
Balance April 30, 2019	$	349,939

The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at the date of issuance and April 30, 2019:

Fair value assumptions – derivative notes:	Date of issuance			April 30, 2019
Risk free interest rate	1.14-2.57		%		2.39	%
Expected term (years)	1.00-0.75			0.90-0.01
Expected volatility	390.76-458.59		%		457.23	%
Expected dividends		0			0

XML 40 R27.htm IDEA: XBRL DOCUMENT

STOCK WARRANTS (Tables)

9 Months Ended

Apr. 30, 2019

Stock Warrants

Schedule of summary of warrant activity

	Number of Shares		Weighted Average Exercise Price
Balance, July 31, 2017		12,500	$	10.00

Warrants granted and assumed		403,750	$	21.56
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, July 31, 2018		416,250	$	21.21

Warrants granted and assumed		195,000		2.05
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, April 30, 2019		611,250	$	15.10

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 41 R28.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)	9 Months Ended
DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative)	Apr. 30, 2019
Description Of Business And History
State of incorporation	Nevada
Date of incorporation	May 01, 2007

XML 42 R29.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		141 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Jan. 31, 2019
Basis Of Presentation And Going Concern
Net loss	$ (22,131,089)	$ (244,058)	$ (26,113,366)	$ (653,899)	$ (35,507,438)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 43 R30.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018	Jul. 31, 2017
Summary Of Significant Policies Details Narrative Abstract
Cash	$ 32,344	$ 2,237	$ 32,344	$ 2,237	$ 2,969	$ 187
FDIC limit	0		0
Impairment expense			2,429,981
Stock based compensation			19,093,205	242,119
Advertising expenses			$ 26,383	$ 24,274

XML 44 R31.htm IDEA: XBRL DOCUMENT

FIXED ASSETS (Details) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Fixed Assets Details Abstract
dHydronator prototype	$ 27,100	$ 27,100
Float Spa and associated equipment	60,000	60,000
Office furniture and equipment	532	532
Less: accumulated depreciation	(45,157)	(29,335)
Fixed Assets	$ 42,475	$ 58,297

XML 45 R32.htm IDEA: XBRL DOCUMENT

FIXED ASSETS (Details Narrative) - USD ($)	9 Months Ended
FIXED ASSETS (Details Narrative) - USD ($)	Apr. 30, 2019	Apr. 30, 2018
Fixed Assets Details Narrative Abstract
Depreciation expense	$ 15,822	$ 15,777

XML 46 R33.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Less: accumulated depreciation	$ (9,884)	$ (6,590)
Intangible Assets, net	26,188	28,287
Patents And Patents Pending [Member]
Intangible Assets, gross	19,699	18,504
Trademarks [Member]
Intangible Assets, gross	1,275	1,275
Website And Domain Names [Member]
Intangible Assets, gross	$ 15,098	$ 15,098

XML 47 R34.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - USD ($)	9 Months Ended
INTANGIBLE ASSETS (Details Narrative) - USD ($)	Apr. 30, 2019	Apr. 30, 2018
Intangible Assets Details Narrative Abstract
Amortization expense	$ 3,294	$ 3,235

XML 48 R35.htm IDEA: XBRL DOCUMENT

ROBOT CACHE – RIGHTS TO TOKENS AND EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2018	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Description of non-cashless warrants exercise price					These non-cashless warrants are exercisable through the earlier of July 31, 2021, and the date that is 30 days after the date that the 5-day volume-weighted average price of the Company’s common stock exceeds the exercise price for the warrants by 25%.
Impairment expense				$ 2,429,981
Common Stock Purchase Agreement [Member]
Class of warrants right to purchase	10,536,315
Common stock shares reserved for future issuance	600,000
Non-cashless warrants to purchase shares	300,000
Common Stock Purchase Agreement [Member] \| Exercise Price Five [Member]
Class of warrant or rights outstanding	1,000,000
Exercise price per share	$ 50.00
Common Stock Purchase Agreement [Member] \| Exercise Price Four [Member]
Class of warrant or rights outstanding	500,000
Exercise price per share	$ 20.00
Common Stock Purchase Agreement [Member] \| Exercise Price Three [Member]
Class of warrant or rights outstanding	500,000
Exercise price per share	$ 15.00
Common Stock Purchase Agreement [Member] \| Exercise Price Two [Member]
Class of warrant or rights outstanding	500,000
Exercise price per share	$ 10.00
Common Stock Purchase Agreement [Member] \| Exercise Price One [Member]
Class of warrant or rights outstanding	500,000
Exercise price per share	$ 7.50
Warrant [Member]
Fair value of stock warrants				$ 749,981
Stock price grant		$ 2.80		$ 2.80
Risk-free interest rate				2.77%
Volatility rate				232.00%
Expected term				3 years
Fair value of common stock issued as consideration				$ 1,680,000
Warrant [Member] \| Minimum [Member]
Exercise price		7.50		$ 7.50
Warrant [Member] \| Maximum [Member]
Exercise price		$ 50.00		$ 50.00

XML 49 R36.htm IDEA: XBRL DOCUMENT

ADVANCES FROM RELATED PARTIES (Details) - USD ($)	9 Months Ended
ADVANCES FROM RELATED PARTIES (Details) - USD ($)	Apr. 30, 2019	Apr. 30, 2018
Advances from related parties principal beginning	$ 159,566
Advances from related parties funds advanced	89,504	$ 142,344
Advances from related parties funds repaid	(106,717)	$ (72,840)
Advances from related parties principal ending	142,353
Accrued interest balance	13,913
B Romanek, President and CEO [Member]
Advances from related parties principal beginning	96,023
Advances from related parties funds advanced	82,654
Advances from related parties funds repaid	(106,713)
Advances from related parties principal ending	71,960
Accrued interest balance	9,907
Shareholder Relative of our President and CEO [Member]
Advances from related parties principal beginning	63,543
Advances from related parties funds advanced	6,850
Advances from related parties funds repaid
Advances from related parties principal ending	70,363
Accrued interest balance	$ 4,006

XML 50 R37.htm IDEA: XBRL DOCUMENT

ADVANCES FROM RELATED PARTIES (Details Narrative) - Chief Executive Officer [Member]	9 Months Ended
	Apr. 30, 2019 Number
Advances from related parties bear interest rate	5.00%
Advances due, days	10

XML 51 R38.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2019	Apr. 25, 2019	Jul. 31, 2018	Jul. 31, 2017
Professional fees	$ 35,424	$ 23,192	$ 90,836	$ 46,336
Preferred stock, shares issued	236,500		236,500				222,500
Common stock price per share	$ (937,625)	$ 2,716,076	$ (937,625)	$ 2,716,076			$ 1,938,090	$ (195,869)
Common stock, shares issued	13,771,032		13,771,032		1,661		13,004,740
Chief Executive Officer [Member]
Professional fees			$ 78,000
Accrued professional fees	$ 88,074		88,074
Deferred compensation	$ 149,780		149,780
Chief Executive Officer [Member] \| On February 1, 2019 [Member]
Professional fees			$ 178,000
Board of Directors [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued						13,000
Common stock price per share						$ 13.55
Preferred stock price per share						$ 1,355
Preferred stock value reserved for future issuance						$ 17,615,000

XML 52 R39.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Apr. 30, 2019	Jul. 31, 2018	Jan. 31, 2018
Notes payable	$ 48,200	$ 76,200
Notes Payable One [Member]
Notes payable	48,200	48,200
Notes Payable Two [Member]
Notes payable
Notes Payable Three [Member]
Notes payable			$ 28,000

XML 53 R40.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Apr. 30, 2019	Jan. 04, 2019	Jul. 31, 2018
Convertible Notes payable, net	$ 138,864		$ 100,000
Convertible Promissory Note [Member]
Convertible Notes payable current	133,932		100,000
Unamortized debt discount
Total, net of unamortized discount	133,932		100,000
Convertible Notes payable, net		$ 150,000
Convertible Promissory Note One [Member]
Convertible Notes payable current	50,000
Unamortized debt discount	(45,068)
Total, net of unamortized discount	4,932
Convertible Notes payable, net	$ 138,864

XML 54 R41.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	9 Months Ended	12 Months Ended
CONVERTIBLE NOTES PAYABLE (Details 1) - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Convertible Notes Payable Details 1Abstract
Beginning Balance	$ 59,785	$ 146,229
Debt discount originated from derivative liabilities	177,500
Initial loss recorded	459,638
Adjustment to derivative liability due to debt settlement	(3,938,461)
Change in fair market value of derivative liabilities	3,591,477	(86,444)
Ending Balance	$ 349,939	$ 59,785

XML 55 R42.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details 2) - Derivative Liabilities [Member]	9 Months Ended
	Apr. 30, 2019
Fair value assumptions - derivative notes:
Risk free interest rate	2.39%
Expected volatility	457.23%
Expected dividends	0.00%
Minimum [Member]
Fair value assumptions - derivative notes:
Expected term (years)	4 days
Maximum [Member]
Fair value assumptions - derivative notes:
Expected term (years)	10 months 25 days
Date Of Issuance [Member]
Fair value assumptions - derivative notes:
Expected dividends	0.00%
Date Of Issuance [Member] \| Minimum [Member]
Fair value assumptions - derivative notes:
Risk free interest rate	1.14%
Expected term (years)	9 months
Expected volatility	390.76%
Date Of Issuance [Member] \| Maximum [Member]
Fair value assumptions - derivative notes:
Risk free interest rate	2.57%
Expected term (years)	1 year
Expected volatility	458.59%

XML 56 R43.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Jan. 04, 2019	Sep. 21, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Sep. 21, 2018	Jul. 31, 2018
Convertible promissory note			$ 138,864		$ 138,864			$ 100,000
Debt discount			150,000		150,000
Derivative liability			289,420		289,420
Initial loss					154,920
Loss on change in derivative liabilities			3,237,594	$ (11,273)	4,051,115	$ (39,274)
Principal amount							$ 150,000
Accrued interest			$ 163,693		$ 163,693		$ 5,474	$ 7,728
Common stock issued to Convertible notes		256,082
Convertible Promissory Note [Member]
Convertible promissory note	$ 150,000
Debt issuance costs	$ 15,500
Interest rate	10.00%
Conversion price description	The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 50% of the lowest trading price of our common stock during the previous 20 days to the date of the notice of conversion.
Due date	Oct. 03, 2019
Debt discount	$ 150,000
Related party convertible promissory note	$ 134,500

XML 57 R44.htm IDEA: XBRL DOCUMENT

STOCK WARRANTS (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Apr. 30, 2019	Jul. 31, 2018
Number of Shares
Outstanding, Beginning Balance	416,250	12,500
Warrants granted and assumed	195,000	403,750
Warrants expired
Warrants canceled
Warrants exercised
Outstanding, Ending Balance	611,250	416,250
Weighted Average Exercise Price Per Share
Weighted Average Exercise Price, Beginning Balance	$ 21.21	$ 10.00
Warrants granted and assumed	2.05	21.56
Warrants expired
Warrants canceled
Warrants exercised
Weighted Average Exercise Price, Ending Balance	$ 15.10	$ 21.21

XML 58 R45.htm IDEA: XBRL DOCUMENT

STOCK WARRANTS (Details Narrative) - USD ($)		1 Months Ended		9 Months Ended
STOCK WARRANTS (Details Narrative) - USD ($)	Jan. 04, 2019	Mar. 25, 2019	Nov. 29, 2018	Apr. 30, 2019	Jul. 31, 2018	Jul. 31, 2017
Debt discount				$ 150,000
Warrant [Member]
Warrants outstanding				611,250	416,250	12,500
Value of warrants				$ 749,981
Stock price grant				$ 2.80
Risk free interest rate				2.77%
Expected term (years)				3 years
Expected volatility				232.00%
Consultant [Member]
Warrants to purchase common shares			20,000
Value of warrants			$ 19,954
Stock price grant			$ 1.01
Exercise price			$ 5.00
Risk free interest rate			2.81%
Expected term (years)			2 years
Expected volatility			394.00%
Lender [Member]
Warrants to purchase common shares	150,000	5,000
Strike price	$ 1.00	$ 10.00
Debt discount	$ 74,699	$ 36,247
Stock price grant	$ 0.50	$ 7.25
Exercise price	$ 1.00	$ 10.00
Risk free interest rate	2.49%	2.49%
Expected term (years)	5 years	3 years
Expected volatility	391.00%	459.00%

XML 59 R46.htm IDEA: XBRL DOCUMENT

SHAREHOLDERS’ DEFICIT (Details Narrative) - USD ($)					1 Months Ended
SHAREHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Dec. 07, 2018	Apr. 06, 2018	Mar. 05, 2018	Jun. 05, 2017	Nov. 29, 2018	Mar. 31, 2018	Jan. 24, 2017	Jul. 31, 2019	Apr. 30, 2019	Apr. 25, 2019	Jan. 29, 2019	Jan. 04, 2019	Nov. 28, 2018	Sep. 28, 2018	Aug. 27, 2018	Jul. 31, 2018	Apr. 30, 2018	Dec. 16, 2017	Jul. 31, 2017	May 12, 2017
Common stock, par value									$ 0.001							$ 0.001
Common stock, shares authorized									500,000,000							500,000,000
Common stock, shares issued								1,661	13,771,032							13,004,740
Common stock, outstanding									13,771,032							13,004,740
Preferred stock, par value									$ 0.001							$ 0.001
Preferred stock, shares authorized									10,000,000							10,000,000
Preferred stock, shares issued									236,500							222,500
Preferred stock, shares outstanding									236,500							222,500
Reverse stock split, description	1:10
Common stock price per share									$ (937,625)							$ 1,938,090	$ 2,716,076		$ (195,869)
Prior Agreement [Member]
Shares payable									47,130
Shares payable value									$ 128,180
Promissory note [Member]
Common stock shares reserved for future issuance						9,500			99,880			99,880
Debt conversion amount to be converted, principle						$ 30,000						$ 10,747
Debt conversion amount to be converted, accrued interest						$ 3,473						$ 1,373
Promissory note [Member] \| Warrant [Member]
Common stock shares reserved for future issuance						19,500
Maturity period						3 years
Strike price						$ 0.20
Preferred B stock [Member]
Preferred stock, par value				$ 0.001					$ 0.001							$ 0.001				$ 0.001
Preferred stock, shares authorized				165,000					16,500							16,500				120,000
Preferred stock, shares issued									16,500							16,500
Preferred stock, shares outstanding									16,500							16,500
Preferred Stock, terms of conversion feature				The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $10.00 divided by the prior day's closing price as quoted on OTC Markets
Preferred stock, liquidation preference				$ 1.00
Preferred A stock [Member]
Preferred stock, par value							$ 0.001		$ 0.001							$ 0.001
Preferred stock, shares authorized							3,000,000		3,000,000							3,000,000
Preferred stock, shares issued									220,000							206,000
Preferred stock, shares outstanding									220,000							206,000
Preferred Stock, terms of conversion feature							The Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (10) shares of common stock for every one (1) share of Series A Preferred Stock
Preferred stock voting rights, description							The holders are further entitled to vote together with the holders of the Company's common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference
Lender [Member]
Shares remain payable to the lender									80
Board of Directors [Member] \| Series A Preferred Stock [Member]
Preferred stock, shares issued										13,000
Common stock price per share										$ 13.55
Preferred stock price per share										$ 1,355
Common stock value reserved for future issuance										$ 17,615,000
Consultant [Member]
Common stock, shares issued									16,200
Shares payable									50
Common stock shares reserved for future issuance					15,000						100,000		25,000	50,000				16,250
Common stock value reserved for future issuance											$ 70,000		$ 26,225	$ 35,000				$ 48,263
Consultant [Member] \| November 29, 2018 [Member]
Common stock, shares issued									12,500
Shares payable									2,500
Consultant [Member] \| June 1, 2018 [Member]
Common stock shares reserved for future issuance									5,000
Common stock value reserved for future issuance									$ 17,550
Consultant [Member] \| Warrant [Member]
Common stock shares reserved for future issuance					20,000
Shares and warrants fair value					$ 35,089
Maturity period					2 years
Strike price					$ 5.00
Consultant [Member] \| Preferred B stock [Member]
Common stock shares reserved for future issuance															1,000
Common stock price per share															$ 3.148
Preferred stock price per share															$ 314.80
Common stock value reserved for future issuance															$ 314,800
Investor [Member] \| Private Placement [Member]
Common stock shares reserved for future issuance		10,000	6,250
Proceeds from private placement		$ 40,000	$ 25,000
Class of warrants or rights reserved for future issuance		25,000	6,250
Maturity period		5 years	3 years
Strike price		$ 2.00	$ 2.00
Consultant One [Member]
Common stock shares reserved for future issuance					12,500
Consultant One [Member] \| November 29, 2018 [Member]
Common stock, shares issued									12,500
Consultant One [Member] \| Warrant [Member]
Common stock shares reserved for future issuance					20,000
Shares and warrants fair value					$ 32,567
Maturity period					2 years
Strike price					$ 5.00

XML 60 R47.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Apr. 30, 2019 USD ($)
Commitments And Contingencies
Description for office lease	Currently the Company leases approximately 750 square feet of 1,300 shared mixed-use office and living space in San Diego, California, at a monthly rent of $3,300, of which 50% is reimbursed by our CEO, Mr. Romanek, for his personal shared use of the space.
Operating lease periodic rent	$ 3,300
Frequency of periodic payments	month-to-month

XML 61 R48.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)				1 Months Ended	9 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jun. 07, 2019	May 03, 2019	Jan. 04, 2019	May 31, 2019	Apr. 30, 2019	Jul. 31, 2019	Sep. 21, 2018	Jul. 31, 2018
Common stock, shares issued					13,771,032	1,661		13,004,740
Debt conversion amount converted or elected to be converted, principal							$ 150,000
Convertible promissory note					$ 138,864			$ 100,000
Convertible Promissory Note [Member]
Convertible promissory note			$ 150,000
Interest rate			10.00%
Conversion price description			The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 50% of the lowest trading price of our common stock during the previous 20 days to the date of the notice of conversion.
Due date			Oct. 03, 2019
Subsequent Event [Member] \| Promissory Note [Member]
Repayment of a promissory note		$ 48,200
Subsequent Event [Member] \| Convertible Promissory Note [Member]
Debt conversion amount converted or elected to be converted, default principal	$ 30,000
Debt conversion amount converted or elected to be converted, principal	35,000			$ 68,932
Debt conversion amount converted or elected to be converted, accrued interest	$ 16,384			$ 17,042
Common stock shares issued upon conversion of convertible promissory notes	26,596			18,499
Subsequent Event [Member] \| Convertible Promissory Note [Member] \| On May 1, 2019 [Member]
Convertible promissory note					$ 200,000
Interest rate					10.00%
Conversion price description					The note is convertible six months after the issuance date at the noteholder’s option into shares of our common stock at a Variable Conversion Price of 65% multiplied by the lowest Trading Price for the Common Stock during the ten (10) Trading Day period ending on the last complete Trading Day prior to the Conversion Date.
Due date					May 01, 2021
Subsequent Event [Member] \| Rescission of prior agreement [Member] \| BurstIQ [Member]
Common stock, shares issued		500,000

EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
C7LR1N_5RI!KVDOWN*M/N\!U& M%=1T8.9)CE]A\G.-T63^.YR 6;BKQ.8H)=/^B\I!&\DG%5L*IZ]A[(0?Q["3 MWDVT=4(\$>*98'-_1D@F0O).\*=)0F7>ZB,U-,^4')$*E]53UQ.;;6(/LW1! M?W9^S[K5-GK*X_LH(RCU# MLFHB\?SDS,1_2DQ7!5(OD)X)7!19!,R-QPB/2>+[],+)&BBY]$(6E\-!-;Z/ M-2KE((P[AD5T?BH/L;O9\/Y^4-5T0J.C-+9U_ 774AJP-497 MMJE;^^3G!8/:N.FMG:O0^&%A9#^]:3+_6/)_4$L#!!0 ( *J*SDYC+KUO MM@, (H1 9 >&PO=V]R:W-H965T!NQCVNV/!IQS[[GW MP+D.K.^B_M9<.&^='V51-1OWTK;7E>5J?O>9: M\^S8!Y6%1WT_\LHLK]SMNE][K;=K<6N+O.*OM=/>6.68U[RJLE%Y=3\M'$?R6K/@BZ@1_R=\WLS M.7:Z5MZ$^-:=_';U29/+CG>]X47299!W?55)WY.P"I\<_L^_[ MYF4S;UG#=Z+X)S^VEXV;N,Z1G[);T7X5]R]<-12ZCNK^=_[."PGO*I$1^^B9D*PP%4!= Q0'(O!3 5P#X;$*B X%= ML!@0JH#PLPR1"HC&@*37RAO$ZM5_SMILNZ[%W:F'&^B:=?^\2*3 @9$9XL3S#IA4'/6QP%+(DP(>BW>)C\>, M#U)0?<[X0/V%8HEEI!' 9!P08#]3%.!E&PTV*3%=RGR+=PBV*3%]"D0QC;HH"O8I,8T*1(D-46S3@&"; M$N13RS GV($$6= 0)?U?HE!L58JLJHNB0#-1;#38I12YU#+/*78@10[415&@ M3XN"G4J14PU1!E RH8H?++<*Q3:ER*:6;9)B"U)D06WW>5&@Z?6+@]FF/:?" M5J7 JD3;@'8*-%6%/N@_(CX S8O!9J; S(3H/ A$+3S8S12XF3"=!X$LFP/% MEJ? \L3XL8I EM'"L-\9\#N)-1X&_!XE=ALQ;'H&3$\LEYEATS-@>J+=WCL% M2BU.5#W1S]N567[)@[%@VS$9=CP#CC?[,3?FT-?;6<0,I7B3Q\*2U^?^H;YQ M#N)6M=W3RF1U?''P2+O'2FU]1U;/!*R_D-5^>"WP*_WPEN*/K#[G5>.\B58^ MS/:/G"%/S4=H>Q/*Z'MP/#22NNZLV'-[Y^V?X'4$L# M!!0 ( *J*SDXX2P4!U0( (\* 9 >&PO=V]R:W-H965T-6H9'K=N'*%+;(Z^9NA^X55E(QD>?_J@X8!I'F^$94O\N=/B[#/ QV?,].E7X6ER^\3XB$09_]-W[FE3&W3 S& M5E3*_0;;D]*B[J,8*C5[ZYYEXYZ7[@TAO1OL@'L'/#B@_SLDO4/RX9"ZY#MF M+M5/3+/50HI+(+M_JV56%.@A,<73C%.?38J3-(79$) - =A,<-;$8W.'8IJA;,*'>'SN M,IRG,$; MY-0;C;$R9"HX@P3?'@BZ/J:"ZHVN_JDBGM$#@J\/!-T?^4P(N.<1U/1342&_ MZVE"TKGZP]V,H';V5.7W,\W)7/GA=D90/WNB HSF*@>W,X+ZV=-3[NLI3NA< MY>"^1U#C>WHJO!LW-;/7!"@:?<9K+@]NXE'!5IP:;3^8H]-AJGK$=@R8G*_M MM.7&@X\PW:CVG&PO M=V]R:W-H965T&,"*+]0V2_KWM0U+R887[!G.G#ES<3YJ\VH[ (?>I%"VP)US_9X0 M6W4@F;W1/2C_I]%&,N=-TQ+;&V!U#)*"T"2Y(Y)QA1E_9DZ\I R!Z_N% M_2G6[FLY,0L/6KSPVG4%_HQ1#0T;A'O6XU>8Z[G%:"[^.YQ!>'A0XG-46MCX M1=5@G98SBY:_A&T'T#F +@$T!I I453^R!PK]RR, M.-U3WYLJ.&,KXC\OWGKON.(+W2N(6AVTEVFTEV&P3959()5=MOJ>QL']AT]/X@)D.-W/SXPL;[W\!U!+ P04 " "JBLY./&#Z+%T# #+#0 &0 M 'AL+W=OO)5'QH3SGJ5Y M.7./0IPFGE=NCRR+RSM^8KG\9\^++!;RLSAXY:E@\:XF9:F' "!>%B>Y.Y_6 M8\_%?,K/(DUR]EPXY3G+XN+?@J7\.G.A^S'PDAR.HAKPYM-3?& _F?AU>B[D ME]=:V249R\N$YT[!]C/W'DXVD%:$&O$[8=>R\^Y4H;QR_E9];'8S%U2*6,JV MHC(1R\>%+5F:5I:DCK_*J-OZK(C=]P_KCW7P,IC7N&1+GOY)=N(X3U\]K\ M0WQ%LQ.0(J"6('U_1<"*@#\)7WOP%<$?ZR%0A&"L!Z((9"R!*@(=2P@5(1Q+ MB!0AT@A>4[^Z(5:QB.?3@E^=HNGI4UQ-'3B)9,MMJ\&ZP^K_9$^4I?*D,(L&@SJ8*@&69D0V"(\*:!5@6PJ%LB@H[Z#I8F@@:;AII&'VT8>30@! M?-&PM':X-^!T#H>9CT4!(#7+XU+M^(B^IQ-9"@IY@$0*O4:AQL;8$AU(7U M1 =6T8$A&NNY601&;KY%F!*D-<_2Q"$*":":O=5(>P\C[:U-'(QP""(M7QN+ M7Q@%(8GL"2/6A!$C881J^2)&72"F% *LM^98X*,%2(C67&N;-0!\Z@\T!+7& M1RT-0>T&0JN!\.;T7H5&(6@(AOHVLGJ)+#)#K0Z1X28,@;$%1$;:^JB>& CL MNQ&PR(DT.0K4ZU,_DI'K>Q(P"]G']24-;)#0E#34"="ZN]U#=+N4"M,+ZHMB M0ON6 ,T] ?L#.S&TK[[P]O+[!,T5LYHB0UKM*R8[$L- M--<:["/=$S$+@ <=V><\M$QZ'^N.J*72! 9F_KS.(2YCQ:&^%93.EI]S41T* M.J/MS>,>58= ;7P!)TMH&5_!R4-SK_@TWUQS?L3%(?2L#XA[S@63 M 8 [69.CO%FU'RG;B^J5RO>BN5XT'X*?U-7):^]O\_]02P,$% @ JHK. M3L!>WV$# @ 108 !D !X;"]W;W)K&ULC57A M;ILP&'P5Q /4"1B"(D!J$U6;M$E1IZV_'?(14 UFMA.ZMY]M7 3!:_8'^[/O MCCL;F[1G_$U4 -)[;V@K,K^2LMLB)(H*&B(>6 >MFBD9;XA4)3\CT7$@)T-J M* I6JQ@UI&[]/#5C!YZG[")IW<*!>^+2-(3_>0+*^LQ?^Q\#+_6YDGH Y6E' MSO #Y,_NP%6%1I53W4 K:M9Z',K,?UQO]XG&&\"O&GHQZ7LZR9&Q-UU\/67^ M2AL""H74"D0U5]@!I5I(V?AM-?WQE9HX[7^H/YOL*LN1"-@Q^EJ?9)7YB>^= MH"07*E]8_P5LGLCW;/AO< 6JX-J)>D?!J#!/K[@(R1JKHJPTY'UHZ]:T_3 3 M8DMS$P)+"$;"^G-": GA_Q*P)> ; AJBF+79$TGRE+/>X\/N=D1_1.LM5JM? MZ$&SV&9.+8]0H]<\Q#A%5RUD,4\#)IA@@CEBMT2$ZSED[X#@:,0@97)T&CB= M!D8 3P061@=(;"#M $G4";@QNT1MXBEJYB5T>@D77D(D4EUU,V!+!F3H!17#VJ#*G6GCP6%4NKN M1O7Y<+,-A62=O;31^.?(_P)02P,$% @ JHK.3M^+&HI= @ K @ !D M !X;"]W;W)K&ULC5;;CILP%/P5Q'N7FR$7$:0F M4=5*K;3::MMG)W$"6H.I[83MW],[QD>VT8?Q-Y(1(Y[VD ME=BXN93UVO/$,28JFZ_.*)FA-\,J22>J'O)UZ)B\K-4C/V MS+.4724M*O+,'7$M2\S_;@EES<8-W(^!E^*22SW@96F-+^0GD:_U,U<]KU,Y M%26I1,$JAY/SQOTBU'1W*@;$WW?EVVKB^=D0H.4HM@=7G M1G:$4JVD?/RQHFZWIB;VVQ_J7TSP*I@#%F3'Z._B)/.-NW2=$SGC*Y4OK/E* M;$"QZ]CHOY,;H0JNG:@UCHP*\^\/P=GMKK*LH6".5_:,>-,DVL@BM4N^FA2QFVV+"'B:\1^S&B"CV[S%[ !-T$$^9[)R&H-/0\%&/C^*! MT1:2&$AE($&T7"9HX 2 ^?H'NXE -]'(311/A(- 00(#-*Z;3'Q73S1*AK M]@#L03PQ:"<&[$0#.P!F.;#R$')G(P%M)("-P?9MDWE9 6 /LK( [2S^6W.[ MQ;B8XNEEEN R2R#J&!98@0*K&<6T&N7CWF>;-4!I8@,#'SY0_!F59$%],Y]0 M["?#KF0K5Y>W^V'&UL?97;CILP$(9?!7&_R\'FM")(&ZJJE5HIVJKMM4.<@-9@ M:CO)]NWK \L2X_0F/O#//]\X([N\4O;*6XR%]]:3@6_\5HCQ*0AXT^(>\4(P3(,>=8-?E7IOQZJ2G@7I!KQC'C_W/6)_ MMYC0Z\:/_/>-E^[4"K415.6(3O@'%C_''9.K8'8Y=#T>>$<'C^'CQG^.GNI" MZ;7@5X>O?#'W5"5[2E_5XNMAXX<*"!/<".6 Y'#!-29$&4F,/Y.G/Z=4@_7G/F@O:3BT3IT9L9NT&/5_,ER:J)Z G(PVS4ICX[_4U6R^7NI0))6@87931IMD83+S31 MK:)>*T"2S9I $LP8L0MC&Z\,8BO%6@$B=P;@+!3H>'"#F+L-H-, :@-X8U!8 M)V4TJ=8,6I,469Y8I:Q5$4SCN'#3)$Z:9$V3AA:-T23+/%F6A):L=EC=.9C4 MB9(Z4*P&V:8K%)@4Z2*/07%8W4')G"B9 \5JI&VV0GD !8M6: !8%L/J\7LMN^]S0 M!(M+J,?LI.]K[C7T/.BW8K$[/PG/L;[$/N3F/?F.V*D;N+>G0EZ%^L(Z4BJP MA D?Y;&T\@F;%P0?A9IFSJY O*N=\8NI!-+PV;XY"5DR;J3Q%JI&< M'5Q0548TCN=1Q8HZ7&5N;2M7F3CKLJCY5@;J7%5,_MWP4ER7(0G?%IZ+4Z[M M0K3*&G;B/[C^V6REF44]RZ&H>*T*40>2'Y?AFCQNZ,P&.,2O@E_5S3BPI>R$ M>+&3KX=E&-N,>,GWVE(P\[CP)UZ6ELGD\:R8XD^B M_%T<=+X,TS X\",[E_I97+_PKJ!9&'35?^,77AJXS<1H[$6IW&^P/RLMJH[% MI%*QU_99U.YY;=\DM O# ;0+H'T 25TMK9#+_!/3;)5)<0UDN_D-LV=,'JG9 MF[U==%OAWIGDE5F]K";S619=+%&'V;08>H,A/2(R[+T$11(;>A=.+YQ@'Y'I!ZK%+B'( L,O&((\GS#!1B'(!0L/!;8!23Y0 M+38"24?FX%@OU"QA@&@5+?/8X=0X%C[BXY!$H]IT>QK2@!%)XKB&); M43K^]"AV# 6.N3L]!$JG'AUL*PK^>^Y.#X%2SWU'L??HF+\H!$J'^Q;=-!<5 MER?75JE@+\ZUZ^EN5OO6;>VZF>@_O.W[OC-Y*FH5[(0V+8YK1(Y":&YRB1], M+KEI-?M)R8_:#A,SEFV_U4ZT:+I>,NH;VM4_4$L#!!0 ( *J*SDZ^9I1B M%@, .H, 9 >&PO=V]R:W-H965T4" MH[,H/ZH]Y]+YS+.B&KM[*0^/GE>M]SQ/J@=QX(6ZLA5EGD@U+'=>=2AYLFE( M>>8%OA]Y>9(6[F34S+V4DY$XRBPM^$OI5,<\3\I_4YZ)\]A%[M?$:[K;RWK" MFXP.R8Z_GG]%7S3)JV3>DXK/ M1/8GW(9&FP81 $X*.$/LW":$FA!T!X9L$K EX*(%H AE*B#0A M&DJ@FD"'$F)-B(<2F"8P@^"U^]<4Q#R1R614BK-3MC5]2.I;!STR57+K>K*I ML.::JHE*S9XF84Q'WJD.I#'3%A-<8HC?Q\P 3!SW,7,;$_013S:"DCYD<3?( M\_T@2\@MZV-6 9U$$\M:K>R ;BR0&)0)P9TC+SGL:T3A9$) M6PR#+6T8P=2\36T0I4$,)\; Q!B0F*$R8W:]D\B/ U@'^?#3P;>5R)4NB*X\ M8-#]/CC5H*';C>".BZ"62TPIH$L2A51O9LW[TU8(R55,_T$MTUY]>'2#C&]E?4K5 M>=F^?;<#*0[ZR\+K/F\F_P%02P,$% @ JHK.3NQ9VC+( @ N0H !D M !X;"]W;W)K&ULC99MCZ(P$,>_"N$#""T"NE$3 M]7*Y2^X2LY?;>UVU*EF@7%MU[]M?'U@6VI'L&VG+?V9^4]IQ%G?&7\6%4AF\ M564MEN%%RN8IBL3A0BLB)JRAM7IS8KPB4DWY.1(-I^1HC*HRPG&<114IZG"U M,&L[OEJPJRR+FNYX(*Y51?B_#2W9?1FB\'WAN3A?I%Z(5HN&G.DO*G\W.ZYF M4>?E6%2T%@6K TY/RW"-GK8HTP9&\5+0N^B- YW*GK%7/?E^7(:Q)J(E/4CM M@JC'C6YI66I/BN-OZS3L8FK#_OC=^U>3O$IF3P3=LO)/<92793@+@R,]D6LI MG]G]&VT32L.@S?X'O=%2R36)BG%@I3"_P>$J)*M:+PJE(F_V6=3F>;=OTKPU M@PUP:X [ Q5[S"!I#9(/ [.;D24SJ7XADJP6G-T#;K]60_2A0$^)VLR#7C1[ M9]ZI;(5:O:VF<;*(;MI1J]E8#>YIT%"Q]15)FG>:2!%T&!C"V&#/ 79"^(H$ MP1$2,-'$V">#1*>P@RGH8&H<3 <.4F>GK"8UFMIJ4(;3V,G%ER$EBF&:%*1) M 9K,H4G],',5QJ7Q9>H(Y.D#G S$R0"7&+TH%PA("?LUBLKFO5H,9I@KVA96=:_'X\2 JO6&N%/W,)6-._3 M3-S*L854:))F#WC@&H>23UQ#0.2=O''-$ 6NE@@JE^Y5!$0^RJAFB *72@35 M2O7S4\Y)8GZC4"%>5GTS.)X,"N MM6G8>JM=7[;&II'XD-NF[B?AYZ(6P9Y)U8Z8IN'$F*2*)IZHK;FH/K*;E/0D M]3!78VZ;*3N1K&D;Q:CK5E?_ 5!+ P04 " "JBLY./N0I>WD# "!#P M&0 'AL+W=O:O*NEVX!R&.=Y[7;@ZLRML9/[):?MGQILJ%'#9[KSTV+-_V1E7I$=^/O"HO M:G>FN67-GXR5_+)PP7V?>"[V!]%->,OY,=^S[TS\ M.#XUXW9&8[?W[T_],7+8E[REMWS\E>Q%8>% MF[C.ENWR4RF>^>4S4P6%KJ.J_\K.K)3P+A,98\/+MO_O;$ZMX)7R(E.I\K?A M6=3]\S)\H:$RPPV(,B!7 Z ?&@3*(+C5@"H#>JM!J S"6PTB91#=:A K@U@S M\(;5[;=KE8M\.6_XQ6F&CCOF76/#72P;8M--]OO??Y,[ULK9\Y("G7OGSI'" M9 .&C#!!Z$\Q]R:&0CC%K#!,-,6L30R9(AZ0;& *>42')!KJM"T%4A MO0,Z<@"@!5D/F*C'U ,F].4?'B= XP1&G,!/< <4=4 -!Q1B+=$!$XX2C0"( MOH,/)DSNC@%[-&&=+TO5(9ITB"2=:$F'QNK&-$T3P.-$:)S(7%W0RED/F&04 MA\PL.Q"C06(S2*3O ((!2S\F:)#$=!!K+%TCF!&[)D%2-$B*5))J01#,2"XF M0<#'!<='=C^UN+!H%I@NB*^+#1B-2NST!%P'P!0"HU57@"A!FH:V9<&5 ! I MT)MUI4#C;H69;^$$X(H!IF0$D.J!J%%2:(F"4QQ,CANT6"$@2FS5X!0'A.,Z M,U8(B!(+_P!G.6 T-U;-!%$26.+@1 >3Q938.@FG,9@<-=B1*=!$QJ>GESK6 M35QH)1'!&4\0QA/MMT&F0!,2:;E@$%LFN' 04SB,$8LI"6X!A%,@U(]F^#_&X5 ;!N%BQ1! M1$J7CPP!41+IN7P,FB:#:QE!M$S7F P!41+KR2">;&Z-[1'1^^#DJV$]UK M+-^;X5(X# 0_J@NO=[UU+_\"4$L#!!0 ( *J*SDY] 6%J7@< &XM 9 M >&PO=V]R:W-H965TGXO5S\ MM7PNBJKW:S:=+T_ZSU7U\F$P6-X_%[-\>52^%//Z+X_E8I97]EZ_5=#(O1HO>\G4VRQ?_?"RFY?M)7_4W M7]Q,GIZKYHO!Z?%+_E3<%M7=RVA1?QIL>WF8S(KYXOB\:3_N_IP%[*F MP4KQQZ1X7^[\WFNF\K,L_VH^?'XXZ2>-HV):W%=-%WG]XZTX*Z;3IJ?:Q]]M MI_WMF$W#W=\WO5^N)E]/YF>^+,[*Z9^3A^KYI)_V>P_%8_XZK6[*]ZNBG9#K M]]K9?RW>BFDM;YS48]R7T^7J_][]Z[(J9VTOM959_FO]!KYMX&-'"&V#$-L@;1NDL9:R MMD$6.X)*-I%+HIML@ZVBFVS"K:+CK38!5]$15YN0J^B8JTW0E8MNL@F[BHZ[ MV@1>14=>;4*OTN@FF^"KZ.CK3?1U=/3U)OIZ)_IFA:$U(U;0.<^K_/1X4;[W M%FMNON0-GM6'NE7=>?/M"F.K/];@6=;?OIU:DQP/WIJ>6LW'M49W-*JK.9,T MNJLYES2FJ[G@&D^&NA2Z4;ZK^20-9;N:*V$HXN:S("$79\@E9-I?N,(8U]5\ ME?P2S;70CR-NODG]D&OS7=*$KF8D:=*N9BSX(:&ZX9) 9G4KC91U-3^$:QS( M5;X30O6?9% GP383M)P)>M6!W>V >!VN)6$EF:\DR5&2D$F/#ZDZ9HQLQG S M)(S#M<3M#..2]A\Q%*/LF+*R*$WX.1:$*C-IDA'K-X)0!^630(;^ M(0VM,I?N9%-WG@#^BM/?6G#_4(#9BD/;6D.O%8>Q#9 .3*,DXWC9'<'9=WI 8!I#C!:WUQHH:YK M[MZ4/DA'YQK% '(:3D[KZ#FA* (% ML %$-$(AJ2WH T#,2'QBIT)\OXN*7@,89CC##-HW6@ HRP%%U_D7*U1T!I]) M 8[9B!WJEU:4=H8Z0D&T #V6H\=8>MK;BKI5-1P)8,(*6TD7Z$B&CQ2\IP ;:@I2UPB$;,3RT4E6DH5N0LU9(1[;-MKR.<6@-722;<9KX).LV[^R[('._M5AK5:W@= ':LA)U )\CWDD&:'Y=IK^F^ MZ+L@,_PRW HRFVH/[@$6X,Y*)1O803F .\=QQU:_$W"'3_X>YS6KA$:M:+?H,LH>H:% 8ON(Q!YYGMCU4"F\@B"SO939 MX';BT9.]B,P^\\(Q"[]=G@LR?/_V(/^]E/^6&N+Y;R5#7*8QJSW A!<(0)^U MGWGAP1VO MJ!,)XF6O MI.L$L"L(Q89'LP%4"IQ*_$X7^/'*GMHH "H%8=?DP?.5 ' 3#K_D, S">PE[ MW +8! DV (X!P";$E!'A?Y41 ;TD$%-&!*&,T [& / AQ)01D@B5$0'D?8@I M(\+A,F*P\[I=\R;R=;YXFLR7O9]E596SU>MUCV59%75WR5$=A^ UQ^J\N5D_7;S8/N*]>F_4$L#!!0 ( *J*SD[7Y?LQV@$ M )\$ 9 >&PO=V]R:W-H965TP"#7CD3NL2],>.>$%WWP*F^DR,(>])*Q:FQINJ('A70Q@=Q1N(HR@FG@\!5 MX7U'517R;-@@X*B0/G-.U9\#,#F5>(>OCN>AZXUSD*H8:0??P?P8C\I:9&5I M!@Y"#U(@!6V)'W?[0^[P'O!S@$EO]LA5)U:@ET_Z+ZK,VDB\L-A5.7^=U$'Z=YI/L&A8.B)> > UX\ %D M%O*9?Z2&5H62$U)S[T?J?O%N']O>U,[I6^'/;/+:>B]5FG\HR,41+9C#C(DW MF-V*()9]E8A#$H?XO_#T/@H3),$<$T^0O"%X)X,T2)!Z@O0-07Q39 B3A$6R MH$@6($AO1&9,[C'"8Y(D>J<7>5 E#ZAD-RHA3'XC0C87A(/J_&AH5,NS\&.Y M\:[3]QC["_8//H_N-ZJZ06ATDL9>4W^96BD-V%2B.UMQ;U^+U6#0&K>]MWLU MS\QL&#DNSP%9WZ3J+U!+ P04 " "JBLY.R#M ,$,# J#@ &0 'AL M+W=O[?SPDN _O<,3Z0V#S/W?E\]V"/#JI][392ZNBMKIIN M'&^TWMXF2;?8R+KH;M16-N:7E6KK0IMANTZZ;2N+Y4"JJX0@Q).Z*)MX,AKF MGMK)2.UT53;RJ8VZ75T7[>\[6:G#.,;Q^\1SN=[H?B*9C+;%6GZ3^OOVJ36C MY&1E6=:RZ4K51*U-/^/:1T)XP('Z4\M"=O4?]4EZ4>NT'C\MQC/J(9"47 MNC=1F,=>3F55]99,'+^LT?CDLR>>O[];GP^+-XMY*3HY5=7/1$P.Q# K4$^I= /R0P2V#7AI1:0GJM!VX)_%H/F25DURY:6(*X MEI!;0NX0DN/^#04Q*W0Q&;7J$+7'FMX6?>O@V]R4W**?'"IL^,W41&=F]Q.6 M9:-DWQNRF+LCAEQ@Q"5F"F'R2\S,Q] 476+N 3O"P1A.;N='2#I F@&":99A1-TE 4#.L1,P9 TA MEC$$ATW!L*D7-A..IX8E@SL"\:3+" ";A_ M,=3 J2OJ?@?3<"%BN(.QW\*>5-Q9T+DJT12Y^WR/_1[F(J>A?8)[&/M-S 1W M TK])N14,#<@ )8A%@H(U@3LBP(3WA\L]S)$>.KV]#T PX*%.@[#XH%]96!" M!$S TH"AOO?^I(67/?*!)&-8(+#?_9[6S4%00.P(+!'$EPA/[N8 B(E ]@FL M(P30$;<3YA H#^2-!$X>@(KDH;,+K"+$5Q'W]#*UF/.*3*%-3LZ.H_TMZFO1 MKLNFBUZ4-B?;X?RY4DI+8Q/=&&L;EZ M./D#4$L#!!0 ( *J*SDXR@J08&PO_85;1:U%O);-^2;3G1C&.[+:=[N[;V M RW1-C>2J"$E)YZZ/_Z>!P"")$C)3KIGMRI5.]N.2(# P<%Y/_Z:IAOY9;E8 MI?_^Y\?-9OWFQQ_3V6.X#-)&O Y7\.0^3I;!!OZ9//R8KI,PF*>/8;A9+GYL M-9N]'Y=!M/JSW*ZB?VS#TWB[VOS[GSO#UI]_^FL:_?37S4]G\6R[#%<;&:SF M4Q@S#^?%IZ-U MTI#MIB=;37]8?/BW[:HA_9;[H5G/R+F>XNOJC9OP(4HW20#C+H-E6'@+X?S\-__# !*P^0I_/-/M^]/Y>UCF 3K<+N)9JD'WYDU9,473F%-2;" =^;A M%_GW\+GX7K/9]#O-SK#=K=S2[?.ZN+2?_.;QSR7HP=MS&G&^"!Z*3^^#15J: MQGSC.DRB&"$WEV?!IO2>/ACQIS^YH'^Z31+Z;I3.8+._A4%2.=7Q<;-_W/:+ M/T]2=6Q_2>%8UG&RB58/?,H M3^/E.E@]ER91KY]'BS"1I[#BAS@I'=-EO#H.9K,0WH$WYOQVQ4S39;!8R)-M M&JW"M+3 3;(MP40C2[Q=1U_@ M2$?TS).K<%-"JA6S @N@"9:%3_H)BPE M$L)+K]BJVM B"NZB1;2)RC=A-)LAW4[E.G@.<.E(J@&' ?_F.\857Y'S;8C[ M2L(%8?\Z2)PCYT_!:@:OWR?Q/84P#)>=>]$)^#/ ^R>@ M\T^A670)%_-X4+-]?K'F!;J>C_%B'B;I7V3XCRW>@\-Y>!_-HDT)G=6=3G'0 M6WG0; "]1Y#(IV"Q#=_*;K/I-?E_BF7*8+MYC)/HG^'\K?3;7K_O>\UVBXX/ M_MEL=KQ^Q[P%CZ,,TH!6"/C>PED.UH8ADHOP?5Z-M?+@T-*U^$,0;]#P BX_#Q2_N>'<'D7)O]5_2:_1Z=7_=+)CNGJ*./A=8 X^AB"=!$L MCH!2'L@?*\0IFUBZ!:9FEQ[VBP\_!,]:F"H]^UL UL=]\,\^BO(OJE#>R_# M]_K72OB_U^M\ ^I?C:N9:.%D:Q9;>G/G>JM&N)=<]7;-XG-X-+V%_WP87][* MJW-Y=3V^&=U.X+D\_'@Y^G@V@5>.JMEN>V_!O,R4XU4:+Z(YW7"4V$(2*Z[N MY=4:Q26@$B7$O0F?PM6VC-"G,>@M0+F2BN<@RZ7 #)+XODQ%U-> ^H5?0,=) MRZ.O81R(9$RV[D/7YU?I=D%SN!Y?!\])#/*.FK^TN' 5HK!/C':^C%:D7!!? MJEK160@"P"QBI8G&+5'T_:=3:V&2%^_GI[=?KW]U<79^.;J3P;GT].)[=RO\MM\SFBWW6< MR_F"K9K4B +7* I,5J!&.44!EBBN*R0*2TXXJY$32A ')7ZUPOMP%RQ0_LP( M\T;:#++$RAPCX?IM44_8,5+I9O=Q(E%ZCT#H]=P#1(0I IEW7A>@8ZU?+0X+,/%VF%[X_\^(]WX M7QJI (@,ZW.0H &MB.*U@*\95WONN7$U]^0EGZ^=IF(UA7M28H51#03V&KLO M]KMNK/N[^^&DP\RS#TZ6#8*57.QT-'U_?G'UZYYB*9ITY/DB_JP$FDS&&Z'6 MZC9@S/][J^\R&2UF\6H6+4(T'=!]Q5_Q;SKO;0JPO'NVQ*K S%Q2:TBRVB4( MN99D275X4J NP-4#ADEG64FBB\/F=?1\LIHE89#2JE;Q)@0I&427:$TV)!F@ MJ@^B+4X#XE"PJ#1MP&$C2$!B0;')*8AJ,.PATIT2I(BH6A FFQ;=PQJ@'>H= M'<'4V=[FX3I.(P "91+D]TF@)>P/CB+*+-8NF%PF<-_V(:9]@5+.0<(*#; MA"%&&P!L@$54>MH(9>@NLICE%E3S;VV"+R5)=CP]O9EW@1E(O<)26+\Q3CBMT=('/O2*#YV%Z2R)UKA[ 6"Y4XX? M^1[4_SAY%E+)Z/X\\KM MM[])H'@7)LX<;6P;))T0+%*)H7 KC%&U=*V) $!6?P\6" MUC0+\032!KHP]1K^[?\,6G[_;2H?0V +CS3+&I !"#0<-%X]/.V-8P"9-P#3 M9O"1V5;=6#+RA6BSAD!T)>)"<@>;#]G*UI G[\%JRWL2B)TV#!MPXBY M[9PVN@J6Y(KX$"T6(6#X=BE/%G!EX1VX"N2*A?FFX7I#EE?9&NPUXUT MQZF MK?#NPL^B_#,>PD-(MH;/$0 .9S-'I&7 Q0+@FH2PN#LT \"JE;E=&IT;O@L< M&M>'D&TUWZIE-DJW>C2=3!$MKV_&4Q"HR,!'J/GN:G+Y3H+8=3J^N70B=PN0 M^Y7CT::1(FI?H[,** $=ZSO0D1[$*7D?'(Z M @'P&H3"T\EXZEQA&U;XPG&WC["P=+M<(O+ M/H817=1S/TZ"N^C$BWCA?1 M#%T$\$K%"4=H5:3=Z0.!/2/)E=L5FKJU8\5Q#<3,-H#>&VJ3&FK#UVWG:\1V M5D2V\.8EX=J"=UIQ"<4R6 4/-(&'U$(-3=LVRY"%/!-QV(%#['>T?B!*[TXRHR)F'V1RU! M6IX%]/G' $3FNS!<$5P UK !G /8391-08)<8@3@3248A0WMZVQU,"BS3^,L M'],0?QR#K+.D=2'O$;@B8D+C?VQ!GE_0<1!NKS;\>7$3I9_D>1 EXA>D6[B< MC+-,5D +MWR*HU0D:-)(6+' ->,PR<,^ -\&!IH=^)EAJJF\C== 3-5&ST?3 M$SF: ANXQ^%$+1%/ESS#7 GJ2&'A_20,CT%P2.AEP2\_PK\#X //B!G1[!&/ M#50/4"E"IC?1:KV%96@9D&5=- MDF[A _#R/[: P7,!GYJQW$]"3:BX5?I63](Z4B,]9:_= %&F5?$,LFH&).7 M[!#/K56$$4TR![#/ )$$21OZ7V\)TNK#[2.XT^7UPW<82#@/ 1K4D@T*APE< M2LUL 8L"#4UURK3FQ,2LA!09(>"^S/%S\9KX C!PI"G;)EN0-\='>YV3F'&'YPZS?GXC:3?"?P/W+""5%Q[M %T&.;RK*1,(^ 4_O,P0 M$W?)A".:XW9FP<(#F*'D!A.379NE#! M+ 7NK5I2ZXW\N;B.T@* SJG%>9+. MB@[!<;)>\6AE[F@]-H0 VP42O8F0$ F"XQ8X+\@Z2PU86C*.-0X+O=[V&Z08 MN-"80<^48A/.'BG^32U+'W=QJ7#YJ"&5XTS?P9QB8A< M*93%^B4E^9\$30@.@1V<(3HX7:$12DQ$'P.\<. /O>:P[;6:70+<0:O3\GSX,1,3$[;JC3(>"\>Z@K]G MBE=,5N(\O$M(3H:E]KR,22B+X&CZD9X<-UN>%B4O4$U,Z1]PKH?J5P31H--2 M/Q^Q?/*P!1X)G].(#@002$08&BL:05D$BR4Z:5&P7=#DR(%8P% ZI*1(4F5U M0D?8<7Q_O$WU%20W)X_-[F)#GL?&96=X.:HQZS@-TVRSP%LW(.HC#9+S+;#> M93P/%YY:-,)-K0H6C1+W B6Y^XAHEJ8DF=D%OLDB!.@A%[!;^+U:R)#@Z>%V M@$TM@AFLEA89T*?58E#PFA%#1,@A3=/'3W8Z @[P+84Z,)D([^_Y'M"G[CF, M\#D,DA0@K^T/P3T087D&:$[ZF,_Q*(.&_#441&)0U23@S>/UQDR?S3W:/@!O MDRK(1:)VS6)XO%9>1XS@31ED2U#'XCE'$##"TAJDZT4&$(&PO$$;(PNCP6III#!Y1C$#81P@:X(:J=-($%K"0$4?M> MK &3T$>-EN$$60T>(U+7>:2\(*NY;4(&\2?,]H%W.DU1)/S\R+IPJ)$577M? MUB0'X\9P;M(GZ&(@.LR!$@N^KA[*@[PM?65G##'$+=397=/JL;C"=K8"GD<9 MV6F2&1';?P"],+0@PEL&B@,+$OP&P8P9WR*UH98^PD$U6)8WJF0[C"][54*U>J*NH916_I3D5'72J9$5MNGA$,L9""NYCH:,= M$F(D>1W-YA\,I#L\\B>UZ$\D*V^YS>;Y@]! MECR!ECR^/FF,83Y(2H!/K8FY]3CLD_\CKNX!Y4-QOP5*LT$3*X[+7NZV6_@_ M@5SJC0AR0956#-%AI^OYW;X\DH>MH==N=^61L*%#%G%8)0@SG7X7_N@.O-:P M+^U )*%%JWW%)\^2GSX#E ^ RH-D0;_BW_U^OR VE7PKE[>CRW>3DXMQ'1IT M 0UVOIG)LW\,0EP':+I(B8BO^6_TL!$O/I G-YPB'\,O&ZS(VZ38!ZB6 \D MTVO!"=#_%[^&=W"!0IID'F/R#=DE4^27S>% _6?GX0^]P:"#9]_SNL,F''T) M&/K\6SW/'PSP#SC_05_:KL:O/W\0FX<=/G[X$Y"P]O!OKDZN;N7IZ/3]V&@@ M-Y-W[V^G\O8*_N_OXTLVP(]__CBY=1KZ90]0XROG03MT/CK:-AF3X9QC;4!6 MR>5J2.-Y&SV 0D_7E8DZ !M.VRE.8R.F(5;?KK$Y SX3:_;[GEMORN4D#ZY MN;K4@OLL>5YOXH8:N#):>.B@3X#(#HK8$$@7"_) M #=36]#2OS5(:P!\@H=1="24S(ZSWT=)BGKO_39%,2O.EKY=XS_;/QBC' =\ M*?=9?F%DAB -':@9Q?9QO(]Q>WD<<@.7=*X8AJAP.*"BHV6S7CYJOF)$SJVG M4S,TP-C>NCI&UH2/M %B>4 M,!=HOH/I+2QL^9Y1$\@H0WP;!/EV$_[]G"KQ.O\8_B6ZQ_!8/L6+[3(\+H4C MDEUF+Y"!K$+.3EHB+UT/U]3!; _DGU;W!Q97=KV+JM4F>'B@.V6;&+N%9 @@ M5OU&M_DC_=MS/?8QJ:+P7-C/N^7G]OB6/9ZR+$H9&?!6-WNK@;HX"EH)R]QT MUTGJ;C4]9:/F&T?6'W8S97%%B.U)/EKDBT%009J_ADJSQX.?;>D'0C)M4-/$KB$L;R)P))1D M26O"MW(?+"2M%#_'6L]!JS%HE@)M480\\+W>@$Z&+1:\/W-I/Z/=5H&<\*8S M](8#WU(93T#Y_70\G3W&:.UB!9) AR^0'LP39T9 9&=+8-G6)+;\8 RZ;P0O MAM$=OOZ :WK#FWE;N#J YN3X)\S&73-VT9YILV])&W@CVZQ.OP5\23\=WZ.U M6+O0);I>W\A6H]__@H (H8E<:?X\+ M.P UH<6WR,:>D@@W.OL%)K!CLH>?Q*8JW*?HDD="Q M@8\S' %RJ[FVZ1G-G*[T)N+X!/U?9=MG ]/J(28#AJ47YUAP0YH42O+X;!ES MT!<:@OSH-X^8Z5.PW9(/;B[N,''7D 5 D^X/\#M5BB-T=JE>K]#6MA'Z+$1.M9+G!&8%]+GZIPKM*WPG M_T]QTA WH$:MPD\>12V0'XLPXG1\!5K/L.MT._ '0[7E]OPW: MTX'L^]ZPA\H\H'ZS+Z89#HF; @*59^^UO6ZG+7O> (C[L>PWO7:O+3O MGKB M]NIV=(':8'?H=7L]7, 0]<)L 7U:@ _Z>;N+"_3;WA!65=*9K,ORF[R]&5U. M1Z>4[^6\;0-4C_8> IK09?RD#+8Z:NES6-"!T(:W7L3/[-7*:SXGP/WFP%#, M(=3<-12G9$&< C:#7$E/ZLD/24-/AH:M)P!Y:L+&M75=WT0T+WY1,;HH>1[T M!R3.(7]%ABK7BVT*U'>6Y5W=Q:LM>@V0IJ[Q V26Y4NDO?AW<9"0;9E-AG&" M1C40[S$%GHACM+S;)JD)B-7Y66B<1[_!G&*3C!/'<$N$[)+U:I*V?C>H2H2J M^&90]?_'@-6230JV"D.2+&.%O2F=$'\P@+WT.UHVL0&C:2:!P\9*(*YY*BEX M?GLPLN( B:HZ7/U=$@_ND4N1V=_V:P;)BK]&DICU=?RX"SE2=EHB! Y\D'G[ M@R9BFEI7JZO7=1[%2;CZ9ZQ]@V/X6QL8?HD60(FCR\M#+*D(2EO?I4!/0XR9DR.9):--M=:.$-4K+-H*<#XZ%EXU@R:U ME^ZT75Y!+:JU0RE$/LL&HR4+HT/*6[^>U&MVLI;\)6WMKJD?7Q M[&G?ZZ&5$W6[][83YB[4BP/MK^>_Q-X#WQ):5\D\DK:1;UB29"^O;D$@O1[] M-CJY&#MYZ1!X:=U;;DF5PY&O=2V.C5"B5UJ2O=Y8PHR6A^@&L[U9A1/KY/T\ M.=/'* ^4N%6.<" M7AM\IOO#6S'G*+57T'NC_Y8^@OO!!;<;LC/P6K!P_H\P=F&763@#>&NP)\"5 M^FD +LCI]X,#[JV.$_1JJ>UFW\+J@L V:+!$[3B5OM<"R7*O4SG+X)Q&7_)@ M%ON!6>_45BI]S_>[LO80"[/GHL0[KH/@7"3E$;4JH5A94"MK.3G3JR&<&$*< MY309TBGLV,!,=#!J(6=Q$5L([S8JNGV(SIB7F*?Y$F16.FT$UQP)'2O W7O MN3%^IC('BT#<[H-:T2R8?/)I8'J]UA0-(&V,QX(SZ=5-Z/?H/XXTOU_&H*RC M,VXWW?11&]IWB)N(6G6!1)&@RFJ"*O8AJ,-*12?' OW&]T$Z).PV.MG%&F3 MA$2^@V$+SX$MI$4J4)$%B.OO-T")/SR@0SQ"\4*A;18(8JU)%-<$5*3W W%: ME+67F0LA?QGPJFCYER*95J19FSL"N@**PX!D&7P&C*7Z,SG18$,F+A(^,K>$ M<=GP[QM##_F:F#!V98PEB&=W!A6$Y3(%##+$B*[X.O /M*@!")]C<23)*WEAJW05S"H97ZU0["LD]:+>]H:K MQ;"VQ:7L5?3B]MCL_HQQ'!274[T+^.&9]C%[C-.0O!^? X1T%M2C-B'U)LYY MTKQ.807 !E7'C6R_Z75[36/N5?C";.2>323PV.04E-TERD\BE)_D[.ME, R0 MRHJ':(Y6A;$'/=\;=KOL7PP>@/L^$/SS%^(^#,B6CXHW23*,I"'72)L!97E0 M3+L@F;"1PDK&U!)+[JX*!:MAK\?Q#2VLSM:Q20='0+(])Q=0H*,DBL$P9.5C M%%-40'Q9_#X'JFB1QG 1#N1C M40X=-10C]Z#*.3$BT]?XIE,0[RKG/=-JLOFKL*)W MC^_QFA^VND=FR!D@TYHKF2I:HJ@1VL'2#1G+%G"A\P,H++;$HP%^Q./@&<:V MR%_4ML1IMJUK(SC H2X1:3@#35DGG1O2X0RY*"!KEU6;$S6;VVMKUKJQN&X^ M-/0%TD;7(6Q(M[#!J*6F\DQ5'&'?Q)?('CES:FCB@&U,4YAJB1%%*45\O90B M31?CR3ST*]2DQYX UZZ)L[EK;FR2FZVN!0 M,DPX6>M7J)#^;H9(4HG?)96_BO-9H1('?KM#:ND.Q7)_UB=>R?KDU6P3H]6J M;653O(+WB1?SOE=JE]UF0;M$N89(^S=6*V59K7P-H??K*?V+2+?X)J3[]0JF M^ :D^RNT %$!VOV(M_QJXMT:#+U.JUJ#\[M P%K[J' JU$W\T<0;H\%[G:'7 M[/C%,ATFYAI)1X&8%$)& MBV+OPSGV/'@KQ_IN6F\4LT"+DUKIH(4G64JHK4KAQ8[NM\E,>XU2+M80+@Q8 M#%1<, A2#B)1*[601B6)A?,"#[,.*6/'"+>BVUF:"@RP2#2Y/NR[SHD\!4#VOU1H*+&$J,LNX2NE#ISR&LU4L]5A,5'(?$21# MK([%*)?UZ213*@*DX!F!L5S*3NAC5M9D<],KUG(XZ'F=3D<>.;>*&3A=C-CH MOFZG?I]'J0+8Q M4+L])+S-,RS.36:)0=E0,\36A1AB'8+@EELBCN"WQ2P[CZ3H3"'ADVY\Q1@7 M-I]G15>LH'"3A62MBJ[)&]+>A3UK(8 1J\V(&H9=-6?8!4EEJ^>OHYF9T69&VYV-AM?KW\A0K*E I%>%O MZF 4K:TN8ZO*[MDEUKP1EUN40/ L5'W57U6VC!BI;)FQ#MXGXX]&8Z] LWSR M]"'IPEA^\:O.2J ((25X$F[@Q6RVO7Z7LD7]1K>7O:P3F]'*:WZ<6Q5]U M2@'_[%S40'9\(*/Z0RV_?E7^D.(Y *^:W6^YI,)][_F^6I/?;?A-_6\MCYFD ME)W]3"A&R\JGCV.V!;]W\CMH'* MB*G9WPC;FHUN*<_K#4-;(UOW-A6H(X%2:4S0=T+(AGI'QF.5WUXH-EM(]W(B4S$7#V['L-OYFE0\\95' M1&?A.XZH:QU1J_J(A#ZB@5\ZHL[W(_I?<$0ET?7]Z&:L.JHH[5H\D0^'>/5Z6JW,*-AJ]@KPJTPP^)U7!2)X5RU*_5E: MT\DKUY0S1&*P/-J[.WW/;YN/6.'$G/O(>=;L5;922+3C*:,)^92$*+'LJU9H M[)R*J!+]: T\GU-/A*GWE2OH;-=+G6]!,J$6O#KA=\178Y,5JCB?7-Z,M%42 M/4Y4SB@72F4NEO_&;U(5M20-52YVNH;+OU>B -5N*5X+)&UJ0FE/N(GC3UEA M)*NTF6K0TA ?5U3W@6*X/B,=0ZEE[E&.+9?/7++-F(RFE )AUPCC6FZ9J+2C M5C!^)<3T(%U1%TOD)7&@+>$FDT3;8NW-8*;P/==NS0%MQJE5VHW E4"PI(0. MKJ4?5"B#J9S^5^.+=9I@M4OF'5\P@##53J\\I.QS55 MT7174O@2AU+7/8,!Q00D5U%ZD94T3#/%(IA M-J+ P05FE]%B0>6!VIH]'"GJ8'4[5'RB(3^B<,'N*92_J0X;:0YG:K6T#=4! M4H.TDK:24H$5<1 1'P MTX=^ML42#Z*.4S#ZF88<^DLOXLH[N-%M#(R0[.^V*\!MK MV#YT"!.N%@L!= "K]&/-G&6T41Y7*Y$]S6?$E+?^1->-=AK@S:8-/H:+>7DG M]@XHMDM%S/(&BKYL,S+%(%SV!].]7D3_V.H2VWR*(1755->JS.!*:4Q_Y)6B MD(7\E2JML.)*<8"C#7(.]H(I@3Q1%26_M?.244[1"NU-CB2NP$H&GF>7CMW5 MJ@4($=6MSLW<0Z#(+UJDT1<=H&8MO-?]-M0!B2YO(DVI_,!UN!OR_9['@G56#;LH8;P.66->^ 9F%V;NDY%6\#XJ&P/M- MRP+G:>6:!MBN_;S3?J( KLK_TR,\W>(']RX/#=?5)%/+?U$RM=!9L/_"9.JJ MF(GOR=3_Y8G'+V5VGF,;H?R5Z!2H@/[->";?U*M+='G))028@T.2Q M?B-$$N4R;7\H(@EG[;0_!I':#;\S$,Z2:FV_H\NMN3 )'F,2=T,Y1X5EE]"6 MA=SIVKH_UJAW2#=%?&,/986T3@B5*8P%DZA5[5BO@%,M;7S)@G+8SHDYK;UV M!=,&=(RV@)-SSB2#*\?4*+ M4.4OE0Y@CR#,/3J$E>!:M,9^'6!%C0U_?TI8A'*;3W]/*(LBE&4&Y9PS8R\ MM79C'O>7FRGB5>O:$&ZP5+LV:J#2PDBR[FMP3Q2@PG4NW.4.U21H\$61^3G< ML*#*^%GE'JHEC+4091LWO>%T+M%4$S]=1%U4+VY[)3>)/\R3^I5Y.S%@">C MJ(*[N[+5/OQ>W0K[*A2#J\T])KV*_$6?Z3-OK M]-OYNMU%^C4L,)B]3LD=Y[;'5"6F<]!LM#2GX>Z69%!%'9<4^R3<;).5G5^2 MZ<<,QXLBY))P86SGN:*]Z'/1#DO,N?R:<]\5%KCS5.%Z]#O]5YVJ[[5WGNK+ MJU+M '89UF('K&4>UKBDKQ:["#YF8\(MWD\MWXLK)5L=^F4E8O&'9K16K,8RJ[M^&FH$1[L09;@EE!V GOE)O,+?(^ M!=76CLJH?J'>M? "!I&G* N$6 "#L +PRDXS.426_]0[[V8VPM1+S?. J;J M6FB%FP*5/XO"A]B3I]@@*TY64:"<%;K^7**2F(!R8#\,BLHGLQ4FQ$96E5;R MA5!=VO%5KA0J->H4:%R&;::4+J@6R."G&6(R!-">QOL\WL3';-V@JOBJM1MN;Q7+^&X1/60MR0B? )J+.)DK1[9I MW59&??,UH2Y,2GW,87.J$CO5K&'\+L>I?3R9CG_^"(@FQ[^,*[,L.M0_>\>K M%9TK..%OT.T>^\UB!!/*V<'B&4/6J)-M5KW ,I>(0Y%AI:9IF=UJYDG5QZ7 8&S%HQ)YTXHP M%-V*.-1#]3C5=A<[L*8S6)X*/"[$46FW=KN*])_ '=E,?L:(E%EDO+S3" M_ M6.V#$,/.&2ENN1D(OR*8,H$[U,I5' *\2)5.KREM682T= MGW'0&U!U!-ZRE9V+IKUFIZ6SM7,\B5QS(-9TAD,WQ\ES?4?N*[ZKXA%,A8*H MOD(1=^.T*OH9 ^K^FU6&-'NSGI&WLN)B)5#TO/:@XP*%X 1D;,O5@-(+BB"+ZVJ*$*KQ_H&I"PA+==39Y=4@JJH]&AWWDTU_AJ@N@ MM#JX)J.XUI:5-.2*ZE([:^2*=91WR O01;&_::F.5K.9+RFULZZ&^'U*2JD] M4@>IZIH::?1%=V_X%N6DG,4O2(K0=9?L^D6<3!=SP<9O57=)M\G8HYB456]) M[%UOJ]8[7+]??%WUT5 !4&@[A!NTVJ@>Q#N +99L'E M"]!!9)S4'U?426^*DW*$RQ*P:A9DA1% Q@T>C$MW&7P*L1DL[R++LE1YP=P[ MGD.(%>WBD%:C&=U+U;R2!7:3R>QI@03XON+RN N.TW -*%KX-@7L<((LHS^N ME:E>U=SRTM1-L:YA8AK"\]T#G)EM,+9)ET"840LG#O%5?7.P!F8&L4;N4F2 MU%AK?A';5"OW3U'XV2G]/ZAN]I[5Y$AU5^-I="N>!;:X7Y 53'?+=/7EQK Q MP'B8!4Z<#X'H""G#V W6=#OVN/<#WP@D7MO5+%Z@P,%N>W7O/#*4K2C:R233 M9&=@?J)%ZM:".G]$9*$"])T\2[TCI1$O<09$#*2*T"QG^A?#Q=:9?? 0 ]2P M1A'+PF6\34+=1Q@A+R@.+D"-3N49$(I%R6R[1.E@IKNW6_4OF'7BC:0GW(., MH[X^(=K\]W;^H$[I#H0,GA'#^/"A*I)AKH@H8KQ9):H'L+1YA#=Z#42#Y&9$ M-]Y:"MR*(%9 3XQ%SR-G:".G8NHF0EW8((I))..*.&55[A0/CAH%X1\HM\-N M<*.ECL9L<%W':5:IQMQ/(GNFG7)>R="V&6H[ N?\@-H[1U-:O&[8/4I8ZC<,R?D*.3SL\DI-V4M6Y9%IB[:4^)QF$9\VOY^!K(S!WP!, M==NS7O2.WM[H=_I%!^K:&4 &X5Q,WMQVS7>2\%XI:HK"Y KV,/5 R'G9UK3U MSRXBE97YRNQHFCKIY*9[4\PCU3DF;/G%1F[9=5 G@B8%N)8<^VK*#BDIUMK] M!Z"1P+2SVW=F&'FJ["_ZB$?3$[3*>'8](3B7)<\PSRI\:=/X!CO'9LN&:P]R M3#)[?/84J26A-L+Z:ZERS%#I%&*>V."#9D9PYRL8F:ZLAQ> 'POI'X%2ACY) M1>II$L8G'6@L5$@<:; $3JX3D[[5D[2.U$C/6%L"[=2T@^I*,W@99;=6$48T M"3>/6CQC5'*TTO^BSICZP^TCH-SE]=O-'=C:!WP$C?$Q5N_696Y 6 HT--4I M%V0=BI)^Y@H[\+EXS>8RM/%F_(%S]IB*+O"UK%U!!GES?-P&,$QG272G+5!O M).U&^&] *JV(1RR!+H,<2K9IJDLJXH>7&6*RE(A7B5K:H7S@4:4KK"+ F6LL M9,:)L#CN6[6DUAOY'%>9+.BHOXE$_6*QZMS!VMQPYR4$W06QZA MV$[1P1BREZL22$LF7J6K'>GUMM^P7DF<+"N!N EGCRO@F%J4T,==7.H=H&^. M,NK\MNPD;=@B)MKX)PY5I/)I7MUT+A.XOEVMA'3 M !6>TUAE'*OIA"Y89!YH^5<)WD"'@\_&T@HW,JMPAK4IE.*0/D;K-;D88(,+ M4AJG^B1JD.T3LEY-,'LK;W0)01 M85TZLK9!*B)G\:91IAU.T;Z%P>T4XFY4BD.DT4:QWS0I MK&A.KL""W%EAE&24]C#Q0J@)HOU&X1?0>T)5^.L>-322UVU=19I. MN^GVX8&,:D9I+#?WH*J=J=T\]_-CJ#P\6TV!L(02BRZ8J,KU22B G8SWF2!/ MK(?D:DUN)0NP5*6/=;^N<6G937*YVZGERR(3 _,5^(1"26!3 M2CB<4>?.6"\,UC*C5#2R'B7$'?5/QTHQ?@ =9>VQ"V(6S4U(-E?,16$=:-F, M^T8J[58;G_#LX5.T5(S;RH4)S(S+&?4'3%]CN8:VH0!&0,AV;1EYE)Z:B4>F MV*3;&8N\4T6^E0X23[\*&IO[#A(L'$=\-(+(%Y'\AH61$%3=:?.2)=2V@\/7M#@+)KKA2?? M(HYE8&P65;F:T9S<)Y1C25)2S7)-<-,:K?I(]AZ >1+1M6:)R("B#\E^0KPD MZW)K7UC]:^Y]H]P2 45G9)OH+YR(U^IWZN-IRI$4V5'7'B2(H$PZ)NRTMZ0+ M$ "X9H=3SY\HOZQ5( 1/2OG^1]./].2XV3<7<]<5..2#!9P^>H/L$1L.ZPZY M\A+(&G7/!=6+CI8OL;AFMZ&U;B.:,#U;$NHHS=GR')#^01.Q0J[\CS+X3 *5 MV@=\>95]F9/EL?PXVB07(/"BT<7(:*^9W4S=L&%&-=>RVNKV/YB.IVC\I3!' MD7619#=@EL'5U:DGOZJ6K.M%0(GHP3Q>;W+?R^97Z88J3 <_UY ?,6:8!EE" M?:K$29$9G8PO7H5UJ)HI*-2A:S%C/\!QE#4^<5=6KB)IY1J@0B,Z^FVS_MSP M2Z\2+7O'S99!RPL*S2J6UZ94PT[+JJJMJ#]1)N,XHAXZC!>&0(M@L42%!TVX M*N[+5.$I%*HF1SB&!1S']Q3HQ1*<#C/$0"2C]S;D.:G0Q-PR:W+&O_5FL8(, MU]\.@&B@$1BK?7EJT0A!M2IE^<4Z"]SE#-:CM/9,KC%B XB.%R&ZO6T\A[-/ MHV6$PKI.?F-A1*B/DJ-[/=>=!^C2\(W1-E:R(4%*T*#P;T M:;485(=G)LX)[0?Z^,F)0<"A>TRH@QT8JZ^MW.O:"N>UY>DKKVQ6OHTO+)8E M0%\N@RSKSZ 1EM8 Y[;$6DXPW[$JCQ3D"D_S?"&M6&,Q3:)PS3!U^$9^01 _M^G*B&SBQ4@T, ^/)8F&H.'5". M0=@DPJB!2Y%$'(>0 2M!V_J] "+V"6L)4T@1FG6TZVT>90Y7*ZJ% E/,/I3X M[A^A2$"W*]3(BC5>5(5>XW;4]?--T4W!U]5#VRMO2U_961;1B&*%:UH]%E?8 MSE; \^@ZY3@)6W.PB(6A!:I)A6"C';^1,1,J699!S7)'\>0.2*&E#*_:W2)* M']F>E'/FLZ!%\A1[BGGU0EU%;1?T6P4?5KZ6&BI!F>*6]6-,2-3)1P_8$HZ7 MP*0&9OV)X2]ZV*IYJXA5-+3%GH_HRR_,J&)[R@+ QH>R(F?S'^ SP=CJ^ MG8*@A$2H')5RCO'"%6:EZ>PQG&\7;#NA]P+7>VZ[8[Z\>;Y!@)B_?YX#'+'< M!\9K@6*!7O0##$_TJ:0V_R'.%W&P$=-U4(R&#[512:JVYSW5]9"#GN^W0%C( MV$(:N7FYVV[A_P0RI3>H43(!P\AS5&%Q8SX&%7YS]4'>C"]&MW CKD\80_O^= ;-OMBFE4Z$P1O:M/"L87EV7MMK]MI MRYXWZ&*#\7[3:_?:L@/WOR=NKVY'%U1H?NAU>SU< .8B60OHTP)\N+KM;IMZ MOGE#6)6K_JMI55Z)*KF6Y'6H4?MB98OTRN]:\:[U4YLU7-W+?0=][\3^O1-[ M96#O]T[LWSNQ?^_$7O((?N_$_KT3^_=.[-\[L;LY[/=.[-\[L7_OQ/Z]$_OW M3NQ5/+.N$WN=7NWN_KB70GO[O6?J]YZIX?>>J=][IO[1/5,KS7HLS.CNFG5T MKZ97ZE[$[WL/U']Q#]3BX9Z-IZH(RW!7]_)$EQL<8:MX2@$MXL=/E.+, =A6DXV2 MI3M\"N9!Z7/[#%75%_[TIU:SV2\^/!E-)U/<\?7->#J^O!T1!'#7[ZXFE^^P MQM+I^.;2M7> ]\?IF3P\*$'![_CR TM#8Y3CBL__%JP:IJI0:464FPK NV9A M@,5J!."[F&, X7R3TBYW%@9XR08 G\T"2R#;44A ECXD1WTV5:>TAPMZ]TDI;S AO?[[6ND5__F!0H[^:Z<' MV\/8];0<+9OYCJNF4GYD^OP9^Y$OR8]<^>W*3>X%_M+27W &(]9E:L_@YNKD MZE:>CD[?CXVP7L%__?W\243^O'/'R>W3CI?0^MJ*9W-#ZQ2 I1T M8DHWYKMO.L*;J:&=:V2Q@[!*J6;#0) L(K906>RYY6S+C M6O88_]4]QF9T(),!US[^K*05&2AIQ3B60$^4Y7I9](4"AO%SARJHL58E< MNIME%U]K-?K]'XH__I+I;,XQ;2P%7!HU-F'HH!P6'ZJ.\?5;SM=R5,&8( MA>5JR@@J;L-HN&Q1>!F<[[# <^TE[[JNJYETO@T]DAI*),3:[V_R]F9T.1V= MHF;Y0LF0=JA=I;7,>1=O>BEH%8:!ZG,?4NU1Y6!4%RM MI,F#T4D!58LK-W^S9ZIL%58UW76A!]8.4!9?9QK\(JDH'V.WF\C9]H)!;0Q@ M+1?-OUG'Q0MOULL1U=&#>^ZLV:E"\,QQ<9UYXLDI6"U_%(,,=5$>E>13'/#1 M=@?9+J22'D)>)%GC17K)^NO.:3=$,3&C6B-KU:IDE6&81NOTJY3-$Y/_<^)F M.&S MW2V26K*S=JR4EN3DTKN$4[^I?=JMKG,",C]?W9OVKY4S5;ZXA\R-SJ025(9J M925E@1Q%I==KO[\#"NC'*DWHDU)2/GGT3Y5>WN,"[",,3<,U"$,55G/[88E% MGE:'=-51GS+GSX>-[A++:P6V+)WZM.B?=U+5?!B:X+/RSA?,&K:XE;)57\6![('RNL;9>FK?O4^?PJLXUY M=ESD4348JK22;)+H4X4=K-7HE)E@M^KKONOKG>[0]?/T_>AF_/[JXFQ\,U5D M5)Z-SR>GD]N7'?I9. .]J^\^5[(Z-'ONAX0NS6[-PRI%E70]W$,YB[AW,O*T+]V@F++D7T7##+G+GO^ M!ZYYJP.FJTTP9-GQ5%^C''/6V2 N448)&U21CG(?5O-@HYIA9L)%_$25T#P3 MT9_)*,K&=%*R,5&Z/=5X4$WC[_(]M3 UG]K*D4*L!26O6L:A>+)W9Z" D %4W?8N3Q5TYL]S=RY M/72P(H1OI0F._+58M1:CF%@PC!(M!UK]*>P#GQ^UJ MCH.I/T=%4U2TUB$5X),Y](]T)_K[RDWLM ?&E'O"?L5:>H*@8I%8]W[GO#$# M(0R:Y CX!RZ!8<+T];"\Q_DO!6P_VVAEME8.5:[P7I' S$CL&*/,\%ZS:"]>F M=>V.N?=>K0[VL<:WL_[A.9F7.654B%>#DBU:X!@Y].=:\75X,@.[0'HS68+&FEIE:9*CQ$6QEU%7*]?.UWR!F$BA52<:..J,FAJ!21O;!)GP30,%P$G5. T%BV_ MX;I!F6R%3O!L@)#/OY8Y)/CA[.675NJK%\B/DU>32?AP?G6(G[G .4:>XT.> MX&CQ&@>_3WH1AC\FML$#\OD?DO^,^X!Z8:F#;H/2N)!B?Y\L8&H3#FA-6(*O M":,K16U603AE6P]/+9!))A72YH",ML@BS:,/1]ZS9]?Q<"JD6N@D[[)Y[EW:\"A>5-.UU.];LQSA?'MWX$Y!03?. MWQ2# ,-.ZIIMWS%:"@Y^,;\L&!U9,(U)7P=54M%'PV>O2F8 4!BM06F:[2)? M%:F7L-']==H4QVJ>GJ#FI][G$@0HPG9%F[O_G'?Y/RN>O?E[R>ZOG('+Q_$7.+O^QQJ#K.CNM;:^Q#2A:M91I*CJU%[4^0TY9? MNH+CFS/]!E!+ P04 " "JBLY..6$U5C<$ J( #P 'AL+W=OF:J"P% MDM)L_?4CY7FA,OM@+\7CY?-+57]_K*KOY,]]438C9]>V3[># M0;/>R7W>_%H]R5(_V5;U/F_U;?UMT#S5,M\T.RG;?3'PAL.;P3Y7I?/E\_%= MRWI@WU2M7+>J*G6B25@I^=*\/C>W)-<9?L@L?QPY0X?DSVTU444KZRAOY;2N MGI]4^6WDN [9JKIIA2F[R[E7I=JKGW+3W36[ZF56U>IG5;9Y(=9U513=K\R# M[D>ZA.;?E)6L6[7N96SSQS37K"/G9JA?^$,UZE$5JOUKY'3_%]+17S&P/J.+ MP_%Z".)M_7_"6&VW:BVC:OV\EV5[B&,M"U-ZV>S44^.0,M_+D7/,0O)R0UC9 M:AK"R\.K=%[S+;IHOCE\5ZLC]@I+ZENE']1\XQIP/,@PB44RYQ'-6$3&=$[C MD!$Q8RP3%J ' 'KO!DBNEKD%Z0.0_@4A1:8O"Q9G))F09,E2:D$& &3P7I B M2\*O%N0U 'G]7I A%;.)!7D#0-[@0D9,A"E?9CR)#=GX3O"8"4%H')$9MSO. M!P#R R[DF HN#-XR94+'D':X!G&:\'AJ07X$(#_B0HJ[Q8*F]UTCY-.83WA( M=74O=1,(.;,C^0F _(0+.>%_Z,9(A>@/BNX0&K:'N$Q<5V@\Y>,Y.P$&^@19 M*&DR3C+=6<,9(P\DY=.9'JBS1/]]9;$@-B9D%1=9*S1:&9,(,DF3!4G9O!MP MEC3-^LW.A:SB(FO%QKHG64IC04/3C7N$D%)<9*?$2:9CN*3W5+=$&PI2B(OO MD!73%6DZQUE 2!\NLC\ZWY+?::IKM-]S(5^XR,(0,YJR63*/6"H>2,3T6,PS M&P[RA(LLBC!9+'AFY@('S>HZSK3%6/Q&$R[D"1=9%.)N+-AO=V;"PE:L7[4> M9 L/V1:@9A\\&Q-RAX?L#ENTY$JO^0K9_&+#@>L09&/\Q[@G"2%=>,BZ )U& MKFQ,R!G>)9UQ,HB0/+SWDL>!U,:$%.)=5"$GHPBYQ$-V";A"Z@\XD%4\9*N M:Z0^)N05#]TKT/#MVWL@D&5\9,OTA^](MKDJ>DW2A^3B7U0N_]"1.*_KW.QA MVIB09OS+:^94),'-+F3/G$?LPFEC0I[QD3T#KD1[G=N'A.,C"P>T=A\3$HZ/ M+!P8LS<&0>+QD<5S?LG<-5(;$Q*/CRR>-S.+4ST<$HZ/+!Q@$F10[?UL2#@! MLG! S%[7"2#S!/AG+ "FW74"R#P!_DD+@!G8F)!] F3[O)WYGN@[ 7C*@JR= M,WS'F8:-"6DG0-;.R=V>5UH;$]).@*P=<-^GMZ8-(.T$V'MG;W=^SDZ) D@[ M0:>=P?%L>B.WJI2;6!?1Z/1U7JR7-3&7P_YY<&VVN[;/11'JM*2<5WEWFFS> M<3RF__(W4$L#!!0 ( *J*SDYKUWPKSP$ '4= : >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'/%V5=/FNG]4SR4>=?4J=JU:?)^/-1I450YMWY".!RD]R,:#C![DXT%.#YJ-!\WH0?/QH#D]Z'H\Z)H>=#,>=$,/NAT/ MNJ4'R13(..4G(:SY6@O@6OA>"P!;^&(+(%OX9@M 6_AJ"V!;^&X+@%OX<@N@ M6_AV"\!;^'HKT%OY>BO06R_PKHU>MOEZ*]!;^7HKT%OY>BO06_EZ*]!;^7HK MT%OY>BO06_EZ*]!;^7H;T-OX>AO0V_AZ&]#;+G!6@@Y+^'H;T-OX>AO0V_AZ M&]#;^'H;T-OX>AO0V_AZ&]#;^'H[T-OY>CO0V_EZ.]#;^7H[T-LO<-:-#KOY M>CO0V_EZ.]#;^7H[T-OY>CO0V_EZ^T#O5)5=7#_G;E=OT[E+?@S_\SO. .Z4 M/P[Q_!FGJ7_N'RB=^RTQG'[/;O-IZE=$^/&5]>$34$L#!!0 ( *J*SDX9 M>](.P0$ '8= 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9RV[",! %T%]! MV5;$^%'Z$+!INVV1VA]PDX%$)+%E&PI_7R= I2(J40'2W1"2<69N@G4VC#XV MEGQO75>-'R=%"/:1,9\55&N?&DM-K,R,JW6(IV[.K,X6>DY,# 9#EIDF4!/Z MH>V13$;/--/+*O2>MM?;UN-$6UN5F0ZE:=BJR0^:]G<-4T=5M\87I?4W<4'2 M>UG'+CY>&R>QZA-VPH3#&]OS>-_;BIPK<_I7-#.;E1GE)EO6\9;46T:?:A5==Q\9L7;%?"]+KY0B;BHX'Z"J7G!SBMJ!CH[K" M]I.?-7"_&S+CJ&]=K+I0'GF\&&D:JYZU"R_YB-1NG9SRDX;'UM?[8;^,6W3? MC[WPGZ)GW>&\MWZY' (DAP3)H4!RW(+D&(+DN /)<0^2XP$D!Q^@!$$1E:.0 MRE%,Y2BH&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( *F*SDZO:0,/>P( $ ) 8 M " ?@( !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ J8K.3GLIB*PQ P NP\ !@ M ( !JP\ 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ JHK.3FD.Z>)\! :Q4 !@ ( !I1T M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK. M3AI 382V 0 T@, !@ ( !,"8 'AL+W=O&UL4$L! A0#% M @ JHK.3K/\P#*V 0 T@, !D ( !""H 'AL+W=O&PO=V]R:W-H965T(M !X M;"]W;W)K&UL4$L! A0#% @ JHK.3L<=\H"W M 0 T@, !D ( !SR\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3E%Z'Z*V 0 T@, !D M ( !F#4 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ JHK.3AC-R@VV 0 T@, !D ( !7SL M 'AL+W=O&PO=V]R:W-H965T@_ !X;"]W;W)K&UL4$L! A0#% @ MJHK.3@X]6NFU 0 T@, !D ( !UD$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3FQ5J9[$ 0 M-P0 !D ( !GT< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3B6JH4,Y @ 0P8 !D M ( !@TT 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ JHK.3F%-?EC< 0 9@0 !D ( !"54 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK. M3F,NO6^V P BA$ !D ( !@UL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3CQ@^BQ= P RPT M !D ( !;V0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3B*L7!1< @ - < !D M ( !T6P 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ JHK.3NQ9VC+( @ N0H !D ( !?74 'AL+W=O MWD# "! M#P &0 @ %\> >&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3M?E M^S': 0 GP0 !D ( !P8, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ JHK.3CEA-58W M! *B \ ( !5\T 'AL+W=O](.P0$ M '8= 3 " <+3 !;0V]N=&5N=%]4>7!E&UL4$L% 3!@ Y #D @0\ +35 $! end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 152 288 1 false 47 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://thctherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://thctherapeutics.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://thctherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) Sheet http://thctherapeutics.com/role/ConsolidatedStatementOfOperations CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT (UNAUDITED) Sheet http://thctherapeutics.com/role/ConsolidatedStatementOfStockholdersDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT (UNAUDITED) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENT OF CASHFLOWS (UNAUDITED) Sheet http://thctherapeutics.com/role/ConsolidatedStatementOfCashflows CONSOLIDATED STATEMENT OF CASHFLOWS (UNAUDITED) Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY Sheet http://thctherapeutics.com/role/DescriptionOfBusinessAndHistory DESCRIPTION OF BUSINESS AND HISTORY Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN Sheet http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcern BASIS OF PRESENTATION AND GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES Sheet http://thctherapeutics.com/role/SummaryOfSignificantPolicies SUMMARY OF SIGNIFICANT POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - FIXED ASSETS Sheet http://thctherapeutics.com/role/FixedAssets FIXED ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - INTANGIBLE ASSETS Sheet http://thctherapeutics.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - ROBOT CACHE ??? RIGHTS TO TOKENS AND EQUITY Sheet http://thctherapeutics.com/role/RobotCacheRightsToTokensAndEquity ROBOT CACHE ??? RIGHTS TO TOKENS AND EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - ADVANCES FROM RELATED PARTIES Sheet http://thctherapeutics.com/role/AdvancesFromRelatedParties ADVANCES FROM RELATED PARTIES Notes 13 false false R14.htm 00000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://thctherapeutics.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 00000015 - Disclosure - NOTES PAYABLE Notes http://thctherapeutics.com/role/NotesPayable NOTES PAYABLE Notes 15 false false R16.htm 00000016 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://thctherapeutics.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 16 false false R17.htm 00000017 - Disclosure - STOCK WARRANTS Sheet http://thctherapeutics.com/role/StockWarrants STOCK WARRANTS Notes 17 false false R18.htm 00000018 - Disclosure - SHAREHOLDERS??? DEFICIT Sheet http://thctherapeutics.com/role/ShareholdersDeficit SHAREHOLDERS??? DEFICIT Notes 18 false false R19.htm 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://thctherapeutics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 00000020 - Disclosure - SUBSEQUENT EVENTS Sheet http://thctherapeutics.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 00000021 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) Sheet http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies SUMMARY OF SIGNIFICANT POLICIES (Policies) Policies 21 false false R22.htm 00000022 - Disclosure - FIXED ASSETS (Tables) Sheet http://thctherapeutics.com/role/FixedAssetsTables FIXED ASSETS (Tables) Tables http://thctherapeutics.com/role/FixedAssets 22 false false R23.htm 00000023 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://thctherapeutics.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://thctherapeutics.com/role/IntangibleAssets 23 false false R24.htm 00000024 - Disclosure - ADVANCES FROM RELATED PARTIES (Tables) Sheet http://thctherapeutics.com/role/AdvancesFromRelatedPartiesTables ADVANCES FROM RELATED PARTIES (Tables) Tables http://thctherapeutics.com/role/AdvancesFromRelatedParties 24 false false R25.htm 00000025 - Disclosure - NOTES PAYABLE (Tables) Notes http://thctherapeutics.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://thctherapeutics.com/role/NotesPayable 25 false false R26.htm 00000026 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://thctherapeutics.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://thctherapeutics.com/role/ConvertibleNotesPayable 26 false false R27.htm 00000027 - Disclosure - STOCK WARRANTS (Tables) Sheet http://thctherapeutics.com/role/StockWarrantsTables STOCK WARRANTS (Tables) Tables http://thctherapeutics.com/role/StockWarrants 27 false false R28.htm 00000028 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) Sheet http://thctherapeutics.com/role/DescriptionOfBusinessAndHistoryDetailsNarrative DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) Details http://thctherapeutics.com/role/DescriptionOfBusinessAndHistory 28 false false R29.htm 00000029 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) Sheet http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcernDetailsNarrative BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) Details http://thctherapeutics.com/role/BasisOfPresentationAndGoingConcern 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) Sheet http://thctherapeutics.com/role/SummaryOfSignificantPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT POLICIES (Details Narrative) Details http://thctherapeutics.com/role/SummaryOfSignificantPoliciesPolicies 30 false false R31.htm 00000031 - Disclosure - FIXED ASSETS (Details) Sheet http://thctherapeutics.com/role/FixedAssetsDetails FIXED ASSETS (Details) Details http://thctherapeutics.com/role/FixedAssetsTables 31 false false R32.htm 00000032 - Disclosure - FIXED ASSETS (Details Narrative) Sheet http://thctherapeutics.com/role/FixedAssetsDetailsNarrative FIXED ASSETS (Details Narrative) Details http://thctherapeutics.com/role/FixedAssetsTables 32 false false R33.htm 00000033 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://thctherapeutics.com/role/IntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://thctherapeutics.com/role/IntangibleAssetsTables 33 false false R34.htm 00000034 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://thctherapeutics.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://thctherapeutics.com/role/IntangibleAssetsTables 34 false false R35.htm 00000035 - Disclosure - ROBOT CACHE ??? RIGHTS TO TOKENS AND EQUITY (Details Narrative) Sheet http://thctherapeutics.com/role/RobotCacheRightsToTokensAndEquityDetailsNarrative ROBOT CACHE ??? RIGHTS TO TOKENS AND EQUITY (Details Narrative) Details http://thctherapeutics.com/role/RobotCacheRightsToTokensAndEquity 35 false false R36.htm 00000036 - Disclosure - ADVANCES FROM RELATED PARTIES (Details) Sheet http://thctherapeutics.com/role/AdvancesFromRelatedPartiesDetails ADVANCES FROM RELATED PARTIES (Details) Details http://thctherapeutics.com/role/AdvancesFromRelatedPartiesTables 36 false false R37.htm 00000037 - Disclosure - ADVANCES FROM RELATED PARTIES (Details Narrative) Sheet http://thctherapeutics.com/role/AdvancesFromRelatedPartiesDetailsNarrative ADVANCES FROM RELATED PARTIES (Details Narrative) Details http://thctherapeutics.com/role/AdvancesFromRelatedPartiesTables 37 false false R38.htm 00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://thctherapeutics.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://thctherapeutics.com/role/RelatedPartyTransactions 38 false false R39.htm 00000039 - Disclosure - NOTES PAYABLE (Details) Notes http://thctherapeutics.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://thctherapeutics.com/role/NotesPayableTables 39 false false R40.htm 00000040 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) Notes http://thctherapeutics.com/role/ConvertibleNotesPayableDetails CONVERTIBLE NOTES PAYABLE (Details) Details http://thctherapeutics.com/role/ConvertibleNotesPayableTables 40 false false R41.htm 00000041 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details 1) Notes http://thctherapeutics.com/role/ConvertibleNotesPayableDetails1 CONVERTIBLE NOTES PAYABLE (Details 1) Details http://thctherapeutics.com/role/ConvertibleNotesPayableTables 41 false false R42.htm 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details 2) Notes http://thctherapeutics.com/role/ConvertibleNotesPayableDetails2 CONVERTIBLE NOTES PAYABLE (Details 2) Details http://thctherapeutics.com/role/ConvertibleNotesPayableTables 42 false false R43.htm 00000043 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://thctherapeutics.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://thctherapeutics.com/role/ConvertibleNotesPayableTables 43 false false R44.htm 00000044 - Disclosure - STOCK WARRANTS (Details) Sheet http://thctherapeutics.com/role/StockWarrantsDetails STOCK WARRANTS (Details) Details http://thctherapeutics.com/role/StockWarrantsTables 44 false false R45.htm 00000045 - Disclosure - STOCK WARRANTS (Details Narrative) Sheet http://thctherapeutics.com/role/StockWarrantsDetailsNarrative STOCK WARRANTS (Details Narrative) Details http://thctherapeutics.com/role/StockWarrantsTables 45 false false R46.htm 00000046 - Disclosure - SHAREHOLDERS??? DEFICIT (Details Narrative) Sheet http://thctherapeutics.com/role/ShareholdersDeficitDetailsNarrative SHAREHOLDERS??? DEFICIT (Details Narrative) Details http://thctherapeutics.com/role/ShareholdersDeficit 46 false false R47.htm 00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://thctherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://thctherapeutics.com/role/CommitmentsAndContingencies 47 false false R48.htm 00000048 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://thctherapeutics.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://thctherapeutics.com/role/SubsequentEvents 48 false false All Reports Book All Reports thct-20190430.xml thct-20190430.xsd thct-20190430_cal.xml thct-20190430_def.xml thct-20190430_lab.xml thct-20190430_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 67 0001477932-19-003523-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-19-003523-xbrl.zip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end

		Page
PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements
	Consolidated Balance Sheets at April 30, 2019 (unaudited), and July 31, 2018	3
	Consolidated Statement of Operations for the three and nine months ended April 30, 2019, and April 30, 2018 (unaudited)	4
	Consolidated Statement of Stockholders’ Equity (deficit) for the nine months ended April 30, 2019, and April 30, 2018 (unaudited)	5
	Consolidated Statement of Cash Flows for the nine months ended April 30, 2019, and April 30, 2018 (unaudited)	6
	Notes to Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures about Market Risks	22
Item 4.	Controls and Procedures	22

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	24

SIGNATURES		25

	April 30, 2019			July 31, 2018
ASSETS
Current assets
Cash	$	32,344		$	2,969
Total current assets		32,344			2,969

Fixed Assets, net		42,475			58,297
Intangible Assets, net		26,188			28,287
Rights to Robotcache Coins		-			2,429,981

Total assets		101,007			2,519,534

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued liabilities	$	195,583		$	178,165
Accrued liabilities due to related parties		163,693			7,728
Advances from related parties		142,353			159,566
Notes payable		48,200			76,200
Convertible Notes payable, net		138,864			100,000
Derivative liability		349,939			59,785
Total current liabilities		1,038,632			581,444

Total liabilities		1,038,632			581,444

Stockholders' equity (deficit)
Common stock; $0.001 par value; 500,000,000 shares authorized; 13,771,032 and 13,004,740 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively		13,771			13,004
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 236,500 and 222,500 series A and B shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively
Preferred A stock; $0.001 par value; 3,000,000 shares authorized; 220,000 and 206,000 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively		220			206
Preferred B stock; $0.001 par value; 16,500 shares authorized; 16,500 and 16,500 shares issued and outstanding as of April 30, 2019 and July 31, 2018, respectively		17			17
Stock payable		128,180			190,245
Additional paid-in capital		34,427,625			11,128,690
Accumulated deficit		(35,507,438	)		(9,394,072	)
Total stockholders' equity (deficit)		(937,625	)		1,938,090

Total liabilities and stockholders' equity (deficit)	$	101,007		$	2,519,534

	For the Three Months Ended						For the Nine Months Ended
	April 30, 2019			April 30, 2018			April 30, 2019			April 30, 2018

Revenues	$	-		$	-		$	-		$	-

Cost of revenues		-			-			-			-

Gross profit		-			-			-			-

Operating expenses
Professional fees		35,424			23,192			90,836			46,336
Consulting fees		18,579,500			135,486			19,093,383			257,641
Payroll expense		46,937			20,569			88,074			41,137
General and administrative expenses		25,009			41,142			76,667			108,191
Depreciation and amortization		6,232			6,213			19,116			19,012
Total operating expenses		18,693,102			226,602			19,368,076			472,317

Loss from operations		(18,693,102	)		(226,602	)		(19,368,076	)		(472,317	)

Other income (expense)
Gain/(loss) on change in derivative liability		(3,237,594	)		11,273			(4,051,115	)		39,274
Gain/(loss) on settlement of debts		-			-			(37,500	)		(132,234	)
Impairment expense		-			-			(2,429,981	)		-
Interest Expense		(200,393	)		(28,729	)		(226,694	)		(88,622	)
Total other income (expense)		(3,437,987	)		(17,456	)		(6,745,290	)		(181,582	)

Net income (loss)	$	(22,131,089	)	$	(244,058	)	$	(26,113,366	)	$	(653,899	)

Basic income (loss) per common share	$	(1.66	)	$	(0.02	)	$	(1.99	)	$	(0.05	)

Basic weighted average common shares outstanding		13,309,529			12,063,758			13,127,462			11,938,914

For the Nine Months Ended April 30, 2018

	Preferred A Stock				Preferred B Stock				Common Stock				Additional Paid-in		Stock		Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Payable		Deficit			Deficit
Balance, July 31, 2017		200,000		200		16,500		17		11,878,990		11,879		3,046,707		-		(3,254,672	)		(195,869	)
Shares for services		-		-		-		-		25,750		26		149,137		48,263		-			197,426
Shares issued for cash investments		-		-		-		-		-		-		-		65,000		-			65,000
Imputed interest		-		-		-		-		-		-		2,121		-		-			2,121
Debt discount		-		-		-		-		-		-		7,590		-		-			7,590
Shares issued for settlement of debt		-		-		-		-		-		-		106,275		59,432		-			165,707
Shares issued for equity investments		-		-		-		-		250,000		250		1,563,750		-		-			1,564,000
Shares issued for investments in coin offerings						-		-		250,000		250		1,563,750		-		-			1,564,000
Net loss		-		-		-		-		-		-		-		-		(653,899	)		(653,899	)
Balance, April 30, 2018		200,000		200		16,500		17		12,404,740		12,405		6,439,330		172,695		(3,908,571	)		2,716,076

For the Nine Months Ended April 30, 2019

	Preferred A Stock				Preferred B Stock				Common Stock				Additional Paid-in		Stock			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Payable			Deficit			Deficit
Balance, July 31, 2018		206,000		206		16,500		17		13,004,740		13,005		11,128,689		190,245			(9,394,072	)		1,938,090
Shares and warrants for services		14,000		14		-		-		356,200		356		19,129,900		(37,065	)		-			19,093,205
Shares and warrants issued for cash investments		-		-		-		-		6,250		6		24,994		(25,000	)		-			-
Settlement of derivative liabilities		-		-		-		-		304,042		304		4,092,719		-			-			4,093,023
Imputed interest		-		-		-		-		-		-		1,803		-			-			1,803
Shares issued for settlement of debt		-		-		-		-		99,800		100		49,520		-			-			49,620
Net loss		-		-		-		-		-		-		-		-			(26,113,366	)		(26,113,366	)
Balance, April 30, 2019		220,000		220		16,500		17		13,771,032		13,771		34,427,625		128,180			(35,507,438	)		(937,625	)

	Principal as of		Nine months ending April 30, 2019					Principal as of		Accrued interest balance As of
	July 31, 2018		Funds advanced		Funds repaid			April 30, 2019		April 30, 2019
B. Romanek, President and CEO	$	96,023	$	82,654	$	(106,713	)	$	71,960	$	9,907
Shareholder Relative of our President and CEO		63,543		6,850		-			70,363		4,006
TOTAL	$	159,566	$	89,504	$	(106,717	)	$	142,353	$	13,913

Fair value assumptions – derivative notes:	Date of issuance			April 30, 2019
Risk free interest rate	1.14-2.57		%		2.39	%
Expected term (years)	1.00-0.75			0.90-0.01
Expected volatility	390.76-458.59		%		457.23	%
Expected dividends		0			0

	Number of Shares		Weighted Average Exercise Price
Balance, July 31, 2017		12,500	$	10.00

Warrants granted and assumed		403,750	$	21.56
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, July 31, 2018		416,250	$	21.21

Warrants granted and assumed		195,000		2.05
Warrants expired		-		-
Warrants canceled		-		-
Warrants exercised		-		-

Balance, April 30, 2019		611,250	$	15.10